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The tooth is a complex ectodermal organ consisting of various 
hard tissues as well as soft connective tissue. The hard tissues 
found in the tooth include: enamel, dentin, and cementum. Teeth 
also contain soft connective tissues like pulp and a periodontal 
ligament composed of fibrous connective tissue with both vas-
cular and neural sections. Whole tooth loss and oral diseases 
such as dental carries, oral trauma, periodontal disease create 
many problems that impact proper oral function. Issues with 
enunciation, mastication, occlusion and general health issues are 
known to be induced by tooth loss or the onset of oral disease. 
(Oshima et. al, 2014)
Currently, there are many procedures using artificial ma-
terials to replace missing or damaged teeth. Dental implants, 
bridges, dentures and crowns all help to replace missing teeth, 
however, many believe that the optimal replacement is to re-
grow tooth tissue or an even an entire tooth in place of the 
missing tooth. 
Due to extensive, active research in embryonic development, 
stem cell biology, and tissue engineering, regenerative therapy 
is a promising method for the restoration of function in miss-
ing or damaged organs including teeth. There are numerous 
tooth-tissue derived stem cells that have been found to aid 
in the development of new teeth allowing for the evoution of 
teeth regeneration techniques. Tooth-tissue regenerative ther-
apy involves transplanting a bioengineered tooth germ grown 
in vitro via stem cells. At the time of implantation, these bio-
engineered specimens must contain all the components of a 
naturally growing tooth in order to be able to function as one 
in the future. Whole tooth replacement transplants a complete, 
bioengineered tooth to replace the missing tooth. Many believe 
that tooth replacement via stem cell therapy will be the treat-
ment of choice for missing or severely damaged teeth. Several 
other methods have been proposed to replace missing teeth 
including three-dimensionally bio engineered teeth and the 
cell-aggregation method. Additional reports have been released 
regarding fully functional bioengineered teeth with correct tis-
sue orientation and the masticatory capabilities of regular teeth. 
This review will discuss the most recent findings on tooth tissue 
engineering and whole tooth regeneration, and will provide the 
most viable method for the near future.
Methods
This review is based on the analysis of scientific articles and original 
works found on the internet. Several different internet databases 
were used including Touro college’s online library and PubMed.
Discussion: Tooth Development
To ensure the success of tooth regeneration techniques, it is 
important to first understand how a biological tooth is formed 
and attempt to mimic those natural steps in the lab. As a tooth 
develops, it undergoes four distinct morphological phases; 
the initiation, bud, cap, and bell stages (Yildrim, 2013). During 
initiation, support structures such as the alveolar bone and 
periodontal ligament begin to develop. The tooth germ is first 
observed as a thickening and propagation of the cells of the 
oral epithelium and these cells form a bud that extends to the 
dental mesenchyme. The dental epithelium continues to under-
go extensive proliferative activity, eventually forming a cap-like 
structure and completing tooth development.
During tooth development, the cells differentiate into three 
different sections: the inner and upper layers and the central 
cell layer that forms the stratum intermedium and stellate re-
ticulum. As they do so, the enamel knot signaling center can 
be identified. At this point, ectomesenchymal cells of the dental 
papilla condense, giving rise to both the dentine and pulp of 
the tooth. The dental follicle forms around the dental papilla 
and enamel, giving rise to the periodontal tissues. The final bell 
stage is heavily defined by the continued proliferation and tissue 
differentiation. In this process, the inner epithelial cells adopt 
a cube shape and produce a considerable amount of glycogen, 
while the cells of the stratum intermedium produce alkaline 
phosphatase and the stellate reticulum adopts a star shape, en-
circled by the outer epithelial layer.
As the tooth continues to grow and differentiate, odonto-
blasts from dental mesenchyme differentiate and build up the 
dentin matrix, while ameloblasts from epithelial cells produce 
the enamel matrix. Once the crown of the tooth has formed, 
tooth root structures start to develop from Hertwig’s epithelial 
root sheath, creating periodontal ligament, dentin, cementum 
and alveolar bone.
Throughout the entire tooth development, the only portion 
that does not have regenerative properties is the dental enamel. 
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Enamel is the only mineralized tooth tissue sourced from the 
dental epithelium. All other mineralized tooth tissue, such as 
dentin, periodontal ligament, alveolar tissue and cementum have 
some form of regenerative properties. These tooth tissues orig-
inate from neural crest-derived dental ectomesenchyme. Dental 
stem cells are believed to play an important role in the regener-
ative properties of these tissues (Dannan 2009).
Dental Stem Cells
Unlike other cells found in the body, stem cells have unique 
capabilities. They are unspecialized, yet can produce specialized 
cell types, even after prolonged periods of inactivity. Stem cells 
are able to proliferate and can be isolated based on unique cell 
surface markers. It is important to note that in vitro culture con-
ditions may alter the cells, thus causing the cells to behave in a 
different manner than they would have in vivo. There are two 
categories of stem cells that can be used: embryonic or somatic 
stem cells. Being that the use of embryonic stem cell is ethically 
controversial, researchers work with strictly somatic, or adult 
human stem cells for clinical application. Somatic stem cells are 
easily accessible and without the controversy of their embryonic 
counterparts, making them the optimal choice for use in dentistry.
There are several types of stem cells that can be found in 
teeth. Dental stem cells are found in the periodontal ligament, 
apical papillae, and the pulp of both adult and children’s teeth. 
Although these stem cells differ in their growth rate in culture, 
cell differentiation and gene expression, they most likely share 
a common lineage. Dental stem cells are derived from neural 
crest cells and all have generic mesenchymal stem cell-like prop-
erties. (Volponi et. al, 2010)
Dental Pulp Stem Cells
Dental pulp stem cells (DPSCs) are a mesenchymal type of stem 
cell located in the center of the tooth. Dental pulp stem cells 
are considered a great candidate for stem cell therapy for many 
reasons. DPSCs are easily accessible for collection and have a 
low morbidity once extracted. They are also known to generate 
more dentin than other stem cells, being easily conserved via 
cryopreservation (Yan, et. al. 2010). There are various methods 
to isolate DPSCs from the dental pulp including size-sieved 
isolation, stem cell colony cultivation, magnetic activated cell 
sorting (MACS), and fluorescence activated cell sorting (FACS). 
In addition, DPSCs were found to generate a dentine structure 
in vivo and differentiate in vitro (Gronthos et.al, 2000). These 
features make DPSCs a prime source of stem cells for 3-dimen-
sional tooth regeneration.
Stem Cells from Human Exfoliated  
Deciduous Teeth 
Stem cells from the pulp of human baby teeth, also known as 
stem cells from human exfoliated deciduous teeth (SHED), 
were found to differentiate into non-dental mesenchymal cell 
derivatives in vitro, produce dentine, and induce bone forma-
tion. SHED differs from DPSCs with respect to their higher 
rate of proliferation, sphere-like cell clustering and, most impor-
tantly, their inability to produce a dentin-pulp-like complex. It is 
believed that the reason for these differences is due to SHED 
being a multipotent stem cell that is less mature than DPSCs. 
SHED were reported to not be able to differentiate into osteo-
blasts, yet managed to form an osteoinductive template, thus 
leading to new bone formation. Following transplantation, SHED 
were found to aid in bone formation and generate dentin. SHED 
were found to be a highly proliferative cell population, capable 
of differentiating into various cells such as neural and glial cells 
as well as odontoblasts. Although there are better types of stem 
cells for use in dentistry, due to its penchants for widespread 
differentiation there is still much potential for SHED stem cells 
in other areas of regenerative medicine, such as in the brain and 
nervous system. (Miura et. al, 2003).
Periodontal Ligament Stem Cells
The periodontal ligament (PDL) has been viewed as a potential 
source of stem cells for a long time. The PDL is a connective 
tissue that acts as a shock absorber during chewing and is 
found between the cementum and the inner wall of the alveo-
lar socket, anchoring both to each other. These stem cells have 
characteristics of mesenchymal stem cells and have potential 
to be used in periodontal regeneration. It is important to note 
that unlike other stem cells, PDLSCs do not have a unique cell 
marker that differentiates them from mesenchymal stem cells. 
Therefore, PDLSCs are not an optimal choice for stem cell re-
search and dental regeneration (Zhu and Liang, 2015).
Root Apical Papilla Stem Cells
Stem cells of the apical papilla (SCAP) are found by the tips of 
growing tooth roots. These cells are only present during root 
development, prior to the eruption of the tooth. Stem cells of 
the apical papilla were reported to differentiate into both adi-
pocytes and odontoblasts. When compared to the proliferative 
potential of DPSCs in vitro, SCAP were noted to proliferate at 
a higher rate, making them a very promising source of stem cells 
for stem cell therapy. Current implant-based methods to re-
place whole teeth have failed to reproduce the necessary root 
structure, causing jaw-bone resorption around the implant due 
to the force of chewing (Volponi et. al, 2013).  When combined 
with periodontal ligament stem cells and transplanted into mini 
pigs, researchers noted formation of periodontal ligament and 
dentine. These results suggest that the necessary technology to 
implant a biological root and place an artificial dental crown on 
it has been attained.
Another point of advocacy is that SCAP can be harvested 
without the ethical issues of stem cell harvesting in embryos. 
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In addition, an important attribute of SCAP is that they are 
believed to be the source of root dentin, while DPSCs are 
the source of the replacement odontoblasts. SCAP could be 
distinguished from other mesenchymal stem cells in a number 
of ways. The most significant difference is that while all other 
mesenchymal stem cells test negatively for hTERT (human telo-
merase reverse transcriptions) activity, SCAP were found to 
test positive for it. This suggests that there is a difference in the 
genetic lineage of stem cells from the apical papilla compared 
to that of other dental stem cells. SCAP seem to come from an 
early population of progenitor cells and may be a better option 
for tissue regeneration (Huang et. al, 2008).
Using Dental Stem Cells for Tooth Tissue 
Regeneration
When stem cells isolated from the apical papilla of human teeth 
and human periodontal ligament were transplanted into mice 
and mini pigs, the successful regeneration of the root and peri-
odontal complex capable of supporting a crown was achieved. 
Being that pigs have an orofacial tissue organization similar to 
humans, the successful regeneration of a bio root and transplan-
tation into pigs shows the tremendous potential of this method 
for use in humans. Unlike other experiments to regenerate 
tooth tissue, this method used human stem cells and not stem 
cells from mice or pigs, proving that human stem cells were 
capable of producing the above mentioned successful results 
(Sonoyama et. al, 2006).
Whole Tooth Regeneration
Whole tooth regeneration is another approach to fix the is-
sues associated with irreversible tooth damage. This method of 
tooth regeneration attempts to grow a whole tooth in vitro 
and transplant it into the mouth. To successfully regenerate a 
whole tooth, the same process that the tooth undergoes when 
it is first formed in the developing embryo must be replicated. 
Organogenesis of the tooth takes place by the interaction of 
mesenchymal and epithelial progenitor stem cells. Once the 
bioengineered tooth germ is produced in vitro, it may be trans-
planted it into the area of tooth loss, thus regenerating a new 
tooth. The biggest challenge is to develop a technique that will 
allow for the mesenchymal-epithelial stem cell interaction while 
in vitro. So far, there are several suggested methods that will 
allow scientists to use dissociated stem cells to bioengineer a 
tooth germ (Oshima et. al, 2014).
The Scaffold Method
The first method which allows for the necessary mesenchy-
mal-epithelial stem cell reaction, is using a biodegradable scaffold. 
Scaffold technology has provided us the with a method to regen-
erate specific tissue by sowing cells on degradable materials. The 
scaffold method has been used to generate tissues in cartilage 
and bone regeneration therapies. Experiments using a collagen 
sponge as the scaffold material have reported successful forma-
tion of small teeth. These lab-grown teeth had all the characteris-
tics found in biological teeth including dentin, enamel and dental 
pulp as well as forming the correct shape and size (Young et. al, 
2002). Despite the scaffold method’s ability to regenerate teeth, 
there are some significant problems with this technique. It has a 
low frequency of tooth formation. This approach fails to provide 
the many precise intercellular reactions, causing irregularities in 
the created tooth tissues, such as in the enamel-dentine complex. 
For proper tooth structure, there needs to be many precise junc-
tions between the enamel, cementum and dentine for normal 
tooth development. These complex junctions are the result of 
very specific mesenchymal-epithelial stem cell tissue interactions, 
resulting in a very precise combination of ameloblasts, cemento-
blasts and odontoblasts, a process the scaffold method has yet to 
mimic perfectly (Thesleff, 2003).
The Cell Aggregation Method
A second approach is known as the cell aggregation method. 
This procedure is used to reconstruct bioengineered organ 
germ and has been able to produce the proper mesenchy-
mal-epithelial cell interaction during the developmental process 
that the scaffold method has failed to produce. Recent stud-
ies have reported that transplanted bioengineered mammary 
gland stem cells successfully caused organ regeneration in vivo 
with the proper structure and cellular arrangement (Zheng et. 
al, 2005). The cell aggregation method was also used to suc-
cessfully regenerate hair follicles (Zheng et. al, 2005). There has 
been much research done using the cell aggregation method to 
successfully regenerate teeth with correct structures. Currently, 
this technique has only been able to create teeth with the prop-
er structure, but to date, only at a low frequency. Although the 
cell aggregation method replicated the organogenesis of bio-
logical teeth partially, a method that has a higher frequency of 
success is being sought (Nakao and Tsuji, 2008).
The Organ Germ Method
The interaction between the epithelial and mesenchymal stem 
cells in the embryo gives rise to the organ germ. It can be con-
cluded from this that to properly reproduce organs, one needs 
to reproduce the steps and conditions that created them in the 
first place. Both tooth and whisker follicle germs were used as 
a source of the disassociated epithelial and mesenchymal stem 
cells. Although there has been successful regeneration of organs 
in the past, they were all produced in vitro. The organ germ meth-
od allows for the regeneration of teeth in vivo as well as in vitro. 
Self-reorganization of the mesenchymal and epithelial 
stem cells is the first step in multicellular aggregation. Self-
reorganization is accomplished by these stem cells moving and 
adhering themselves to select cells until there is the necessary 
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equilibrium. After the proper cell configuration has been accom-
plished through self-reorganization, the next step is the initiation 
of organogenesis by the mesenchymal and epithelial stem cells. 
These stem cells regulate the morphogenesis and differentiation 
as well. It is important to note that the frequency of successful 
self-reorganization and tissue regeneration is dependent on the 
source of the stem cells used in this procedure.
In research performed by Nakao, the organ germ method 
successfully produced tooth germ with the correct structure, 
resulting in transplantation that yielded tooth growth.  Similarly, 
when growing whole teeth in vitro and then transplanting them, 
the bioengineered teeth were able to attach themselves to the 
mouth and form both nerve fibers and blood vessels from the 
implanted stem cells. This method used completely disassociat-
ed mesenchymal and epithelial stem cells to generate the nec-
essary tooth germ resulting in successful tooth transplantation 
both in vivo and in vitro.
When the experiment was first conducted, single cells from 
the incisor tooth germ at cap stage from the lower jaws of 
mice were used. These explants failed to produce a complete 
tooth, yet managed to generate bone or keratinized oral ep-
ithelium-like structures. The explants that failed to form cell 
compartmentalization at high cell density, failed to produce 
the correct tooth structure as well. To form a tooth with the 
correct cell compartmentation of epithelial and mesenchymal 
stem cells, the cells that could compartmentalize at high den-
sity were then collected and injected into the adjacent areas 
via a collagen gel drop. After just one day, there was already 
evidence of tooth germ formation with the correct compart-
mentalization of stem cells. This bioengineered tooth germ 
was then transplanted into sub renal capsules in mice. After 
transplantation, the formed tissue was observed histologically 
and was found to contain odontoblasts, dentin, enamel, dental 
pulp, Tomes’ process, root analog, alveolar bone, periodontal 
ligaments and blood vessels in the same layout as natural teeth. 
This transplantation produced successful results 100% of the 
time in 50 different transplants. 
Analysis of the regenerated teeth showed mRNA for specific 
markers for periodontal ligaments and ameloblasts. To find out 
if tooth germ taken from bioengineered teeth would also pro-
duce the same successful results, the origin of the mesenchyme 
and epithelium cells from the tooth germ of GFP-transgenic 
mice were analyzed. The mesenchymal cells derived from GFP-
transgenic mice were found to contain dental pulp and odonto-
blasts as well as produce alveolar bone and periodontal follicles, 
which are normally derived from dental follicles. The epithelial 
cells from these mice produced ameloblasts. It was also deter-
mined that bio engineered tooth germ did not develop into 
teeth as frequently as natural tooth germ. This is a distinct indi-
cation that the developmental stage of the natural tooth germ 
is vital for successful regeneration of tooth germ.
To prove that bioengineered tooth germ successfully pro-
duces teeth in vitro with the correct cell types, time-course 
images were observed. These images proved that the tooth 
germ successfully produced the necessary cell types in proper 
fashion. After successfully growing a tooth in the renal capsule, 
the next step was to check if it can be successfully transplanted 
and develop into a fully functioning tooth.  Bioengineered teeth 
were allowed to grow in the sub renal capsule for a duration of 
two weeks. After transplanting the tooth into the oral cavity of 
a mouse, there were successful results. There was formation of 
a correct tooth structure with all the components that natural 
teeth have including dental pulp, dental root, enamel, dentin, and 
periodontal ligaments. The size of these regenerated teeth was 
found to be within a 1.1-fold increase, thus ensuring that we 
have attained a method for successful whole tooth replication 
with the proper proportions as well as with the necessary com-
ponents. (Nakao et. al, 20007) 
Although these results provide us with a viable method to 
regenerate teeth successfully in mice, there are still many things 
that need to be investigated before this method can be consid-
ered for successful whole-tooth regeneration in humans. There 
are a few more things that this experiment did not determine, 
such as the hardness of the regenerated tooth and its response 
to mechanical stress (Ikeda et. al, 2008).
Although there have been no reported cases of transplant-
ing a tooth grown with the organ germ method into a human, 
there have been studies that prove that teeth grown in this 
manner and implanted in mice exhibit the appropriate hardness 
and normal function. To determine whether the regenerated 
teeth were as hard as natural teeth, the Knoop hardness test 
was performed. It is used to determine the hardness of brittle 
materials. By testing multiple times throughout the growth of 
the bioengineered teeth, the result values showed the same 
significant increase in dentin and enamel hardness as is found in 
natural teeth between three and nine weeks, proving that they 
can successfully take the place of missing teeth.
In order to determine if the regenerated tooth successfully 
replaces the missing tooth, the regenerated tooth’s response 
to mechanical stress must be examined. It is believed that in 
order to regrow a fully functioning tooth, the tooth must in-
teract with the oral and maxofacial regions by means of the 
periodontal ligament. This is because the periodontal ligament 
is known to induce alveolar bone remodeling when under me-
chanical stress (Ikeda et. al, 2008). Histochemical analysis of 
the periodontal ligament revealed a connection between the 
tooth and alveolar bone, showing the successful interaction 
between the tooth and the oral and maxofacial regions via the 
PDL. When the regenerated tooth was subjected to mechani-
cal stress, localization of osteoblasts and osteoclasts occurred. 
These cells have been found when the PDL of normal teeth 
was subjected to mechanical stress as well, proving that the 
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regenerated tooth is able to properly respond to mechanical 
stress. (Ikeda et. al, 2008)
There are those that believe the successful regeneration of 
teeth in mice does not translate into successful results in regen-
erating human teeth.  Unlike humans, mice are known to only 
grow molars and incisors separated by a toothless region known 
as the diastema. Mice also only possess one set of teeth that grow 
continuously throughout their life. Thus, mice may not be the best 
model for tooth regeneration in humans (Huysseune and Thesleff, 
2004). Being that whole teeth were successfully regenerated in 
the diastema as well as in the lower jaw-bone of mice there is 
evidence to suggest that despite notable differences between 
human and mouse mouths, the regeneration of teeth in mice is 
not exclusive to mice and may be done in humans as well.
Conclusion
Although there have been no reports of successful whole tooth 
regeneration in humans, scientists appear to be on the right track. The 
research presented above indicate that although the cell aggregation 
method is a promising technique to regenerate whole teeth, there is 
still much work to be done before this will be the treatment of choice 
to replace missing teeth. Being that a bio root composed of human 
stem cells has been reported to be successfully transplanted into 
mini pigs, there is strong reason to believe that this method may be 
applied to humans in the near future. This review highlights differences 
between mice and humans that may affect the success of regeneration 
in humans. Despite there being extensive research and roadblocks 
ahead in the development of tooth regeneration techniques, progress 
and success with model organisms has introduced an element of hope 
for science to provide cures and resolutions to damaging oral diseases 
and encourage improved overall dental health.
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In 2005, there were 1.6 million amputees residing in the US, 
with that number expected to double by the year 2050. Of that 
number, 41,000 people live with major upper extremity limb 
loss (Ziegler-Graham, et. al. 2008). The loss of a limb is a dev-
astating experience but an amputee’s quality of life can be dra-
matically improved with the use of a prosthetic device. Creating 
a truly functional prosthetic has been, and continues to be, a 
tremendous challenge. The importance of providing patients 
with advanced prosthetics and thereby enabling them to func-
tion normally can’t be understated. This is especially true for 
upper limb amputees (ULAs) who are severely inhibited in ac-
complishing even simple everyday activities. For example, trans-
humeral amputees require a prosthetic device that can provide 
full function of the elbow, wrist, and hand. The objective of this 
paper is to familiarize the reader with the current prosthetic 
technology, as well as discuss the areas where further advance-
ments are required in order to equip transhumeral amputees 
with the full range of motion, sensory input, and practicality of 
a true biological limb.
Methods
Research papers and articles were obtained primarily through 
databases such as ProQuest, Ebsco, and PubMed accessed 
through the Touro College library. Google Scholar was also 
used to search for pertinent material. Relevant keywords were 
used to mine for source material and the references found 
within them were further retrieved as additional sources. The 
librarians of Touro College were also extremely helpful in gain-
ing access to articles which aren’t publicly available via the web. 
Available Upper Limb Prosthesis
Prosthetic limbs can be classified into the following two cat-
egories: body-powered and myoelectric. The former uses har-
nesses and straps attached to the patient’s residual limb and 
body to move the artificial prosthesis. In the case of a transhu-
meral amputee, manually locking the joints would be necessary 
to switch between functions, such as movement of the elbow, 
wrist, and hand. The terminal device is usually a mechanical 
hook, but can be interchanged for many useful tools to fit the 
patient’s specific task. The approximate cost of such a device 
is about $7,000 (Resnik, et. al. 2012). This form of prosthetic, 
while inexpensive and simple to use, is limited by the patient’s 
own strength. Additional disadvantages include limited abili-
ty to perform relatively simple movements, moving only one 
joint at a time, and having an inhuman-like appearance. Even so, 
body-powered prostheses are still widely used by about 30% of 
ULAs today (Ostile, et. al. 2012).  Most patients, however, will 
choose to use the more advanced, battery powered myoelec-
tric prosthesis. One of the great advantages of this prosthesis is 
its ability to bypass the amputee’s limited strength and instead 
use an external, artificial power source to enable movement. 
Additionally, the myoelectric prosthesis uses electromyography 
(EMG) signals to control the operation of the artificial limb, un-
like the manual body-powered prosthetic. This is possible due to 
the neuro-muscular system which remains intact in the ULA’s 
residual arm even after amputation (Sudarsan, Sekaran, 2012). 
It’s this EMG signaling which allows the myoelectric prosthe-
sis to interact so seamlessly with its wearer. Unfortunately, the 
cost of a transhumeral myoelectric prosthesis can be as high as 
$100,000 (Resnik, et. al. 2012).
EMG Signaling in Myoelectric Prostheses
The nervous system is made up of billions of neurons, all 
connected throughout the body. These neurons act as a com-
munications pathway through the means of electrical signals 
and neurotransmitters at synapses. An electromyograph mea-
sures the strength of the action potentials with the use of an 
electrode placed at target skeletal muscle. Skeletal muscle is 
composed of contractible bundles of cells attached to bone. 
Abstract
The 21st century continues to produce major advancements in prosthetic limb technology. Specifically, improvements to the myo-
electric prosthesis have helped numerous upper limb amputees, especially transhumeral patients . Targeted muscle reinnervation 
surgery has allowed for more seamless control of the prosthetic device by creating new control centers for the unused nerves 
of the residual arm . Additionally, improvements in pattern recognition technology have enabled transhumeral amputees to gain 
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implanted totally beneath the patient’s skin have dramatically improved accuracy and performance of the electromyography 
readings . One of the most current and promising developments has been targeted sensory reinnervation . Preliminary studies have 
shown that this surgery can provide a dual flow of both motor and sensory information simultaneously between the patient’s 
residual limb and the prosthesis . Studies also indicate that using osseointegration surgery to connect the prosthetic device directly 
to the patient’s bone has improved its performance and made it more comfortable for the user. Finally, by undergoing extensive 
training and rehabilitation under the guidance of therapists knowledgeable with upper limb prostheses, transhumeral amputees 
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in improving prosthetic devices so that one day they can truly replace biological limbs .  
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The muscle’s contractions control skeletal movement, usually 
induced voluntarily by impulses transmitted through the neu-
ronal network to the motor neurons. The transmission occurs 
through the depolarization of the muscle fibers to generate 
an electric current, thus allowing the EMG signals to be mea-
sured (Raez, et. al. 2006). When an amputee is fitted with a 
myoelectric prosthetic, electrodes that measure EMG activity 
are placed at a single pair of flexion and extension muscles on 
the residual limb. A ULA’s myoelectric prosthesis then retrieves 
the EMG signals generated by these two muscles to promote 
locomotion. However, the prosthesis is limited to controlling 
only one joint at a time. To switch from one joint to anoth-
er (e.g. elbow to wrist), the patient must co-contract a pair of 
muscles, thereby signaling to the prosthesis to switch joints. A 
common pair used by a transhumeral amputee is the biceps 
brachii and triceps brachii. Alternatively, a patient may also use 
a remote controlled by shoulder or foot movement to switch 
joints. The strength of the EMG signal produced at these sites 
determines the prosthesis’s velocity. For example, the amputee 
may use a biceps contraction to close the prosthetic hand, and 
a triceps contraction to open it, thereby promoting movement 
singularly controlled by the patient’s nervous system. However, 
this becomes increasingly less intuitive with higher levels of am-
putation due to diminished levels of residual muscles available 
in the arm. For example, transhumeral amputees must use the 
biceps/triceps to control all distal prosthetic functions, as de-
picted in figure 1 (Cheesborough, et. al. 2015). Operation of the 
terminal device, wrist, and elbow needs to be done sequential-
ly which besides being a very slow and cumbersome process, 
also requires much cognitive oversight because the same bi-
ceps/triceps need to move even the arm muscles not natively 
controlled by them (Kuiken, et. al. 2004, Carlsen, et. al. 2014). 
To allow for more seamless use of the myoelectric prostheses, 
an innovative surgery termed targeted muscle reinnervation 
(TMR) was introduced.
Targeted Muscle Reinnervation
The concept of targeted muscle reinnervation surgery was 
first introduced in the year 2004 to help a patient with bilateral 
amputations of the shoulders gain further control of the pros-
thesis (Kuiken, et. al. 2004). TMR surgery utilizes nonfunction-
al muscles as amplifiers for the patient’s dormant nerves that 
were originally attached to the amputated limb. This enables the 
nerves to produce signals in those muscles, thus providing a 
source for intuitive prosthetic locomotion. For example, con-
ventional control of a myoelectric prosthesis for a ULA with a 
transhumeral amputation is with EMG signals from the biceps 
brachii, as well as from the triceps brachii. Granted, this may 
provide intuitive control of elbow flexion and extension, but not 
forearm supination/pronation, nor hand opening/closing. These 
movements require cumbersome mode switches because the 
limited residual muscles must control physiologically unrelated 
movements. (Cheesborough, et. al. 2015, Carlsen, et. al. 2014, 
Figure 1 Conventional myoelectric control for 
transhumeral amputation. (Cheesborough, et. al. 2015).
Figure 2 Normal anatomy of the human body (Kuiken, et. al. 2009).
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Kuiken, et. al. 2009, Zhou, et. al. 2007). Luckily, however, the me-
dian, ulnar, and radial nerves of the upper arm remain intact 
even after amputation (see figure 2), and consequently motor 
commands for the missing limb continue to travel through the 
residual nerves. Through TMR surgery, these nerves can be 
transferred to innervate other muscles in the body. Specifically, 
the median nerve is transferred to the short head of the bi-
ceps muscle to allow for hand closing (or pronation), while the 
distal radial nerve innervates the lateral head of the triceps to 
provide signaling for hand opening (or supination), as depicted 
in figure 3 (Carlsen, et. al. 2014). Ergo, through the use of TMR 
surgery patients will have gained four myoelectric electric sites 
in place of the standard two (figure 4). This allows for very in-
tuitive control of the prosthesis; attempting to flex/extend the 
elbow causes the native contraction of the long head of biceps/
triceps, while attempting to close/open the hand activates the 
short head of the biceps/lateral head of triceps which have been 
newly innervated by the median/radial nerve, respectively. Since 
there are more than one head to the biceps and triceps, one of 
each can be sacrificed as a recipient signal amplifier. This would 
not sacrifice the intuitive elbow flexion/extension signals that’s 
provided by the remaining biceps/triceps muscles with native 
innervation via the musculocutaneous and radial nerves, respec-
tively. Additionally, the four distinct EMG signals can be used to 
simultaneously control multiple joints, thus avoiding the tradi-
tional and tedious mode switching which is normally required 
(Cheesborough, et. al. 2015). While this use of TMR greatly in-
creases a patient’s control of the prosthesis, it’s still limited to 
two simultaneous degrees of freedom: elbow flexion/extension 
and hand opening/closing. Further movements like wrist rota-
tion still require cumbersome and unintuitive mode switches. 
However, by applying pattern-recognition techniques together 
with TMR surgery, substantially more motor control can be 
extracted from the reinnervated muscles (Zhou, et. al. 2007). 
Unfortunately, a difficulty that remains even post TMR surgery 
is separating the distinct amplitudes of the surface EMG signals 
on different muscles so that the prosthesis can recognize the 
intended movements of the amputee (Schultz, Kuiken, 2011). 
Additionally, further study is required to perfect the safety and 
long-term efficacy of TMR surgery, as well as making it more 
widely available to the masses.
Pattern-Recognition Techniques
Targeted muscle reinnervation provides a rich source of motor 
control information. In traditional TMR surgery, the median nerve 
is transferred to control hand closing, and the radial nerve to con-
trol hand opening. In contrast, a non-amputee’s body will normally 
use these nerves to innervate dozens of muscles in the forearm, 
wrist, hand, and fingers. The goal of pattern-recognition tech-
niques is to enable an amputee to control all these movements 
in the myoelectric prosthesis simply and dexterously. High-density 
electrode arrays are placed over the patients reinnervated target 
muscles as the muscles attempt many different motions involving 
the elbow, wrist, hand, and fingers. The specific patterns produced 
by the combined EMG signals are processed by software which 
Figure 3 Anatomy of a transhumeral amputee (Kuiken, et. al. 2009)
Figure 4 Conventional myoelectric control for transhumeral amputation, with targeted muscle reinnervation. Patients use natively innervated 
biceps and triceps to control the elbow and reinnervated biceps and triceps to control the hand (Cheesborough, et. al. 2015).
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deciphers which specific movement is being performed, hence 
the name “pattern-recognition”. Detailed mappings of EMG ampli-
tudes across the reinnervated muscle site of a TMR patient show 
distinctive patterns of activity as the subject attempts a variety of 
thumb, finger, and wrist movements. The pattern-recognition soft-
ware has been shown to be 95% accurate in predicting a patient’s 
16 intended arm movements (8 degrees of freedom). To highlight, 
without pattern-recognition the conventional myoelectric control 
methods can only use EMG amplitude at specific myoelectric con-
trol sites, and ergo can’t take advantage of the true complexity of 
information. Accordingly, the muscles reinnervated by the median 
and radial nerves operate only hand opening/closing. However, by 
using pattern-recognition software, information can be extracted 
about the subject’s desire to perform wrist flexion/extension/
rotation, and even movement of the thumb, index finger, or dig-
its (Zhou, et. al. 2007). Further investigation was accomplished in 
2009 that demonstrated pattern-recognition control for real-time 
use of myoelectric prostheses (Kuiken, et. al. 2009). A very brief 
explanation of how pattern-recognition techniques works is as 
follows: patients provide example contractions for each of the 
prosthesis movements (e.g., elbow supination, hand close, etc.), 
and the algorithm learns which EMG patterns correlate to each 
intended movement. Thus, when a patient later desires to move 
the prosthesis, the algorithm predicts the desired movement from 
the previously learned pattern of EMG signals (Cheesborough, 
et. al. 2015). This starkly contrasts to conventional EMG readings 
in that pattern-recognition doesn’t simply use EMG signal ampli-
tudes, but rather utilizes numerous EMG recordings to globally 
classify the patient’s intended movements. The use of pattern 
recognition enables TMR patients to significantly outperform con-
ventional nonpattern-recognition in the following two tasks: 1) a 
box and blocks task, and 2) a clothespin relocation task. Both of 
these tasks are validated and standardized measures of gross hand 
function first developed by occupational therapists. The box and 
blocks task requires the patient to move one inch blocks from 
one compartment to another during an allotted time period, while 
the clothespin task requires the movement of clothespins from a 
horizontal bar to a vertical bar also during an allotted time period 
(Mathiowetz, et. al. 1985, Kuiken, et. al. 2004, Miller, et. al. 2008). 
Patients moved 40% more blocks and completed clothespin re-
location in 25% less time when using pattern-recognition over 
conventional myoelectric control. Additionally, patients’ personal 
preference favored pattern-recognition over conventional control 
(Hargrove, et. al. 2013).
Electromyography Electrode Configuration
Though TMR surgery, along with advanced pattern-recognition, 
can provide vast amounts of neural information, it requires the 
use of a high density (HD) electrode array with over 125 elec-
trodes placed over the reinnervated muscles. The placement of 
these electrodes is clinically challenging, and even after placement, 
the input of electromyography signals is slow. Preliminary stud-
ies show that by using advanced electrode selection algorithms, 
the number of electrode placements can be radically reduced 
to just a dozen. These electrodes can provide sufficient neu-
ral information to classify the user’s intended movements with 
99.1% accuracy in regards to 8 basic joint movements (elbow, 
wrist rotation, wrist flexion/extension, hand open/close). In a 
16-class analysis which includes 8 additional finger movements, 
the classification accuracy was 93%. It’s important to note that 
as the number of applied electrodes decreases, exact electrode 
placement becomes increasingly more integral. Thereupon, 
it’s important to keep electrodes stably located over muscles, 
while being cautious to place them in the most accurate posi-
tions possible (Huang, et. al. 2008). Further studies show that 
by increasing electrode distance, as well as their orientation in 
regard to muscle fibers, pattern-recognition performance can 
be improved in the event of electrode shift (Young, et. al. 2011, 
Young, et. al. 2012). EMG signals are an integral mechanism for 
helping ULAs to gain full use of their myoelectric prosthesis. 
Therefore, ensuring that accurate readings can be obtained re-
peatedly and accurately is essential.
Implanted EMG Sensors
Though advancements in electrode configuration have greatly 
enhanced the accuracy of readings, they still have severe limita-
tions such as poor skin contact (thus causing electrode liftoff), 
skin impedance changes due to sweating, lack of repeatable 
electrode placement due to day-to-day donning, as well as wire 
breakages (Weir, et. al. 2009, Pasquina, et. al. 2015). Hence, de-
veloping methods to solve these multitudes of issues are of the 
upmost importance. One method showing great promise is the 
use of fully implanted sensors beneath a patient’s skin to ensure 
accurate EMG readings. These sensors are cylindrically shaped, 
and about 16 mm long (Figure 5). Each of these tiny sensors 
are capable of magnetically transmitting vast amounts of data 
directly to the retrofitted prosthesis. Furthermore, the ability 
to place these electrodes directly within residual limb muscles 
allows for stronger and more reliable signals that remain static 
despite body movement and sweating. Additionally, in the case 
of a transradial amputee these implanted electrodes present 
the possibility to record data from superficial and deep muscles 
simultaneously, allowing for more intuitive control by provid-
ing signals from the actual muscles responsible for hand and 
wrist locomotion prior to amputation (Pasquina, et. al. 2015). 
Unfortunately, a major technological issue with this system that 
still requires further research is  reducing power consumption, 
and thus enabling the patient to have a portable prosthesis 





No prosthesis can be called a true replacement of a biologi-
cal limb without providing sensory feedback to its user. Tactile 
sensation is one of the earliest developed and basic human 
senses, providing a rich source of information about environ-
mental stimuli. However, even when a patient uses an advanced 
myoelectric prosthesis they’re still reliant on their limited visual 
feedback, wherefore hindering natural control of the prosthesis. 
Surprisingly, one of the reasons why body-powered prosthe-
ses continue to see widespread use is because the wearer can 
sense its movement through the cables attached to his body 
(Marasco, et.al. 2009). Therefore, proving tactile sensory infor-
mation to the amputee is integral in providing a lifelike prosthe-
sis. Unexpectedly, a potential source for proving this feedback 
was first discovered accidentally, as an unintended result of TMR 
surgery on a bilateral shoulder disarticulation amputee. After 
undergoing TMR surgery to transfer his residual brachial plexus 
nerves to the pectoralis muscles, touching the skin overlying 
the reinnervated muscles produced sensation in different areas 
of his phantom limb (Kuiken, et. al. 2004). With this knowledge, 
the targeted reinnervation surgery was extended to include 
reattaching sensory nerves as well, dubbed targeted sensory re-
innervation (TSR). In the reinnervation surgery of a short-trans-
humeral amputee, the distal ends of the patient’s supraclavic-
ular and intercostobrachial cutaneous nerves were attached 
to the ulnar and median nerves, respectively (see figure 6). Six 
months after the operation, the patient reported sensation in 
her phantom hand when her reinnervated pectoralis muscles 
were stimulated. All modalities of cutaneous sensation were 
present including graded pressure, thermal feedback, vibration, 
and edge detection (i.e. sharp vs dull). Stimulation of each of 
these sensations within the reinnervated region was interpret-
ed by the patient as occurring in her missing hand (Kuiken, et. 
al. 2007a). Further studies have similarly shown how sensory 
feedback can be felt by an amputee post targeted reinnervation 
surgery (Kuiken, et. al. 2007b, Schultz, et. al. 2009). However, the 
above mentioned studies have been limited mainly to patients 
with shoulder-level amputations who underwent targeted re-
innervation surgery to reinnervate the brachial plexus to the 
pectoralis muscle group. Since a transhumeral amputee still 
needs the residual nerves to innervate the upper arm it’s unfea-
sible to simply transfer the brachial plexus to reinnervate the 
pectoralis muscle group. To help solve this issue, a recent study 
has attempted to extend the scope of TSR surgery to a transhu-
meral patient. By using an improved variation of the TSR surgery, 
along with an incorporated sensory feedback device, a patient 
can now feel, and accordingly coordinate, the strength of force 
applied by the myoelectric prosthesis when handling an object, 
without auditory or visual stimuli. Previously, TMR patients sim-
ply obtained sensory reinnervation directly on top of the rein-
nervated muscle sites, which can lead to over-crowding when 
placing all the necessary hardware and EMG sensors. Hence, 
the ability to place the reinnervated sensory site distant from 
the reinnervated muscle site, but close enough to be viable, is a 
tremendous advancement in creating a viable sensory feed-back 
system for myoelectric prosthesis users. During the TSR surgery, 
the transhumeral patient’s median and ulnar nerve are located 
and their high sensory nerve content fascicles isolated. These 
Figure 5 (A) Size example of an implantable electrode. (B) The 
prosthetic. (C) The magnetic coil built into the prosthetic frame that 
powers and receives EMG information (adapted from Pasquina, et . 
al. 2015).
Figure 6:  Schematics of a TR surgery. Green, arm nerves; blue, skin 
sensory nerves; dotted lines, nerves routed beneath muscles. (A) 
skin nerves were cut, and the distal ends were sewn to the hand 
nerves to provide neural conduits for the regenerating nerve fibers. 
(B) Diagrams of skin sensation provided by each nerve in the 
normal hand (Adapted from Kuiken, et. al. 2007b)
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fascicles are dissected out of the main nerve trunk, transected 
distally, and coapted to the interocostobrachial cutaneous nerve 
and axillary nerve, respectively (see figure 7). The remainder of 
the nerve trunks are used to reinnervate portions of biceps and 
triceps as done in a classical TMR surgery. In addition to creating 
two spatially separated wide spread areas with discrete sensa-
tion for individual digits in the two nerve territories, called hand 
maps (see figure 8), the patient is able to utilize this sensory 
feedback to execute tasks while operating a myoelectric train-
ing arm, without having to rely on visual guidance or auditory 
cues. Furthermore, the above mentioned over-crowding prob-
lem is alleviated with this innovative surgical technique, as the 
sensory fascicles are directed to cutaneous areas distant from 
the muscle electrode sites. In the aforementioned study, the pa-
tient showed sensory feedback when gripping and releasing a 
ball, detected the difference between small and large blocks, as 
well as their difference in stiffness. Additionally, the patient dis-
criminated between levels of applied force to the reinnervated 
area. Finally, the study demonstrated the ability to have a dual 
flow of motor and sensory information simultaneously between 
the patient’s residual limb and the prosthesis. Additionally, fur-
ther research is required to create a portable and wearable 
device that can viably transfer all the sensory and motor infor-
mation between the prosthesis and its wearer. This was a single 
case study of a transhumeral patient and further investigation 
is required to test the efficacy of TSR with a real myoelectric 
prosthesis, as well as whether the sensory pathways will remain 
long-term (Herbert, et. al. 2014, Zuo, Olson, 2014).
Osseointegration 
An unfortunate occurrence amongst amputees is prosthesis 
Figure 7: A fascicle of the median nerve (blue) is coapted to the 
intercostobrachial cutaneous nerve while a fascicle of the ulnar 
nerve (red) is connected to the cutaneous branch of the axillary 
nerve. (Herbert, et. al. 2014)
Figure 8: Transfer sensation for the median and ulnar nerve territories, mapped on transhumeral residual limb at 15 months post-operatively. 
The dots are 1 cm apart (Herbert, et. al. 2014).
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abandonment which can occur when patients refrain from 
wearing their prosthetic device due to problems including lack 
of comfort, stability, and durability. Mean rejection rates as high 
as 45% and 35% were observed for body-powered and electric 
prostheses respectively in pediatric populations, while adult 
populations had somewhat lower rates of 26% and 23%, respec-
tively (Biddiss, Chau, 2007). However, by performing an osse-
ointegration surgery which directly attaches the prosthesis to 
the patient’s bone, one avoids the need for an unwieldly socket. 
This enables the prosthesis to always fit firmly, comfortably, and 
correctly, consequently giving the patient a more natural pros-
thetic limb to mimic the amputated biological one. The implant 
system includes a threaded titanium implant, which is inserted 
intramedullary into the transhumeral amputee’s humerus bone, 
as depicted in figure 9 (Jönsson, et. al. 2011). As of yet, the FDA 
has not approved osteointegration trials for ULAs in the US, 
though one European group has successfully implanted devices 
in over 100 patients around the world (Cheesborough, et. al. 
2015). Important to note is that after the osseointegration sur-
gery, the patient must adapt to having a permanent appendage 
abutting from the limb.
Rehabilitation and Prosthesis Training
Prosthesis training during rehabilitation directly affects an indi-
vidual’s level of function, and thus providing post-op amputees 
with proper instruction on how to use their prosthetic limb 
is vital. Training with therapists knowledgeable in upper limb 
prosthetic components and control is a significant portion of 
prosthetic rehabilitation leading to functional success of the 
ULA (Carlsen, et. al. 2014). Important to note is that fitting 
a patient with a congenital upper limb absence within 11 
months of age leads to a greater acceptance than when fitted 
at an older age. Similarly, individuals fitted with a prosthetic 3 
months after injury are less likely to reject the prosthetic de-
vice than patients fitted 6 months after surgery (Biddiss, Chau, 
2007). Consequently, it’s important to fit the patient with a 
prosthetic device and start the rehabilitation process as soon 
as possible. The rehabilitation process can be classified into a 
three-phase process. Phase one promotes healing of the resid-
ual limb wound, starting at the time of injury and continuing 
until all wounds have successfully closed and are infection free. 
The length of time spent in this phase varies depending on the 
extent of the patient’s injury, but approximately three weeks 
after injury phase two begins and introduces pre-prosthetic 
training. The rehabilitation goal of pre-prosthetic training is to 
prepare the patient to receive a correctly fitting and function-
al prosthesis. This begins upon wound closure and ends with 
procurement of a preparatory training prosthesis. Patients 
will receive physical therapy to achieve improved flexibility 
and strength, as well as to educate them in avoiding incorrect 
postures that may lead to overuse injury of the upper body. 
Additionally, they learn how to perform activities of daily living, 
like writing, with just one hand when the prosthesis is unavail-
able. The third and final phase begins prosthetic training with 
the goal of the prosthesis becoming an integrated part of the 
patient’s life. The therapy’s focus is to help the amputee master 
the mechanical actions required for prosthetic control and 
eventually achieve independence in all activities of daily living. 
To help further this goal, the patient is fitted with varied types 
of prosthetic devices to gain experience accomplishing many 
different tasks so as to gauge and refine his skill sets when op-
erating diverse types of prostheses. Hence, many patients will 
own multiple prosthetic devices and will use them accordingly 
for different tasks. The amputees are also trained in how to 
care for their prosthetic devices, to put on and remove them 
by themselves, as well as perform even complicated activities 
of daily living (Smurr, et. al. 2008). The rehabilitation for a post 
targeted muscle reinnervation surgery patient is somewhat 
more complicated, since each nerve that’s being used for rein-
nervation contains numerous motor neurons. These neurons 
control many muscle fibers that work in conjunction to create 
nerve actions and thereupon move the body. For example, the 
radial nerve innervates hand extensor muscles, wrist extensor 
muscles, and supination muscles. However, a surgeon can’t be 
certain exactly which nerve fibers will reinnervate the new tar-
get muscle. Hence, the patient must first attempt to perform 
all the actions controlled by the transferred nerves in order 
to see which will actually develop and innervate the muscle. 
The first noticeable reinnervation will usually occur at about 3 
months after surgery. At this point, the patient can finally begin 
exercises to strengthen the reinnervated muscle over the next 
few months, followed by the patient learning to elicit strong, 
reliable EMG signals for the myoelectric prosthesis to receive. 
Whenever possible, the most intuitive movements that yield 
strong and reliable EMG signals will be used to move the pros-
thesis. As an example, the patient’s attempt at extension of 
the phantom hand (radial nerve) hopefully will produce the 
strongest and most physiological appropriate signal for pros-
thetic hand opening, therefore making prosthesis movement 
intuitive for the subject. Over the long rehabilitation process, 
it’s integral for the success of the patient that the occupational 
Figure 9:  Transhumeral osseointegration patient being fitted with a 
prosthetic device (A-C) (Jönsson, et. al. 2011).
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therapists, physical therapists, and prosthetists understand the 
principles of TMR, peripheral nerve distribution, specifics of 
the surgery, as well as the different possible post-op outcomes 
for each patient (Stubblefield, et. al. 2009). This will enable an 
amputee to truly gain the most from his prosthetic device and 
thereby return to functioning as fully and naturally as possible.
Conclusion
Science continues to make great strides in advancing prosthesis 
technology and thus increasing the quality of life of countless 
amputees. Electromyography signaling and targeted muscle re-
innervation surgery continues to pave the way for leading edge 
prosthetic limbs. Advanced pattern recognition software is con-
stantly being improved and perfected, while targeted sensory re-
innervation surgery stands at the forefront of current scientific 
research in providing upper limb amputees with truly advanced 
replacements for their amputated biological limbs. Of course, 
additional work is needed to improve the control algorithms so 
that the amputee may interact seamlessly with his myoelectric 
prosthesis. Additionally, further study is needed to test the effi-
cacy of wireless, implantable EMG electrodes. Osseointegration 
surgery remains a promising new method to comfortably sus-
pend a transhumeral amputee’s prosthesis. Additionally, targeted 
sensory reinnervation helps produce a real-time, dual flow of 
mechanical and sensory information between the prosthesis 
and its wearer. One of the biggest challenges remaining is to 
create a way to minimize power consumption of the prosthesis, 
while still providing its wearer with all the technology needed 
to provide the full range of motor output and sensory input of 
a real limb. Additionally, the life-time cost of providing a patient 
with a prosthesis can be astronomical and further advance-
ments are needed to lessen the cost so that it can be a viable 
clinical option. The human body is a wonder and even a simple 
task like typing on a keyboard is truly a wonderment of seamless 
interaction of neurons and muscles. Hence, though a current 
myoelectric prosthesis is indeed an advanced appendage, it’s 
still far less advanced than one’s natural biological limb. Overall, 
however, the future seems extremely hopeful in one day pro-
viding a transhumeral amputee with a fully functional prosthetic 
limb to truly replace a lost biological one. 
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On February 27th 2017, the World Health Organization 
(WHO) published a list of the top twelve resistant bacteria that 
greatly endanger human health (Press Association, 2017). Drug 
resistant and multi-drug resistant bacteria are one of the most 
serious public health threats the world faces today. Antibacterial 
resistance is the ability of bacteria to survive even in the pres-
ence of antibiotics. The development of antibiotics has made a 
great impact on the medical field by enabling doctors and health 
professionals to successfully combat many diseases. However, 
with the rise of the use of antibiotics, drug resistance has 
evolved, and according to WHO statistics, 700,000 people die 
annually from infections and diseases that have resulted from 
such resistant bacteria (Press Association, 2017).
Method
The research discussed in this paper was compiled from var-
ious published articles obtained from Touro’s online database 
including Proquest as well as PubMed’s database to research 
the actions of antibiotics, drug resistant bacteria, and the use of 
silver nanoparticles against drug resistant bacteria. 
A. Antibiotics and their mechanism of action
Antibiotics are natural or synthetic agents that fight and inhibit 
the growth of bacteria. Antibiotics are grouped into different 
classes based on their mechanism of action, and they can either 
disrupt the cell membrane, or they can inhibit cell wall synthesis, 
protein synthesis, DNA replication and repair, RNA synthesis, 
or various metabolic pathways.
1. Inhibition of Cell Wall Synthesis
Bacterial cell walls are comprised of peptidoglycan, the cytoplasmic 
membrane, and in gram negative bacteria, the outer membrane. 
The peptidoglycan, the strongest layer of the cell wall, is a netlike 
arrangement of glycan and peptide strands. The biosynthesis of 
the peptidoglycan is catalyzed by thirty different enzymes (Shah, 
2015). Transglycosylases and transpeptidases are two enzymes 
which aid in the final steps of the cell wall synthesis by adding 
new peptidoglycan units to extend the sugar chain and by link-
ing the amides of the peptide strands, respectively (Walsh, 2000). 
Numerous antibiotics, like the B-lactam class of antibiotics, target 
different steps in the synthesis of the peptidoglycan. Penicillins 
and cephalosporins act as pseudo-substrates for the penicillin 
binding proteins (PBPs), the active site of the transpeptidases, in 
order to prevent the cross-linking of the PG.  The cross-linking 
action of the transpeptidases is responsible for the strength of 
the PG, and without it, the bacterial cell wall is significantly weak-
er and therefore more prone to lysis. When B-lactam antibiotics 
bind to the PBPs, the oxygen from the serine residue located near 
the PBP attacks the B-lactam ring and forms a penicilloyl-enzyme 
complex. The serine is then acylated by the b-lactam which thus 
inactivates transpeptidases (Walsh, 2000). Consequently, trans-
peptidases can no longer bind to the substrate, and therefore the 
enzyme cannot complete the cross linking action (Andersson, et. 
al. 2001) (Bockstael, Aerschot, 2009). 
Vancomycin is a drug that belongs to the glycopeptide class of 
antibiotics. Like the B-lactams, vancomycin targets the synthesis 
of the cell wall. However, rather than targeting the enzymes 
involved in the production of the PG, vancomycin targets the 
substrate by making five hydrogen bonds with the D-ala-D-ala 
terminus of each uncross-linked peptidoglycan (Lange et. al. 
2007).  By blocking the substrate of both the transpeptidases 
and transglycosylases, vancomycin and other glycopeptides in-
hibit the cross linking of the peptidoglycan, resulting in a weaker 
cell wall that is subject to osmotic lysis (Walsh, 2000)
2. Disruption of the Cell Membrane
The cell membrane of bacterial cells are semipermeable mem-
branes that are comprised of phospholipids, carbohydrates, and 
proteins.  Antibiotics like polymyxins and lipopeptides have the 
ability to disrupt the bacterial cell membrane. Polymyxins like 
colistin are cationic cyclic peptides that bind to the phospholip-
ids in the bi-layer. By interacting with the negatively charged cell 
membrane (Taneja, Kaur, 2016), colistin disrupts the bacterial cell 
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membrane by displacing divalent ions, like calcium and magne-
sium, from the lipids present on surface of the cell. The disruption 
of the cell membrane causes cell leakage and ultimately cell death 
(Biswas, et. al, 2012) (Bockstael, Aerschot, 2009). Similarly, amino-
glycosides can also displace these divalent ions to increase the 
membrane’s permeability, resulting in the leakage of intracellular 
content and cell death (Lange, et. al. 2007).
Furthermore, daptomycin, a lipopeptide, can also disrupt the 
cell membrane. However, rather than displacing calcium and 
magnesium ions, daptomycin forms pores in the membrane by 
inserting its tail into the membrane. Consequently, there is a 
potassium efflux, and as potassium ions leave the cell, cell de-
polarization occurs (Shah, 2015) (Bockstael, Aerschot, 2009). 
Besides for causing cell depolarization, daptomycin can also 
inhibit the production of lipoteichoic acid which is responsi-
ble for regulating both cell division and cell shape (Bockstael, 
Aerschot, 2009). 
3. Inhibition of Protein Synthesis
In addition to targeting the synthesis of the cell wall and cell 
membrane, other antibiotics exert their effects by inhibiting 
bacterial protein synthesis. Ribosomes are essential to the syn-
thesis of proteins as they translate the genes from mRNA into 
proteins through the three steps of initiation, elongation, and 
termination. The bacterial 70S ribosome has two subunits: the 
50s subunit and the 30s subunit. While the large 50s subunit 
contains a 5S rRNA, a 23S rRNA and 36 proteins, the small-
er 30S subunit is comprised of 16S rRNA and 21 proteins. 
Antibiotics can exert their effects by targeting either the 30S or 
the 50S subunit (Bockstael, Aerschot, 2009). 
Targeting the 30S Subunit
The 30S subunit contains the site where the codons are recog-
nized by their corresponding tRNA anticodons. Transfer RNAs 
help with the process of translation by acting at either the A site, 
the P site, or the E site (Lange, et. al. 2007). 
Aminoglycosides like gentamicin and tobramycin interact with 
the 16s RNA located in the 30S subunit. By hydrogen bonding 
with the substituents on the aminoglycoside cyclitol ring in the 
16s RNA located at the A site, mistranslation occurs, and as a 
result abnormal proteins are produced. These aberrant proteins 
are then incorporated into the bacterial cell wall, ultimately re-
sulting in a weak cell wall which is associated with cell leakage and 
further penetration of the drug into the cell (Lange, et. al. 2007) 
(Bockstael, Aerschot, 2009).
Tetracyclines bind to the 30s subunit (Lange, et. al. 2007) to 
prevent the elongation step of protein synthesis. By blocking the 
substrate of the incoming tRNAs, these antibiotics prevent new 
amino acids from being added to the growing amino acid chain 
(Shah, 2015). 
Targeting the 50S Subunit
While the antibiotics discussed above inhibit protein synthesis 
via the 30S subunit, many other drugs have the ability to affect 
protein synthesis through the 50S subunit. The 50S subunit is 
associated with peptidyl transferase activity as well as the for-
mation of peptide bonds (Bockstael, Aerschot, 2009).
Chloramphenicol, a broad spectrum antibiotic that is used 
against both gram positive and negative bacteria, binds to the 
23s RNA on the 50S subunit. This class of drugs inhibits the for-
mation of peptide bonds by preventing the tRNAs from binding 
to the A site (Bockstael, Aerschot, 2009). 
The antibiotic class of macrolides binds to the 23S rRNA. 
Consequently, the exit tunnel that helps transport the peptide 
away from the peptidyl transferase center is blocked. 
Lincosamides, like clindamycin, attack both the A site and P site 
located in the peptidyl-transferase center (Lange, et. al.2007). 
As a result, lincosamides inhibit the initiation of peptide chain 
synthesis and detach tRNAs from the ribosome (Bockstael, 
Aerschot, 2009). 
Streptogramins affect protein synthesis and the action of the 
peptidyl transferase center activity by binding to the 23S subunit 
on the 50S ribosome. There are two types of streptogramins, 
Type A and Type B. While type A prevents the step of elonga-
tion by blocking the substrate of the peptidyl-transferase center, 
type B stimulates the premature release of incomplete peptide 
bonds by inhibiting peptide bond synthesis (Bockstael, Aerschot, 
2009).
Oxazolidinones act by targeting the 50S subunit. The drug 
linezolid binds to the 23S subunit located on the 50S ribosome. 
By binding to this subunit, the formation of the complex be-
tween tRNA, mRNA, and the ribosome is blocked which thus 
inhibits the formation of the first peptide bond. If the complex 
is already formed, oxazolidinones can exert their effects by pre-
venting the translocation of the peptidyl RNA from the A site to 
the P site (Bockstael, Aerschot, 2009).
4. Inhibition of Metabolic Processes
Some antibiotics can interfere with various metabolic pro-
cesses that are vital to the survival of bacteria. Folate and folic 
acid are essential for the synthesis of purines, thymidines, and 
some amino acids (Lange, et.al. 2007). The folic acid pathway 
is catalyzed by dihydropteroate synthetase and dihydrofolate 
reductase, two enzymes which aid in the production of 7, 8 
dihydropteroate and tetrahydrofolate, respectively (Shledon Jr., 
2005). Drugs like sulphonamide and trimethoprim block dif-
ferent steps in this folic acid pathway, and while sulphonamide 
competitively binds to p-aminobenozic acid in order to prevent 
the actions of dihydropteroate synthetase, trimethoprim binds 
to the enzyme dihydrofolate reductase to prevent the reduction 
of dihydrofolic acid to tetrahydrofolic acid (Bockstael, Aerschot, 
2009) (Sheldon Jr., 2005). 
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5. Inhibition of DNA Replication
Topoisomerases I, II, III, and IV are enzymes that are essential 
for DNA replication in bacterial species (Walsh, 2000). Bacterial 
DNA is negatively supercoiled, and during DNA replication, 
topoisomerase II, DNA gyrase, removes positive supercoils, 
breaks the double bond, and decreases the linking number by 
two. Furthermore, during DNA replication, topoisomerase IV 
unlinks the daughter chromosomes (Bockstael, Aerschot, 2009). 
Topoisomerases II and IV are vital for DNA topology, replica-
tion, and decatenation, and quinolone antibiotics target these 
enzymes. By interacting with the complex formed between DNA 
and DNA gyrase, quinolones make conformational changes that 
affect the activity of both topoisomerases II and IV, and as a result, 
DNA replication is blocked (Bockstael, Aerschot, 2009).
The process of transcription, the transferring of genes from 
DNA to mRNA, is mediated by the multi-subunit enzyme RNA 
polymerase. The antibiotic rifamycin targets DNA transcription 
by binding to the beta subunit of RNA polymerase. Rifamycin 
blocks the entry of the first nucleotide, thereby blocking the 
action of RNA polymerase and inhibiting mRNA synthesis 
(Bockstael, Aerschot, 2009). 
B. Mechanism of Resistance
Resistance can be classified as either intrinsic or extrinsic. 
Intrinsic resistance is resistance that is inherent to a specific 
species of bacteria. For example, the bacteria belonging to the 
genus of Enterobacter, Klebsiella, and Escherichia coli are all re-
sistant to methicillin, clindamycin, and vancomycin (James, 1999). 
Various species of bacteria all differ in the variation of their 
cell walls, efflux pumps, and biofilms, all of which lends itself to 
different bacteria’s innate resistance to certain drugs (Sheldon 
Jr., 2005).  
Extrinsic or acquired resistance, on the other hand, arises 
when bacteria acquire new resistance to numerous drugs via 
different mechanisms. Resistant bacteria can degrade and modify 
enzymes, alter the targets of antibiotics, change the permeability 
of their cell wall, or alter metabolic pathways to prevent drugs 
from penetrating and affecting their cells (Sheldon Jr., 2005). 
1. Enzymatic Degradation or Alteration
Some bacterial species can resist a wide array of drugs by enzy-
matic degradation and alteration. By producing an enzyme that 
destroys an antibiotic, bacterial species can cause various antibi-
otics to become ineffective. Antibiotics like penicillins, carbapen-
ems, and cephalosporins all contain a B-lactam ring which binds 
to PBPs on the peptidoglycan to prevent cross linkage of the 
cell wall (James, 1999). In response, various bacteria produce 
different classes of B-lactamases to hydrolyze the four mem-
bered B-lactam rings and thereby inactivate these antibiotics 
(Sibanda, Okoh, 2007). 
Similar to the B-lactamases, the aminoglycoside modifying 
enzymes (AMEs) are enzymes that cause bacterial resistance to 
aminoglycosides. Some microorganisms can produce enzymes 
that modify drugs. Aminoglycosides like kanamycin, gentamicin, 
streptomycin, and neomycin can either be acylated, adenylated, 
or phosphorylated by aminoglycoside acetyltransferase, adenyl-
transferase, and phosphoryltransferase. Consequently, the mod-
ified antibiotics can no longer exert their antibacterial effects 
(James, 1999) (Gabani, et. al 2012). 
2. Alteration of Targets
 In order to have a combative effect on bacteria, antibiotics must 
bind to their intended receptors. Therefore, in response to vari-
ous antibiotics, bacteria can reduce the affinity of the antibiotics 
by modifying the structure of the drugs’ active site. Different bac-
terial species like methicillin-resistant Staphylococcus aureus and 
Streptococcus pneumoniae produce new penicillin binding pro-
teins, PBP2a and PBP2b respectively, in the presence of antibiotics. 
These modified active sites have a lower affinity for B-lactams 
which, in turn, prevent the drugs from properly binding and having 
an antibacterial effect (James, 1999). Furthermore, substituting at 
least one amino acid in the PBP can result in a lower affinity of the 
drug, and as a result the bacterial cell wall is not destroyed by the 
antibiotic (Gabani, et. al. 2012) (Sibanda, Okoh, 2007).
In different species of bacteria, the N^6 amino group of an adenine 
residue located in 23S rRNA is methylated, and as a result bac-
terial resistance to macrolides, lincosamides, and streptogramin 
B arises. The mechanism behind this resistance is associated with 
the reduced affinity of the binding sites that results from con-
formational changes from the methylation (Sibanda, Okoh, 2007). 
3. Alteration of Permeability
In addition to altering the targets of antibiotics, drug resistant 
bacteria can modify the permeability of their cell wall in order 
to prevent or decrease the entrance of various drugs into the 
cell. A drug’s concentration in the bacterial cell determines the 
efficacy of the drug on the pathogen, and it is through both 
porins and efflux pumps that drug resistant bacteria have the 
ability to decrease the amount of drug that reaches the cell 
(Lange, et.al. 2007) (James, 1999) (Sheldon Jr., 2005).




Porins are protein channels that exist solely in the outer mem-
branes of gram negative bacteria.  These channels are highly 
specific, and depending on size, shape, and charge, certain mole-
cules can pass through to the inside of the cell. Being hydrophilic 
molecules, antibiotics easily enter the cell through these protein 
channels. Research has shown that when bacteria lose porins in 
their outer membrane, drug resistance emerges since less of the 
antibiotic can enter into the cell. For example, when the amount 
of OPrD porins were decreased in Pseudomonas, the imipenem 
class of antibiotics could not enter the bacterial cell. Similarly, 
resistance to imipenem and meropenem occurred after the 
amount of 29-kDa Porins was reduced in Acinetobacter bau-
mannii. Multi-drug resistant bacteria like Klebsiella pneumoni-
ae also display resistance to cephalosporins and carbapenems 
after losing OmpK35 and OmpK36, outer membrane proteins 
(Santajit, Indrawattana, 2016). 
Efflux Pumps
Efflux pumps actively transport drugs out of the bacterial cell 
thereby decreasing the intracellular concentration of different 
antibiotics. There are five different categories of efflux pumps 
that exist in either gram positive or gram negative bacteria. The 
ABC, RND, MFS, SMR, and Multidrug and toxic compound ex-
trusion family transporter efflux pumps all bind to the drug in 
the phospholipid bilayer, and thereafter export it out of the cell 
to different locations. While gram positive bacteria transporters 
work by pumping the drug out of the cell across the cytoplasmic 
membrane, gram negative efflux pumps can either extrude the 
antibiotic across the membrane and into the periplasmic space, or 
directly into the external medium. As these efflux pumps quickly 
extrude the antibiotics out, the concentration of antibiotics can-
not accumulate to a high enough level to have an antibacterial 
effect (Zgurskaya, 2002) (Lomovskaya, Watkins, 2001).
4. Altered Metabolic Pathway
Resistant bacteria have come up with alternate routes to obtain 
metabolic products that are blocked by antibiotics. The folic acid 
pathway produces pyridine thymidylate, an essential molecule in 
the synthesis of DNA.  In order to circumvent antibiotics that 
target the folate pathway, Enterococcus either uses folinic acid 
from its host cell, or mutates to have the ability to produce 
thymine (Mambrio-Jones, Hoek, 2010) (Sheldon Jr., 2005).
Discussion: 
C. Combating Drug Resistance
According to statistics, it is predicted that an estimated 10 
million people will die from drug-resistant bacterial infections 
by 2050 if no viable solution is discovered (Press Association, 
2017). Therefore, finding effective treatments for drug resistant 
bacteria is of extreme importance.  Over the last few years, 
much research has been done to determine proper treatments 
for such deadly infections. This paper will discuss the effective-
ness of silver nanoparticles against drug resistant bacteria. 
1. Silver Nanoparticles
Silver is widely known for its antimicrobial properties, and 
therefore, silver nanoparticles (Ag NPs) have been widely 
studied as a potential antibacterial agent against drug-resistant 
bacteria. Various studies on different strains of bacteria were 
performed to uncover the antibacterial effects of Ag NPs. More 
specifically, the studies focused on the size, dose, and shape of 
these silver particles coupled with the potential toxicity they 
pose to human cells. 
There are various methods to create nanoparticles. Ag NPs 
can be synthesized into different shapes and sizes via physical 
processes like laser ablation, evaporation, and condensation, or 
through chemical processes like hydrazine, sodium borohydride, 
and green synthesis (Nurani, et.al. 2015). 
1. Mode of Action of Silver Nanoparticles
After determining the bactericidal properties of silver nanopar-
ticles, the mechanism behind their antimicrobial effects was 
studied. Various studies using transmission electron microscopy 
(TEM) and other methods verified that Ag NPs have the ability to 
cause damage to bacterial cells through a wide array of different 
mechanisms. 
A Kirby-Bauer sensitivity test was performed, and by using var-
ious antibiotic discs with different silver resistant bacterial strains, 
the zone of inhibition was measured. It was found that the bac-
teria showed modified susceptibility to cephalosporins, glycopep-
tides, aminoglycosides, and fluoroquinolones, thereby indicating 
the mechanism of action of Ag NPs. Based on the action of these 
antibiotics and the bacteria’s altered zone of inhibitions, this study 
showed that these particles interact with the cell wall, proteins, 
and DNA (Lara et. al. 2010). 
Because of their small size, silver nanoparticles have the ability 
to attach to the surface of the cell membrane and disrupt its 
function. The positive charge of the Ag NPs allows them to elec-
trostatically interact with the negatively charged membrane (Lara, 
et.al. 2011). As transmission electron microscopy has shown with 
E. coli cell membranes, silver nanoparticles disrupt the cell mem-
brane, increase the cell’s permeability, and ultimately cause cell 
death (Dakal, et. al. 2016) (Mambrio-Jones, Hoek, 2010). 
Furthermore, silver has a high affinity for sulfur and phospho-
rus (Nurani, et.al. 2015). Therefore, Ag NPs can also adsorb to 
the cell membrane by interacting with thiol (SH) groups on the 
cell membrane. As a result of this interaction, a new bond be-
tween sulfur and silver (S-Ag) is formed, and the creation of 
this new bond blocks both respiration and the electron trans-
fer. Ultimately, this results in the collapse of the proton motive 
force. Without the proton motive force, the cell membrane 
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is disrupted and cell leakage followed by cell death ensues 
(Mijnendonckx, et. al. 2013). 
Moreover, after weakening the cell membrane, these parti-
cles have the ability to penetrate the bacteria (Lara, et.al. 2010) 
(Mijnendonckx, et.al. 2013). Additionally, in gram negative bacte-
ria, porins help facilitate the entry of Ag NPs into the cell. Once 
inside, these Ag NPs interact with various molecules resulting in 
further cell damage (Dakal, et. al. 2016). 
Ag NPs have a significant effect on DNA replication. Silver 
particles interact with thiol groups resulting in conformational 
changes that ultimately inhibit the activity of various enzymes 
(Mijnendonckx, et.al. 2013).  Furthermore, when silver particles 
bind to the guanine base, pyrimidine dimerization occurs, and 
DNA replication is inhibited. Silver particles can also affect pro-
tein production and translation by interacting with and subse-
quently denaturing ribosomes (Dakal, et.al. 2016). 
Moreover, silver nanoparticles are oxidized into silver ions 
upon entering the bacterial cell. Ag ions cause damage and cell 
death by interacting with lipids, proteins, and DNA. Silver ions 
also interact with nucleosides in addition to forming complexes 
with nucleic acids. Furthermore, these ions bind and dimerize 
DNA and RNA, block the expression of proteins and enzymes 
involved in ATP production, and generate free radicals (Lara, 
et.al. 2010) (Mijnendonckx, et.al. 2013). 
Reactive oxygen species can be endogenously produced from nat-
ural metabolic processes like aerobic respiration. Metal ions, like 
silver, have the ability to catalyze the generation of free radicals 
in the presence of oxygen (Mambrio-Jones,Hoek, 2010), and spin 
resonance measurements have shown that silver ions increase 
the production of reactive oxygen species (Mijnendonckx, et.al. 
2013) (Mambrio-Jones, Hoek, 2010) (Kim, et. al. 2007). These free 
radicals then act upon the mitochondrial membranes to induce 
necrosis and cell death. Furthermore, ROS oxidize lipids, nucleic 
acids, and proteins, thus disrupting the level of homeostasis by 
inducing oxidative stress and cell damage. 
In addition to increasing the production of ROS, silver particles 
also decrease the levels of glutathione, an antioxidant, by reducing 
it into glutathione disulfide. Moreover, NPs inhibit the action of 
NADPH-dependent flavoenzyme, catalase, glutathione peroxidase, 
and superoxide dismutase, anti-oxidative enzymes that quench free 
radicals. These enzymes are dependent on thiol groups, but since 
silver ions interact with thiol groups, these enzymes cannot prop-
erly quench the reactive oxygen species (Mijnendonckx, et.al. 2013) 
(Dakal, et.al. 2016).  
Phosphorylation and dephosphorylation are important signaling 
processes in bacterial growth. Phosphorylated proteins guide DNA 
replication and recombination, metabolism, and bacterial cell cycle. 
Silver nanoparticles block this signaling pathway to prevent the 
production and action of phosphorylated proteins. Furthermore, 
phosphorylated tyrosine kinases aid in the transport of exopoly-
saccharide and capsular polysaccharides. Therefore, to prevent 
bacterial growth, Ag NPs can also dephosphorylate these tyrosine 
residues (Dakal, et. al. 2016) (Shirvastava, et.al. 2007).
Effects of Silver Nanoparticles on Gram Positive 
and Gram Negative Bacteria
A great deal of controversy exists regarding the efficacy of silver 
nanoparticles in both gram negative and gram positive bacteria. 
In some studies, the Ag NPs had an equal effect in both types of 
bacteria, rendering silver as a potential broad antibacterial agent 
(Lara, et. al. 2010). However, other studies found that these par-
ticles are more effective in gram negative bacteria. This phenom-
enon is attributed to the differences in the composition of the 
cell wall in both gram positive and gram negative bacteria. The 
peptidoglycan in gram positive bacteria is very thick, averaging 
around 20-80 nm, and rigidly cross linked. Because of this thick, 
rigid membrane, there are fewer sites for the silver to adhere to, 
making it harder for the particles to adsorb and penetrate the 
cell. On the other hand, the cell wall of gram negative bacteria is 
composed of a much thinner, roughly 7-8 nm, and weaker PG. In 
addition, the membrane of gram negative bacteria contains the 
lipopolysaccharide (LPS). Because of its negative charge, the LPS 
increases the silver nanoparticles’ ability to successfully bind to 
the cell’s surface. The thinner and weaker PG coupled with the 
negatively charged LPS makes gram negative bacteria more sus-
ceptible to silver nanoparticles (Feng, et.al. 2000) (Shirvastava, 
et.al. 2007) (Dakal. et.al. 2016). 
2. Size of  Silver Nanoparticles
Particle size, shape, and dose all contribute to the efficacy and 
toxicity of silver particles. Extensive research has been done in 
attempt to uncover the antibacterial effects of different sized 
Ag NPs. Using the disk diffusion method, one study compared 
the efficacy of different sized nanoparticles against both gram 
positive and gram negative bacteria. The relationship between 
size and efficacy of Ag NPs has been extensively researched, and 
it was concluded that the two are inversely related; the small-
er the diameter of the particle, the more effective it is against 
drug-resistant bacteria. The efficacy of smaller nanoparticles 
compared to larger NPs can be attributed to the relationship 
between surface area and size. Surface area and particle size is 
inversely related; the smaller the particles are, the larger their 
surface area is (Rai, et. al. 2014). As a result of the increased 
surface area, the smaller particles can interact with the bacterial 
cell more efficiently (Rai, et.al. 2009) (Haider, Kang, 2015). 
3. Dose of Silver Nanoparticles
After determining the mode of action of Ag NPs, researchers 
began to study the dose required to have a bactericidal effect. By 
using various doses, 0.0, 6.25, 12.5, 25.0, and 50.0 mM, against dif-
ferent strains of bacteria, it was found that dose and antibacterial 
effect were directly related; the higher the dose of the Ag NPs, 
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the more effective they were. The highest dose, 50.0 mM, was the 
most successful at killing bacteria (Lara, et.al. 2010). Furthermore, 
the dose required to have a combative effect was found to be 
bacteria specific for each genus (Morones, et. al. 2005). 
4. Shape of  Silver Nanoparticles
In addition to amount and size, shape also plays a role in the 
efficacy of the silver nanoparticles against drug-resistant bacteria. 
Facets are flat surfaces that are present on geometric shapes. 
Because of their large densities, facets have a higher surface 
reactivity, and therefore Ag NPs with more {111} facets, facets 
that are cut through the x, y, and z planes, have a greater effect 
against bacteria (Mambrio-Jones, Hoek, 2010). Some research has 
shown that triangular shaped particles are more effective than 
both sphere and rod shaped particles at combating drug resistant 
bacteria.  The increased surface area and antibacterial effect of 
triangle shaped particles can be due to their geometric structure 
which contains numerous facets (Mambrio-Jones, Hoek, 2010) 
(Raza, et.al. 2016) (Pal, et.al. 2007) (Mijnendonckx, et.al. 2013).
However, other research found contradictory results. Using 
the disk diffusion method, the zone of inhibition of Pseudomonas 
aeruginosa was measured with the use of five different sized 
and shaped particles: S1, S2, S3, S4, and S5, was measured. While 
S1, S2, S3, S5 were all sphere shaped varying in size, S4 was 
triangular shaped. After placing the particles in the center of 
the sampled bacteria on an agar plate, the zone of inhibition of 
S2, the smallest sphere particle, was 1.5 mm, while the zone of 
inhibition for the triangular shaped particles was 1.4 mm. This 
demonstrated that the smallest sphere particle had a greater 
effect than the triangular shaped one (Raza, et.al. 2016).  Using 
x-ray diffraction, it was determined that the smaller spherical 
shaped particles also contained high atomic density facets that 
are found in triangular shaped Ag NPs which evidently contrib-
uted to the sphere’s greater bactericidal effect. Furthermore, 
the sphere shaped Ag NPs acted as acids and interacted with 
bases, sulfur and phosphorus containing compounds, to cause 
damage to both the cell membrane and DNA (Raza, et.al. 2016). 
5. Toxicity of Silver Nanoparticles
The toxicity of any antimicrobial agent is a major issue of con-
cern, and despite silver particles’ potential to act as an antimi-
crobial agent, at certain levels, silver nanoparticles can be toxic 
to all mammals, including humans.  Research has shown that Ag 
NPs stimulate an immune response and induce apoptosis via the 
JNK and ROS signaling pathways. As indicated by the levels of 
glutathione, silver particles induce oxidative stress by decreas-
ing the amount of the glutathione in the body. Additionally, due 
to their high surface area, Ag NPs can also generate free radicals 
from the respiratory chain. This imbalance between ROS and 
antioxidant levels results in damage to both lipids and proteins 
(Arora et.al. 2008) (Mambrio-Jones, Hoek, 2010). Silver NPs 
also interact with the mitochondria to increase oxidative stress 
and to disrupt ATP production, ultimately causing damage to 
DNA. Ag NPs also affects protein folding. This increased stress 
in the cell leads to cytotoxicity and apoptosis. Furthermore, Ag 
NPs can enter the nucleus and induce genotoxicity by causing 
DNA mutations, base damages, and strand breaks. Finally, these 
particles induce carcinogenesis by activating different signaling 
cascades and inflammatory responses (Dakal, et.al 2016). 
In a few studies, it was found that the dose of Ag NPs needed 
to induce apoptosis was different from the dose required to stim-
ulate necrosis, 0.78-1.56 vs. 12.5 μg. Therefore, it was concluded 
that a safe dosing range of silver can be determined (Mambrio-
Jones, Hoek, 2010). However, a contradictory conclusion was 
reached by AshaRani et. al who found silver nanoparticles can be 
toxic to humans at any dose (AshaRani et.al. 2009) (Mambrio-
Jones, Hoek, 2010).  Therefore, due to this discrepancy, further 
research in regards to the toxicity of Ag NPs must be conducted.
Figure 2 
(Dakal, et.al. 2016)
1 . The mode of action of Ag NPs:
2 . Adsorption to cell surface
3 . Penetration into the cell to cause damage to various biomolecules 
4 . Generate ROS




a) Bacterial cells before treatment of Ag NPs
b & c) Cells after use of Ag NPs
NPs attach to the surface of cell and penetrate inside the cell.
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6. Resistance to Silver Nanoparticles
As is the case with antibiotics, bacterial resistance to silver is a 
major concern. When bacteria are exposed to silver nanopar-
ticles, it results in the natural selection of bacteria, thus causing 
bacterial resistance to silver particles.  
Bacterial resistance to silver NPs can be encoded in the plas-
mid or in the chromosome as it is seen in both Salmonella and E. 
coli respectively (Mambrio-Jones, Hoek, 2010). In Salmonella, the 
resistance to silver ions is attributed to nine genes on the plasmid. 
Furthermore, resistance is also associated with the SilCBA and 
SilP efflux pumps, the SilE and SilF periplasmic binding proteins, 
and in Escherichia coli porin loss. However, resistance to silver 
nanoparticles as a result of a one point mutation is not very com-
mon because of the complexity of silver’s actions (Chopra, 2007).
Additionally, since silver nanoparticles have a high surface area, 
they can aggregate and combine together, causing them to lose 
their antibacterial effect (Nurani, et.al. 2015) (Beyth, et.al. 2015). 
Furthermore, because of its high surface energy, Ag NPs can be-
come contaminated by the air, and therefore Ag NPs are syn-
thesized with either chitosan, alginate, or gelatin, biodegradable 
polymer matrixes, to prevent their oxidation (Nurani, et.al. 2015). 
7. Combination of antibiotics and AG NPs
The synergy of two drugs or compounds has the potential to 
successfully combat drug-resistant bacteria by acting through 
different mechanisms. Therefore, after determining the bacteri-
cidal effect of silver nanoparticles, many researchers attempted 
to determine the effects of the use of Ag NPs in conjunction 
with the use of antibiotics against different strains of bacteria. 
To determine the synergy of Ag NPs with drugs, silver particles 
were used with amoxicillin against samples of E. coli. By com-
paring the minimum inhibitory concentration of various doses 
of silver nanoparticles alone, the use of different amounts of 
amoxicillin by itself, in addition to the combined effects of both 
silver NPs and amoxicillin, the advantages of combination ther-
apy was identified.  
The combined effect of amoxicillin and Ag NPs was seen 
to have a greater bactericidal effect than each of them alone. 
Furthermore, when the two were administered together, a lower 
dose of both amoxicillin and silver nanoparticles were needed to 
stimulate an antibacterial effect as opposed to when each one 
was given alone (Allahverdiyev, et. al. 2011) (Li, et. al 2005). 
The success for this synergy can be attributed to a few differ-
ent theories. With combination therapy, the two compounds or 
drugs that are used usually target different steps, pathways, or 
enzymes. Therefore, if bacteria resist the action of one antibiot-
ic, the other compound can still exert its antimicrobial effects 
through a different non-resistant mechanism.
Additionally, in non-resistant bacteria, the synergy of the two 
can be attributed to the chelation reaction that occurs between 
both the hydroxy and amino groups of the B-lactam and the Ag 
NPs. The binding between the silver and the amoxicillin in addi-
tion to the binding between the antibiotic with other drug par-
ticles resulted in the formation of a new compound. This newly 
synthesized antimicrobial agent, containing silver on the inside 
and amoxicillin on the outside, attaches to the surface of the cell 
membrane and causes more damage because of the synergy of 
the two compounds. Additionally, the amoxicillin disrupted the 
cell wall which increased the penetration of the Ag NPs into the 
cell.  Moreover, from this chelation reaction, silver nanoparticles 
prevent DNA from unwinding, thus resulting in further damage 
to bacterial DNA (Li, et. al. 2005) (Allahverdiyev, et. al. 2011).
Furthermore, silver nanoparticles can be used as a drug carri-
er. While antibiotics are usually hydrophilic, silver nanoparticles 
are hydrophobic. Therefore, these nanoparticles can interact 
with the hydrophobic bacterial cell membrane more easily than 
antibiotics, enabling the transport of hydrophilic antibiotics to 
the bacterial cell surface (Li, et. al. 2005). 
Conclusions
This paper attempted to explain the mechanism of action and 
mechanism of resistance of antibiotics and drug resistant bacte-
ria, respectively. As antibiotic resistance continues to emerge, re-
searchers are constantly searching for new antimicrobial agents. 
Silver nanoparticles have gained much attention as a possible 
tool in combating drug resistant bacteria, and studies have prov-
en the efficacy of Ag NPs to induce cell damage and cell death. 
However, despite the growing potential of silver nanoparticles, 
Figure 4
(Li, et. al. 2005)
The formation of a new antimicrobial agent through the chelation 
reaction between amoxicillin and silver nanoparticles
Figure 5
(Allahverdiyev, et. al. 2011)
The mechanism of action of the combination of B-lactam antibiotics 
with silver nanoparticles is shown:  The newly formed antibacterial 
agent interacts with and destroys the surface of the cell. The Ag NPs 
also prevent DNA from unwinding.
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further research must be conducted before implementing silver 
nanoparticles into clinical trials as a promising way of replacing 
or supplementing the currently used antibiotics. 
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The development of a drug is a process of converting a biologi-
cally active compound into a product that is safe and effective, it 
is a long and expensive process. The performance of a drug, the 
efficiency of the drug in carrying out the desired action, is depen-
dent on the drug’s properties. Chemical and physical properties 
of a drug determine the drug’s ability to react with the necessary 
components along the path to achieving the desired effect. One 
of the factors determining a drug’s performance and effectiveness 
is the aqueous solubility of the drug (Gareth, 2007).
Solubility of a Compound
IUPAC defines solubility as the composition of a saturated 
solution in terms of the amount of solute in proportion to 
solvent (McNaught, Wilkinson, 2006). Solubility is the term 
used to describe a solid, liquid, or a gas’s ability to dissolve in 
a solvent. Aqueous solubility of a molecule changes depending 
on the electrostatic charge of the molecule and the degree of 
ionization. The dipoles in the water molecules are attracted to 
the charged molecules forming a shell around the molecule and 
solvating it (Trevor et.al. 2015).
Solubility of a compound depends also on its structure and 
polarity. Polar groups can hydrogen bond with water molecules 
and be solvated, nonpolar groups are insoluble in aqueous solu-
tion. Therefore, the aqueous solubility of a compound increases 
as the number of polar groups on the compound increases. In 
addition, if the polar groups on a compound have the ability to 
ionize in water, the compound will be further soluble. Lipid sol-
uble compounds are those with more nonpolar groups and they 
may contain functional groups such as benzene rings, ethers and 
esters. Amphipathic compounds with polar and non-polar parts 
are soluble in both aqueous and lipid solvents (Gareth, 2007). 
Drug Solubility
Solubility is a fundamental property that must be considered 
when evaluating a drug. The solubility of a drug can range from 
fully soluble, like ethanol in water, to poorly soluble, often referred 
to as insoluble (Clugston, Fleming, 2000). The Biopharmaceutics 
Classification System (BCS), is a guide from the U.S. Food and 
Drug Administration and is used to regulate and classify drugs 
based on aqueous solubility and membrane permeability. Class 
I drugs have high aqueous solubility and high membrane perme-
ability, Class II drugs have low aqueous solubility and high mem-
brane permeability, Class III have high aqueous solubility and low 
membrane permeability, and Class IV drugs have low aqueous 
solubility and low membrane permeability. Solubility of a drug is 
determined based on the drug’s solubility over a pH range of 1 to 
7.5 and is considered very soluble if the highest dose strength is 
soluble in <250 ml of water. The membrane permeability of a drug 
is measured by the extent of absorption and a drug is considered 
highly permeable when the absorption in humans is > 90% of an 
administered dose (FDA, BCS, 2016). Since cells typically contain 
65% water, a drug must be water soluble to be effective. A drug 
must be absorbed before entering the bloodstream in order for 
the drug to be transported via the systemic circulation to its site 
of action. The more soluble the drug the greater amount of ab-
sorbed drug in the bloodstream. More drug in the bloodstream 
increases the gradient between the bloodstream and the extra-
cellular fluid, in this way diffusion of the drug from the blood to 
the extracellular fluid will be facilitated (Trevor et. al. 2015). In 
addition, the more water soluble the drug the higher the bioavail-
ability (Gareth, 2007). The amount of drug that is absorbed by the 
bloodstream, divided by the amount that was administered, is the 
bioavailability of that drug administered in that specific manner. 
Drug absorbed / drug administered = bioavailability of the drug 
(Trevor et. al. 2015).
Oral drugs are the most common form of drug administration. 
They are easy to administer, are less specific in their sterility re-
quirements, they are most cost effective, have a high patient com-
pliance, and there is flexibility in the dosage form. For this reason 
many pharmaceutical companies prefer to produce bioequivalent 
oral drugs. The difficulty with oral bioequivalent drugs is their low 
aqueous solubility and therefore low bioavailability. Oral drugs 
must first dissolve in the aqueous gastric fluid in order to be 
transported to the site of action. Therefore, solubility of a drug is 
an important factor in determining the concentration of a drug 
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that is required to achieve a desired response. More than 40% of 
pharmaceutical developments are poorly soluble in water. Low 
solubility of a drug slows the absorption rate, decreasing the bio-
availability. Thus, solubility enhancement methods are necessary. 
Increasing a drug’s solubility is a challenge faced by the drug de-
velopment industry, especially the solubility of oral drugs (Savjani 
et. al. 2012). Increasing the solubility of Class II drugs that have 
low solubility and high permeability would be very productive. 
The rate limiting step for Class II drugs, according to the BCS, is 
the insolubility of the drug, therefore increasing the solubility will 
increase the bioavailability of those drugs. 
There are many methods that are currently used to increase 
the solubility of new chemical entities (NCE’s). There are phys-
ical and chemical modifications that can be made to a drug to 
increase its solubility. Particle size reduction can be employed, as 
well as solid dispersion, nanosuspension, colloidal particles, and 
changes to the crystal form. Additionally, chemical changes to pH 
as well as complexation and salt formation affect the solubility 
(Savjani et. al. 2012). 
Other methods include the use of surfactants, micelles, lipo-
somes and inclusion complexes (Gareth, 2007). These methods 
utilize the hydrophobic effect in increasing the solubility of a mol-
ecule. Cyclodextrins and cyclodextrin derivatives form inclusion 
complexes with insoluble drugs. Inclusion complexes apply guest-
host chemistry in the formation of the complex. This paper will 
focus on cyclodextrins and cyclodextrin derivatives as a method 
to increase the solubility of a poorly soluble drug.
Methods
This study was completed by analyzing various articles collect-
ed from databases including Touro Library and PubMed. The re-
search collected mainly explored cyclodextrins and their ability 
to form guest-host complexes.
Discussion: 
Cyclodextrin and Cyclodextrin Derivatives 
Cyclodextrins (CD’s), and their derivatives are amphipathic mol-
ecules capable of forming guest-host complexes with drug mol-
ecules. The complex improves the drug solubility and ultimately 
the bioavailability of insoluble drugs. Cyclodextrins are used as a 
drug delivery system because of their potential to change phys-
ical, chemical and biological properties of a drug by forming a 
guest-host complex (Gareth, 2007). From a microscopial point 
of view, each guest molecule is micro-encapsulated leading to 
changes in the chemical and physical properties of the molecule. 
Cyclodextrins and their derivatives can improve the solubility of 
a molecule, modify a liquid substance to a powder, and mask a bad 
taste, smell or color of a drug (Chaudhary, Patel, 2013).
Cyclodextrin Structure
Cyclodextrins are cylindrical oligosaccharides typically made up 
of six, seven, or eight glucose units. The cyclodextrin ring form is 
composed of α-D-glucopyranoside units with 1→4 linkage like
in amylose (Gareth, 2007). When glucose is degraded by the en-
zyme glucosyltransferase, a product of the chain splitting can un-
dergo an intramolecular reaction to form cyclic molecules, cy-
clodextrins. Each glucose molecule in the cyclodextrin contains 
two secondary alcohols and a primary alcohol. Alpha (α), beta
(β), or gamma (γ) cyclodextrins, depending on whether they
contain six, seven, or eight glycosyl units respectively, are classi-
fied as natural cyclodextrins. Chemically derived cyclodextrins 
are hydroxypropyl-β-cyclodextrin, randomly methylated-β-cy-
clodextrin, and sulfobutylether-β-cyclodextrin. These deriva-
tives are often preferred due to their enhanced physiochemical 
and biopharmaceutical properties (Gidwani, Vyas, 2015). 
Cyclodextrin Synthesis
B. macerans is the microbe responsible for the formation of 
cyclodextrins. A method to synthesize cyclodextrins is to treat 
starch with amylase from Bacillus macerans. A crude product 
of cyclodextrin is then obtained with about 60% αCD, 20%
βCD, and 20% γCD. The product also contains small amounts
of other materials including proteins. To purify the different 
Figure 2 Top – bottom: α, β, γ CD derivatives (Gidwani, Vyas, 2015)
Figure 1 Cyclodextrin Structure (Brewster, Loftsson, 2007)
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cyclodextrin derivatives, various forms of glucosyltransferases 
are genetically engineered. These glucosyltransferases are active 
towards the production of specific cyclodextrin derivatives. The 
glucosyltransferase enzymes distinguish the six, seven, or eight 
glucopyranose units from the non-reducing end of an amylose 
and alter the linkage to produce a specific cyclodextrin deriva-
tive (Brewster, Loftsson, 2007).
Hydropathy of Cyclodextrin
Cyclodextrins are amphipathic molecules. They have hydropho-
bic and hydrophilic character. Cyclodextrins have a hydropho-
bic interior and hydrophilic exterior. The polar exterior of the 
cyclodextrin forms hydrogen bonds with the aqueous solution. 
The hydrophobic effect drives the non-polar portion of the cy-
clodextrin inwards, away from the aqueous solution, forming a 
hydrophobic cavity. This property enables the cyclodextrin to 
form guest-host inclusion complexes with hydrophobic mole-
cules (Chaudhary, Patel, 2013). 
Cyclodextrins can encapsulate many molecules. The nonpo-
lar hydrophobic molecule interacts with the nonpolar groups 
in the interior of the cyclodextrin, while the polar hydroxyl 
groups on the exterior surface of the cyclodextrin are hydro-
philic. Hydrophobic molecules the size of one or two benzene 
rings can fit into the cyclodextrin cavity. The cyclodextrins in 
the complex increase the aqueous solubility of the guest mol-
ecule, often a drug. The interactions between the cyclodextrin 
and the drug form the inclusion complex, the cyclodextrin host 
molecule with the guest drug (Tiwari et. al. 2010).
Cyclodextrin-Drug Complex 
A number of forces are responsible for the complex formation; 
hydrogen bonding, van der Waals interactions, release of con-
formational strain, and exclusion of high energy water bonds 
in the cyclodextrin cavity. Thermodynamic interactions are the 
main drive in the formation of the cyclodextrin-guest complex. 
Thermodynamically, the interaction between the cyclodextrin 
host, the guest molecule, and the solvent, must overall be fa-
vorable in order for the reaction to proceed (Chaudhary, Patel, 
2013). The cyclodextrin complex formation is usually enthalpy 
driven. In an aqueous solution the cyclodextrin cavity contains 
polar water molecules that are readily exchanged for non-po-
lar hydrophobic guest molecules. The water molecules situated 
inside the non-polar environment of the cyclodextrin cavity do 
not have a full complement of hydrogen bonds and are higher 
in energy than the water molecules outside the cyclodextrin. 
Liberating the water molecules that are enthalpy-rich, high in 
energy, is a driving force for the complexation. Sterically, the 
size and certain functional groups of the guest molecule deter-
mine the ability of the guest to fit into the cyclodextrin cavity. 
Additionally, the complex formation is dependent on the chem-
ical properties of the guest molecule (Brewster, Loftsson, 2007).
The formation of the cyclodextrin-drug complex can be 
achieved through several methods. The kneading method is 
a simple and inexpensive method and is therefore the most 
commonly used method for preparing the complex (Savjani et. 
al. 2012). This method converts the cyclodextrin into a paste 
by saturating the cyclodextrin or cyclodextrin derivative with 
water or hydroalcoholic solution. The drug is then added to the 
paste and the mixture is kneaded. The kneading can be done ei-
ther in the laboratory or using machines for large scale achieve-
ment of the complex. An additional method, the lyophilization/
freeze-drying technique, works with a solution of cyclodextrin 
and drug. The solvent in the solution is removed by freezing the 
solution and then drying it by rapidly reducing the pressure, 
generating a powder. The increased surface area of the powder 
enables considerable interactions between the cyclodextrin and 
the drug (Savjani et. al. 2012).
Cyclodextrins can increase the solubility of the guest mol-
ecule in three patterns when graphed with cyclodextrin con-
centration and drug solubility. AL profiles indicate a linear in-
crease in drug solubility as the concentration of cyclodextrin 
is increased. AP systems have a curve that deviates in a positive 
direction from the linearity indicating that the cyclodextrin is 
proportionally more effective at higher concentrations. AN 
relationships have a negative deviation from the linearity indi-
cating that at higher concentrations cyclodextrin’s effectiveness 
decreases (Brewster, Loftsson, 2007). 
Complex Dissociation
Once a product of drug-cyclodextrin is obtained, the complex 
must dissociate to release free drug upon reaching the site of 
action. When drug is encapsulated within the cyclodextrin there 
are factors that cause the complex to dissociate and release 
free drug. The drug and cyclodextrin interactions are non-co-
valent interactions that are in dynamic equilibrium, constantly 
associating and dissociating. There are two important factors 
concerning the complex’s non-covalent interactions; firstly the 
complexation strength, defined by K, and secondly the complex 
lifetime. In a 1:1 complex ratio of drug to cyclodextrin the com-
plexation strength, the K constant, is defined by the equation: 
K = kf / kt = [DCyD] / [Df] [CyDf] where kf and kt are the 
forward and reverse rate constants, [DCyD] is the complex 
concentration and [Df] and [CyDf] are free drug and free cy-
clodextrin respectively. 
Dilution is a major factor assumed to play a role in the disso-
ciation of the complex. 1000-fold dilution of a drug with a low 
binding constant to cyclodextrin decreased the complexation 
percentage from 98% to 5.7%. The fraction of complexed drug 
decreased from 99.5% to 47.5% in the presence of 1000-fold 
dilution of a drug with a high binding constant to cyclodextrin. 
Therapeutically, the complexed drug is diluted either 
in the plasma or in the aqueous extracellular fluid. A 1mL 
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drug-cyclodextrin complex administered via intravenous in-
jection is diluted in the plasma by a factor of 1:3,500, in the 
extracellular fluid the factor is 1:21,000. Dilution alone is not 
sufficient in orally administered drugs because the complex 
resides in the gastrointestinal tract before reaching the site 
of action. 
Drug binding to plasma protein is another factor responsible 
for complex dissociation. If a drug has the ability to bind to 
plasma protein the complex would dissociate further to release 
more free drug according to Le Chatelier’s principle. Drugs with 
a high binding constant to cyclodextrin that have the ability to 
bind moderately to proteins, in 1000-fold dilution, are further 
dissociated and only 31.9% complexed drug remains. If the drug 
binds more tightly to proteins the factor of complexed drug 
decreases to 8.9%. 
Furthermore, if a drug is lipophilic and can be taken up by tissue 
more drug would be released from the complex. The cyclodextrin 
would remain in the aqueous solution and drug would be taken up 
by tissue. This mechanism is especially useful in drug administered 
at a site that has insignificant dilution (Stella et. al. 1999).
The dissociation process is driven mainly by an increase of 
water molecules in the surrounding environment and happens 
relatively fast. In a dilute environment there is a concentration 
gradient which shifts the equilibrium to the left, dissociating the 
cyclodextrin and the drug, thereby releasing free drug to be 
absorbed. In the body’s dynamic environment, it is not likely 
that the drug will encounter another cyclodextrin with which 
to form a complex and in this way it remains free in the solution 
(Chaudhary, Patel, 2013).
Complexed Drug Pharmacokinetics
The effect of cyclodextrins on the pharmacokinetics of com-
plexed drug must be considered before cyclodextrin complex-
ation can be applied. Kurkov et. al. studied the effect of com-
plexation on the pharmacokinetics of close to 200 drugs. The 
results concluded that the hydroxypropyl-β-cyclodextrin does
not have a significant effect on the pharmacokinetics of the 
drugs. However, although not altered, some drug is lost due to 
the complexation. The hydrophilic cyclodextrins are excreted 
unchanged by the kidneys and any drug still encapsulated is 
excreted too. This is especially true when the drug has a high 
binding constant to cyclodextrin (Kurkov et. al. 2012).
Toxicological Considerations
Orally administered cyclodextrins are not significantly ab-
sorbed in their intact form from the gastrointestinal tract. The 
Cyclodextrins range from 1000 Da to over 2000 Da in molecu-
lar weight and are hydrophilic with significant hydrogen bonding 
donors and acceptors, therefore they cannot be absorbed in 
their original form. Natural α-cyclodextrin and β-cyclodex-
trin cannot be hydrolyzed by human salivary and pancreatic 
amylases and in general oral administration is not associated 
with significant adverse effects and is well tolerated. After IV 
injection α-cyclodextrin is mainly excreted unchanged in the
urine. β-cyclodextrin is nephrotoxic when administered paren-
terally but non-toxic in the topical, buccal, rectal or oral form 
and can be found in numerous marketed drugs. The metabolism 
of γ-cyclodextrin is similar to that of starch and linear dextrins
and only small amounts are absorbed intact. After iv injection 
the γ-cyclodextrin is mainly excreted unchanged in the urine
(Brewster, Loftsson, 2007).
Ibuprofen-Cyclodextrin
Ibuprofen is a nonsteroidal anti-inflammatory drug (NSAID) 
used to treat mild to moderate pain and fever. Ibuprofen works 
by inhibiting cyclooxygenase, an enzyme that converts arachi-
donic acid to cyclic endoperoxides. Cyclic endoperoxides are 
precursors to prostaglandins responsible for inflammation 
(PubChem, 2004). 
Ibuprofen is a poorly water soluble drug. Although it contains 
a carboxylic acid functional group which can hydrogen bond 
with water and be solvated, the alkyl groups and the benzene 
ring are non-polar and make the drug poorly soluble. Ibuprofen 
is complexed with cyclodextrin derivatives to increase its solu-
bility (Hussein et. al. 2007). 
Khaled Hussein, et al. conducted a study on the ibupro-
fen-β-cyclodextrin complex (Hussein et. al. 2007). A solid
complex of ibuprofen, MW 206.3 g/mol, and β-cyclodextrin, 
MW 1,135.0 g/mol, was prepared. Using controlled Particle 
Deposition (CPD) with supercritical carbon dioxide the ibu-
profen-β-cyclodextrin complex was formed. The CPD method
dissolves the desired solution in supercritical carbon dioxide 
which then enters the pores of the carrier at extremely high 
pressure and precipitates following a rapid pressure drop. 
The “n-hexane wash” method determined whether the com-
plex was formed. β-cyclodextrin and its complexes are insol-
uble in n-hexane but the free drug is soluble. The supernatant 
liquid that was insoluble was separated, dried and then analyzed 
by high-performance liquid chromatography (HPLC). HPLC de-
termined the product yield as well as the content of ibuprofen 
in the complex. The inclusion yield of the complex was deter-
mined using the following equation:
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Percent of included ibuprofen= [complexed amount 
of ibuprofen/free amount + complexed amount] x 100 
49.83±3.65 inclusion yield % was calculated. 
Infrared spectroscopy of pure ibuprofen showed all the 
characteristic peaks including the carbonyl peak at 1,706 cm-1. 
The complexed drug’s infrared spectroscopy had a very week 
carbonyl peak indicating that the drug molecule was encapsu-
lated inside the β-cyclodextrin. Morphological changes were
also observed. Pure ibuprofen is rough needle-shaped crystals 
and β-cyclodextrin is parallelogram shaped. The shape of the
complexed particles appeared smaller in size and different than 
pure drug or pure β-cyclodextrin. This observation adds to the
evidence of the ibuprofen-β-cyclodextrin complex formation. 
The complex was tested for drug release using a flow sys-
tem with a dissolution vessel at pH 5 and 37°C. A sample of 
pure ibuprofen and a sample of complexed ibuprofen, each 
containing 3mg ibuprofen, were added to the vessel. Samples 
were taken from the dissolution fluid at set intervals and were 
studied spectrophotometrically. Kw, the dissolution coefficient, 
was calculated. Kw corresponds to the time when 63.2% of the 
drug is dissolved. 
The dissolution of pure ibuprofen in vitro at pH 5 showed 
poor dissolution after 15 minutes and after 75 minutes. The 
complexed drug had a significantly higher dissolution rate and 
amount, due to the presence of the β-cyclodextrin. The disso-
lution rate of the complexed product was 0.086±0.002 min-¹, 
the rate of pure ibuprofen was excluded from analysis since it 
did not reach 63.2% within 72 minutes. The dissolved amount of 
drug after 15 minutes was determined to be 71.9±3.62% for the 
complexed prepared using the CPD method, and 22.0±3.56% 
for pure drug. After 72 minutes, 93.5±2.89% of drug dissolved 
from the ibuprofen-β-cyclodextrin complex and from pure
ibuprofen sample only 59.5±4.86% of drug dissolved. The com-
plexed drug had a significant increase in aqueous solubility.
Imatinib-Cyclodextrin
Imatinib, known as Gleevec, is an oral tablet or a capsule used 
for the treatment of Philadelphia chromosome positive chronic 
myeloid leukemia (CML) or gastrointestinal stromal tumors. 
Imatinib works by inhibiting protein tyrosine kinase, the growth 
factor receptor that causes unregulated cell growth of cancer 
cells (PubChem, 2005).
Aqueous solubility of imatinib is charge dependent and varies 
depending on the pH. The active compound, imatinib, can be 
mono, di, tri and tetra protonated. The more protonated the 
compound the greater the overall charge of the compound. 
Increased charge increases the aqueous solubility. At a pH below 
5.5 the formation of different protonated species of imatinib 
results in a charged drug that is water soluble. However, the free 
base form of imatinib is neutral, uncharged, and therefore poorly 
soluble. To increase the aqueous solubility of the free base form 
of imatinib, the drug was complexed with β-cyclodextrin and
with randomly methylated β-cyclodextrin (RAMEB). Szabolcs
Beni, et al. performed a study determining the effectiveness of 
cyclodextrin and cyclodextrin derivatives in increasing the solu-
bility of the neutral drug form (Beni et. al. 2007).
In a solution of Na2CO3 at a pH of 10.5, 2 mg of imatinib 
was added to a 1 ml solution of varying concentrations of β-cy-
clodextrin, 0-13 mM. The mixture was shaken for two days at 
25.0 ± 0.5°C and a complexed product of 1:1 stoichiometry 
was formed.
The aqueous solubility of the free base form of imatinib was 
enhanced by complexing it with β-cyclodextrin. At a pH of 10
the linear AL phase solubility diagram indicated the improve-
ment in the solubility of the drug. With increased cyclodextrin 
concentration, the solubility of the drug increased linearly, com-
plexation increased the drug solubility tenfold.
Titration of pure imatinib with KOH precipitated above a 
pH of 6.5. Titration of 1mM imatinib in the presence of four-
fold β-cyclodextrin or randomly methylated β-cyclodextrin
(RAMEB) did not precipitate due to the complex’s effect on 
the solubility. The most stable form of the imatinib-cyclodex-
trin complex formed with the neutral form of imatinib. This is 
because the neutral imatinib is most hydrophobic and interacts 
most with the hydrophobic interior of the cyclodextrin. The af-
finity of imatinib towards cyclodextrin decreased as the charge 
on the drug increased.
¹H NMR chemical shift titration method quantified the 
non-covalent molecular interactions. At a titration of pH 3.5 the 
predominant imatinib species was the deprotonated form. The 
mono and tri protonated forms were present in smaller quan-
tities. Interactions between the imatinib forms and the β-cyclo-
dextrin was evident. The data collected suggests that the ben-
zamide fragment of imatinib is involved in the inclusion complex. 
2D ROESY NMR spectra was recorded at the same pH to 
verify the data. The evidence suggested that the imatinib inclu-
sion proceeds through the narrower part of the cyclodextrin 
host. For steric reasons the inclusion proceeds in an unusual 
way, through the narrower part of the cyclodextrin. The result 
33
Cyclodextrin as a Drug Carrier Increasing Drug Solubility
of the study concluded that a tenfold increase in the imatinib 
solubility was achieved with 12mM β-cyclodextrin complex-
ation. The increased aqueous solubility of imatinib greatly in-
creases the effectiveness of the anti-cancer drug.
Praziquantel-Cyclodextrin
Praziquantel (PZQ) is a Class II drug, according to the BCS, 
used for the treatment of schistosomiasis. The drug works by 
causing severe spasm and paralysis to the worms’ muscles and 
the worms are then destroyed in the intestines or passed in the 
stool. It is classified as a Class II drug due to its high membrane 
permeability but low aqueous solubility. The low aqueous solu-
bility is due to its lipophilic character (PubChem, 2005). 
As a Class II drug, a high dose of praziquantel is necessary in 
order for it to be effective. Improving the aqueous solubility of 
praziquantel can potentially result in the classification of the drug 
as a BCS-Class I compound. To increase the aqueous solubility 
of praziquantel the drug was complexed with β-cyclodextrin
and hydroxypropyl-β-cyclodextrin. A study was conducted to
determine whether this Class II drug can be complexed with cy-
clodextrin and behave like a Class I drug (Maragos et. al. 2009).
The praziquantel-cyclodextrin complexes were formed via 
the kneading method. 0.080 grams of praziquantel was mixed 
with cyclodextrin in varying ratios; 1:1, 1:2, and 1:4 molar ratios. 
The complexed praziquantel-β-cyclodextrin reached equilibra-
tion within 12 hours and the praziquantel-hydroxypropyl-β-cy-
clodextrin complex reached equilibration after a 24 hour 
period. Heating the samples at 70°C for an hour prior to the 
experiment accelerated the reaction and also increased the for-
mation of the praziquantel-cyclodextrin complex. The concen-
tration of praziquantel in the binary system remained constant 
while it was in a shaking bath at 25°C for 72 hours. 
The aqueous solubility of the lipophilic drug had a 4-5-fold 
increase upon complexation with cyclodextrin. Calculations 
of the praziquantel solubility in 0.01 M cyclodextrin versus 
the solubility of praziquantel without cyclodextrin calculated 
a solubility enhancement factor of 4.5. Preheating the samples 
at 70°C for one hour prior to the experiment increased the 
solubility enhancement factor; a factor of 5.5 was calculated for 
the praziquantel-β-cyclodextrin complex and 6.0 for the prazi-
quantel-hydroxypropyl-β-cyclodextrin complex. Preheating the
sample before complexation enhanced the drug complexation 
by increasing the dissolved amount of praziquantel that inter-
acted with the cyclodextrin to form inclusion complexes.
The content of praziquantel in the product was determined 
spectrometrically. The isoquinoline ring of the praziquantel in-
serted in the cyclodextrin cavity. The phase solubility diagrams 
were linear. The praziquantel complexation was stronger with 
β-cyclodextrin than with the hydroxypropyl-β-cyclodextrin
derivative as revealed by the complexation constants, K values, 
Figure 3 AL phase solubility diagram (Beni et. al. 2007)
Figure 4 Proposed imatinib-CD complex (Beni et. al. 2007)
Figure 5 Phase solubility diagrams of praziquantel 
with cyclodextrin (Maragos et. al. 2009)
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obtained from the diagram. Furthermore, the complexation en-
hancement as a result of preheating the sample was more signif-
icant in the hydroxypropyl-β-cyclodextrin complex as reflected
in the K values. 
Praziquantel complexation with different molar ratios of 
cyclodextrin was studied. The praziquantel complex with 
β-cyclodextrin had the highest drug concentration in a 1:2
praziquantel-cyclodextrin ratio. The optimum praziquantel-hy-
droxypropyl-β-cyclodextrin complex molar ratio was 1:4. The
different behaviors of the cyclodextrin derivatives are a result of 
hydrogen bond formation between the drug and cyclodextrin. 
After complexation with β-cyclodextrin and hydroxypro-
pyl-β-cyclodextrin the drug was reevaluated in terms of the
BCS. The solubility/dose ratio, in relation to the dose and in-
testinal content, was calculated using solubility values of prazi-
quantel in the presence and absence of β-cyclodextrin and
hydroxypropyl-β-cyclodextrin. At a low dose of 150 mg the
praziquantel complexed with β-cyclodextrin or hydroxypro-
pyl-β-cyclodextrin had a higher solubility/dose ratio than pure
drug. The solubility was increased while the dose decreased. The 
low dose form of praziquantel, 150 mg, thus classified as a BCS-
Class I drug. 
Camptothecin-Cyclodextrin
Camptothecin is an antineoplastic agent that displays broad spec-
trum activity in the treatment of various cancers. Camptothecin 
is used against human lung cancer, prostate, breast, colon, stom-
ach, and ovarian carcinomas and in the treatment of melanoma, 
lymphomas, and sarcomas. An alkaloid isolated from the bark 
of the Chinese tree Camptotheca acuminata, camptothecin 
works by inhibiting the enzyme topoisomerase I. Inhibition of 
topoisomerase I prevents DNA relegation leading to DNA 
damage and apoptosis (PubChem, 2005). Camptothecin is prac-
tically insoluble in aqueous solution at a pH above 7 the drug is 
converted to a water soluble but less active carboxylate form. 
Jichao Kang, et al. performed a study complexing camptothecin 
with cyclodextrin in attempt to increase the solubility of the 
pharmaceutically important drug (Kang et. al. 2002).
The solubility of the drug complexed with cyclodextrin was 
determined by placing 5 mg of camptothecin in 1.0 ml of a 0.02 
M HCl solution containing different amounts of cyclodextrin. 
Analysis of the results gave a linear graph, the solubility of 
camptothecin increased linearly with the increasing concentra-
tions of various cyclodextrins. Camptothecin in the β-cyclodex-
trin complex had the highest increase in solubility, increasing 
by about six-fold. α-cyclodextrin increased the camptothecin
solubility three-fold and γ-cyclodextrin increased the drug’s sol-
ubility five-fold. Of the modified cyclodextrin, RDM-β-CD ex-
hibited the greatest increase in camptothecin’s solubility. At 25% 
weight / volume concentration of RDM-β-CD, the solubility of
camptothecin increased by a factor of 170. The methyl groups 
significantly increase the solubilizing effect of this cyclodextrin 
derivative by disrupting the intramolecular hydrogen bonding 
and enlarging the cyclodextrin cavity.
Conclusion
Drug solubility is an important factor in determining the efficacy 
of a drug. The low aqueous solubility of many pharmaceutical 
developments is an area of constant research. This paper stud-
ied the effect of cyclodextrins on the solubility of poorly soluble 
drugs. Cyclodextrins and their derivatives, by forming guest-
host complexes, encapsulate an insoluble drug and increase its 
aqueous solubility. The cyclodextrin carries the drug through 
the aqueous solution and the complex dissociates upon reach-
ing the site of action. The cyclodextrin drug carrier transports 
the insoluble drugs without altering the drug or causing signifi-
cant harm to the patient.
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Untreated obstructive sleep apnea has been strongly linked to 
many serious diseases and early mortality. It can be the underly-
ing cause of certain diseases, and it can cause rapid progression 
or early onset of others. Perhaps even more alarming, is that 
many incidences of sudden death, especially heart attacks, have 
been attributed to untreated obstructive sleep apnea. The basic 
understanding of its severity is that untreated obstructive sleep 
apnea inflicts significant and multi-faceted trauma on the body. 
This trauma is mainly due to nightly deprivation of oxygen in 
the blood, sleep deprivation, constant hyper stimulation of the 
sympathetic nervous system, and enormous strain on the heart. 
It is noteworthy that there are also secondary physical, mental, 
and emotional health concerns associated with untreated sleep 
apnea. In a random sample of several hundred individuals pre-
senting to a sleep clinic with symptoms typical of sleep apnea, 
it was observed that the vast majority of the patients subse-
quently diagnosed with obstructive sleep apnea had at least 
one other serious health issue. The percentage of people with 
additional health problems tended to be much higher among 
those 40 years of age and older- i.e. in the individuals who had 
gone through many more years of trauma to their bodies before 
seeking treatment (personal observation, Chang, et.al. 2013).
It is also especially critical to explore the effects of untreat-
ed sleep apnea because it effects many more people than was 
previously thought (up to 24% of adult men) (Peppard, et.al. 
2000) and because there has been a steady rise in the diagno-
sis of sleep apnea with the increased incidence of obesity. In 
addition to the obesity factor, it is now known that the general 
aging process is a major risk factor in the development of sleep 
apnea. Consequently, it may be prudent to study the diagnos-
tic methods and treatment options for sleep apnea for those 
involved in geriatric care (Adegunsoye, Ramachandran, 2012). 
Several studies indicate that post-menopausal women are at 
increased risk for developing obstructive sleep apnea because 
the female sex hormones which help dilate the airway decrease 
after menopause (Chang, et.al. 2013). This paper will explore the 
question of how untreated sleep apnea effects the body and the 
implications of these effects.
Methods
Relevant material was scoured mainly from the web, from con-
versations and correspondence with a veteran pulmonologist 
and sleep specialist, and from personal experience observing 
and interviewing patients and studying polysomnography data at 
a sleep clinic over a period of about two months. Only materials 
from authoritative sources were used. An effort was made to 
gather information on the interaction between sleep apnea and 
numerous medical conditions thus broadening the scope of the 
paper. This was done in order get as full a picture as possible on 
how sleep apnea may affect the body. Material on the effective-
ness of treatment of sleep apnea was also considered pertinent 
to understanding the mechanisms of this condition and are in-
cluded in the discussion accordingly.
Definition ofTerms
Sleep apnea: Sleep apnea is defined as a cessation of breathing 
of ten seconds or more while asleep (Tsara, et.al. 2009). There 
are two main types of sleep apnea: Obstructive Sleep Apnea, and 
Central Sleep Apnea.
Obstructive Sleep Apnea (OSA): OSA is an anatomical condi-
tion where, while asleep, the muscles in the throat relax to an 
extent that the airway collapses. Specifically, there may be sev-
eral different muscles responsible for this. Sleep apnea is more 
common in people who have a narrow airway. A narrow airway 
can be genetic, it can be caused by inflammation, or it can be 
due to obesity. (Obese individuals often have excess submucosal 
adipose tissue which can build up around the airway thereby 
causing the airway to compress.) Defects in, or damage to, the 
face or neck in areas which affect the airway may also be a risk 
factor for OSA. OSA can affect adults or children, but is more 
common in adults (Tsara, et.al. 2009). OSA can be a factor in de-
termining the cause of Sudden Infantile Death Syndrome (SIDS), 
and a family history of OSA may be considered a risk factor in 
SIDS (Thach, 2008).
Central Sleep Apnea (CSA): CSA is a condition where the 
apneustic center in the brain stem fails to send nerve impulses 
necessary for breathing. CSA can occur without an obstruct-
ed airway. However, OSA and CSA are often clinically related. 
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When a patient who has CSA and OSA is treated just for the 
OSA, the CSA part of the sleep apnea is often minimized or 
even eliminated (Costanzo, et.al. 2015). It is possible that the 
disordered breathing caused by the OSA may contribute to the 
apneustic center malfunction- either directly or by a secondary 
mechanism. CSA can also be accompanied by irregular breath-
ing patterns. For example, the Cheyne-Stokes respiration is a 
common symptom of primary CSA (Tsara, et.al. 2009, Costanzo, 
et.al. 2015). (Cheyne-Stokes respiration is a breathing pattern 
where there are rapid or deep breaths followed by a decrease 
and secession of breathing. This is usually in a cycle which can 
last anywhere from 30 seconds to two minutes.) CSA can also 
be secondary to illness or trauma, and it can be caused by 
certain medications and substances. It is noteworthy that if a 
newborn has sleep apnea, it is often CSA (Tsara, et.al. 2009) and 
may be a factor in determining the cause of SIDS (Thach, 2008).
Hypopnea: A hypopnea is a partial closure of the airway which 
is often characterized by loud snoring. (The snoring is caused 
by the fluttering of the air passage walls as they come in close 
proximity while breathing.) This partial closing is classified as 
a hypopnea when the obstruction is severe enough to cause 
oxygen desaturation in the blood.
Polysomnography: A polysomnography is a sleep study. During 
a sleep study, the individual is attached to electrodes and other 
machinery which collect information about the person’s sleep. 
This information will include how long the patient spent in each 
phase of sleep, whether or not the patient has OSA or CSA, ox-
ygen saturation or desaturation in the blood, breathing patterns, 
and many other items of relevance. A polysomnography can be 
used to diagnose sleep apnea.
Apnea-Hypopnea Index (AHI): An AHI is a score of how many 
events of apnea and hypopnea occur per hour. For example, if 
six times in the course of an hour, a patient stops breathing for 
ten seconds or more and/or has an oxygen desaturation, then 
the patient will have an AHI of 6 (or an event on average of 
every ten minutes).
Sleep Disordered Breathing: Sleep disordered breathing is a 
general term used to refer to any abnormal breathing issues 
or abnormal breathing patterns which can occur when one is 
asleep.
Continuous Positive Airway Pressure Machine (CPAP 
Machine): A CPAP Machine is a medical device which blows air 
through the nose to the back of the airway to keep it open while 
a person is asleep. It is currently the most effective standard 
treatment for sleep apnea. The machine can be adjusted to apply 
more or less pressure as needed, and modern machines are 
often self-adjusting. Other machines are available to treat more 
complicated cases, but they too incorporate positive pressure 
to treat the OSA component of any sleep disordered breathing. 
There are surgeries which can be performed to help eliminate 
OSA, but they are only about 50% effective. Some dental devices 
have been developed to treat OSA, but they too are often insuf-
ficient as effective treatment (Peker, et.al. 2002).
Discussion
The most obvious area of concern with sleep apnea is the fact 
that when breathing stops, oxygen doesn’t enter the lungs. 
This, in turn, leads to oxygen desaturation in the blood. This 
hypoventilation has been linked to a number of conditions such 
as systemic hypertension (Peppard, et.al. 2000), pulmonary hy-
pertension (average pressure in the pulmonary arteries greater 
than 25mmHg (resting)) (Adegunsoye, Ramachandran, 2012), 
polycythemia (high red blood cell count), heart problems, be-
havioral issues, emotional issues (Sheu, et.al. 2015), and birth 
defects (Tsara, et.al. 2009, Adegunsoye, Ramachandran, 2012). 
It has also been reported that early treatment is effective in 
eliminating these negative effects, and it is therefore of para-
mount importance to recognize, diagnose, and treat sleep apnea 
syndrome at the earliest possible opportunity (Adegunsoye, 
Ramachandran, 2012).
Systemic hypertension can be due to numerous factors involv-
ing OSA. One factor is that the hypoxia may lead to a pressor 
effect as an attempt by the body to get more oxygen (Peppard, 
et.al. 2000, Tkacova, et.al. 2014). Another contributing factor to 
hypertension is fluid and sodium retention due to sympathetic 
nervous system activation of the renin angiotensin aldosterone 
system effecting the kidneys (Bradley, Floras, 2003, Nishizaka, 
et.al. 2004). Many patients with untreated OSA have swelling in 
their legs (personal observation). It is noteworthy that admin-
istration of oxygen does not prevent the hypertensive effect of 
untreated OSA (Leung, Bradley, 2001).
The increased risk for developing hypertension due to un-
treated OSA is present even in individuals diagnosed with mild 
sleep apnea (AHI of approx. 5) (Peppard, et.al. 2000). The risk 
for developing hypertension is, however, directly related to the 
severity of the sleep apnea. Several studies show that individu-
als with more severe sleep apnea were more likely to develop 
hypertension than those with milder sleep apnea (Peppard, et.al. 
2000, Peker, et.al. 2002, Nieto, et.al. 2000). The likelihood of de-
veloping hypertension is present regardless of gender, race, or 
ethnicity, and it is usually manifest in individuals middle age or 
older (Nieto, et.al. 2000). Severity of sleep apnea is based on AHI 
and on ODI (oxygen desaturation index) (Tkacova, et.al. 2014). 
If treatment for OSA is initiated before the onset of hyperten-
sion, then chronic hypertension as well as other cardiovascular 
disease may be avoided. Additionally, treatment for the OSA has 
a much greater impact on lowering blood pressure than does 
weight loss (Nieto, et.al. 2000, Tkacova, et.al. 2014, Lavie, et.al. 
2000). Even in the event that hypertension has already set in, 
studies show that it can be minimized significantly after approx-
imately 9 weeks of treatment (Milleron, et.al. 2004). The associ-
ation between sleep apnea and hypertension is so strong that 
38
Binyamin S. Kanter
sleep apnea should be seriously considered in the diagnosis and 
treatment of high blood pressure (Lavie, et.al. 2000). 
Many studies have demonstrated that endothelial cells are 
severely damaged and impaired by hypoxic conditions, and 
the extent of endothelial cell damage has also been associated 
with the AHI index (Lui, et.al. 2013). The damage may occur in 
the form of apoptosis of endothelial cells, in the form of cell 
cycle arrest, and in a number of other ways which play a role in 
many of the adverse effects of untreated sleep apnea (Iida, et.al. 
2002). Endothelial cell damage and dysfunction is connected to 
inflammation, atherosclerosis, renal damage, impaired vasodila-
tion ability and nitric oxide production, and many other severe 
health issues (Bruno, et.al. 2013). Additionally, oxidative stress 
seems to be one of the main causes for endothelial cell damage. 
The extent of oxidative stress is likewise directly correlated to 
the severity of the sleep apnea (Del ben, et.al. 2012). It is ex-
tremely important to realize that the individual with untreated 
OSA is at increased risk of arterial stiffness, which can lead to 
heart disease and other severe health issues even if they expe-
rience very minimal symptoms (Kohler, et.al. 2008).
Hypoxia is known to cause an increase in reactive oxygen 
species. The mechanism for this phenomenon is not clear, but 
some studies suggest that this is due to the lack of a strong 
electron acceptor in the absence of oxygen. When there are no 
electron acceptors, the electrons have no place to go and there-
fore remain unbound as superoxide radicals or as other reac-
tive oxygen species (ROS) (Kondoh, et.al. 2013). Compounding 
this problem is the reperfusion following the apneic episode 
which also causes an increase in ROS. Reperfusion may cause 
an increase in ROS for two reasons. One is that cell function 
has been impaired due to the lack of oxygen and is altogether 
not running efficiently enough to rid itself of the ROS. Second 
is that the sudden influx of oxygen overloads the cell which 
cannot process it fast enough. Studies show that hypoxia and 
subsequent reperfusion can cause damage to the epithelial lin-
ing of blood vessels. This damage can cause and/or contribute to 
atherosclerosis (Sawatari, et.al. 2016).
Aside from the ROS caused by reperfusion, there are other 
ROS released by a number of granular leukocytes in response 
to hypoxemia. The increased presence of ROS is a general 
danger to the body and has been linked to cancer and other 
illnesses. This is especially a concern for cancers which originate 
in endothelial cells because they are most directly affected by 
ROS (Kondoh, et.al. 2013). This is especially the case when the 
body experiences this kind of oxidative stress night after night 
for years on end (Adegunsoye, Ramachandran, 2012, Milleron, 
et.al. 2004). Proper treatment of OSA solves the problem of 
oxidative stress and can help reverse some or all of the damage 
caused by it (Del ben, et.al. 2012, Bayram, et.al. 2009).
Pulmonary hypertension in particular, is one cause for right 
sided heart failure and has an especially grim prognosis if left 
untreated. Pulmonary hypertension can be caused by a number 
of conditions, but its link to OSA and general sleep disordered 
breathing is strong enough that the American College of Chest 
Physicians recommends that patients presenting with pulmo-
nary hypertension be evaluated for sleep disordered breathing. 
The pathophysiology of pulmonary hypertension in sleep dis-
ordered breathing is that the hypoxia caused by the breathing 
disorder in turn causes hypertrophy of the pulmonary arteries. 
This hypertrophy decreases perfusion of blood in the lungs. The 
situation is even more disastrous for individuals with emphy-
sema or fibrosis of the lung. The heart tries to compensate for 
the decrease in perfusion by working harder, and this attempted 
compensation puts enormous strain on the right ventricle. This 
strain is unsustainable and leads to right sided heart failure and a 
subsequent general dyspnea even at rest. If left untreated, death 
typically occurs within three years of diagnosis (Adegunsoye, 
Ramachandran, 2012). The mechanism of how hypoxia causes 
the initial hypertrophy of the pulmonary arteries needs elucida-
tion, but it seems to be related to endothelial cell dysfunction. 
(It is also noteworthy that obese individuals are more likely 
to develop pulmonary hypertension with OSA (Adegunsoye, 
Ramachandran, 2012).) 
Aside from hypertrophy of the pulmonary arteries which 
can cause pulmonary hypertension, there is the direct effect 
of hypoxia in the form of pulmonary vasoconstriction. The rea-
son for vasoconstriction during an hypoxic event is due to an 
attempt by the body to keep ventilation and perfusion in sync. 
In the absence of oxygen, vasoconstriction will lessen perfusion. 
This, however, will also cause an increase in pulmonary artery 
pressure. This pressure is primarily a concern while the individ-
ual is sleeping. However, about 20% of patients with elevated 
pulmonary artery pressure while sleeping will eventually devel-
op pulmonary hypertension even while awake. This may be be-
cause the increased blood pressure can directly cause damage 
to blood vessels and result in the hardening and stenosis of 
those damaged vessels.
Another area of concern in untreated OSA is the effect of 
prolonged sympathetic nervous system stimulation. When 
a person with OSA has an event, the body responds to the 
obstructed breathing by activating the fight or flight response. 
This occurs for each event- all night, every night. One effect of 
this stimulation is vasoconstriction and an increased heart rate- 
both of which raise blood pressure. Eventually, this can lead to 
chronic systemic and pulmonary hypertension (Adegunsoye, 
Ramachandran, 2012).
Chronic systemic hypertension is known to negatively affect 
cardiovascular health and increase mortality. It has also been 
reported that hypertension in individuals with untreated OSA is 
particularly difficult to control, and that in attempting to control 
the high blood pressure, beta blockers are the most effective, 
suggesting that a major contributing factor to the high blood 
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pressure is sympathetic stimulation (Leung, Bradley, 2001).
Even in the absence of chronic hypertension development, 
there is, concern of vascular endothelial dysfunction. Over-
stimulation of the sympathetic nervous system can, in of itself, 
lead to vascular endothelial dysfunction. The pathophysiology of 
the damage is, similar to what is found in patients with chronic 
hypertension: Vasoconstriction creates more resistance in the 
blood vessels. Resistance, especially if prolonged, can cause 
damage to the vasculature and lead to hardening of the blood 
vessels (Adegunsoye, Ramachandran, 2012). The damage can 
be quite significant because the effects of sympathetic system 
over-stimulation linger into the wake hours as well (Tkacova, 
et.al. 2014).
The constant presence of catecholamine levels also puts the 
untreated OSA patient at greater risk for thromboembolism 
because high levels of catecholamines tends to lead to platelet 
aggregation. This and other phenomena which can predispose 
an individual to thromboembolism can be reversed with effec-
tive treatment. The reversal of which suggests that the hyperco-
agulability in individuals with OSA is indeed caused by the OSA 
(Adegunsoye, Ramachandran, 2012).
There is a secondary problem associated with untreated OSA 
of the sleep deprived individual. The way the body clears the 
obstructed breathing is by jolting the person out of deep sleep 
long enough to return muscle tone to the airway and open it 
back up.  This arousal from deep sleep is called a Respiratory 
Effort- Related Arousal or RERA. A RERA can be present even 
in the absence of a clinically defined apnea- for example if the 
breathing stops for less than 10 seconds, or if there is no sig-
nificant oxygen desaturation during an event (Tsara, et.al. 2009). 
There are serious health risks associated with sleep deprivation 
as well as physiological effects and secondary risks. Psychological 
effects could include depression, apathy, and irritably. Secondary 
risks could include general fatigue or falling asleep while driving 
(Adegunsoye, Ramachandran, 2012).
Sleep deprivation and hypoxia are both known causes of in-
flammation. Inflammation is an independent factor in endothe-
lial cell dysfunction and has also been linked to certain cancers 
(Lui, et.al. 2013). Several factors which cause inflammation are 
found in high levels in individuals with untreated OSA. Proper 
treatment is effective in stopping the inflammatory response 
(Adegunsoye, Ramachandran, 2012, Shamsuzzaman, et.al. 2003).
Another factor associated with OSA which causes sleep 
deprivation is nocturia. Nocturia is a condition where an indi-
vidual’s sleep is interrupted multiple times in order to empty the 
bladder. The pathophysiology of this condition is that attempt-
ing to breathe with an obstructed airway causes an enormous 
amount of intrathoracic pressure which results in a much larger 
than usual volume of blood to enter the heart. In some individu-
als, this overfilling causes the release of atrial nauturetic peptide 
(ANP). ANP in turn causes the kidneys to excrete more water. 
The reason this system is activated is because the overfilling of 
blood in the heart mimics the mechanics of increased blood 
volume. Increased blood volume increases blood pressure. As a 
result, the body, thinking that it has too much blood, will want 
to get rid of the excess volume by way of diuresis (Umlauf, et.al. 
2004). Patients with OSA report that their nocturia subsides 
once they comply with effective treatment (Personal communi-
cation with patients).
In addition to the mimicking of increased blood volume which 
causes the release ANP, ANP excretion is also increased due to 
acidosis. The lack of oxygen caused by OSA can certainly lead to 
at least a temporary acidosis, and this may further contribute to 
nocturia. ANP also directly inhibits the excretion of vasopres-
sin. Vasopressin normally plays a role in the decrease in urine 
production while asleep. If vasopressin is inhibited, then urine 
production will not decrease and the individual may experience 
nocturia. In one study of carefully selected individuals diagnosed 
with OSA, blood levels of ANP, as well as urine levels of ANP and 
increased urine volume were directly correlated with untreated 
OSA. It is also noteworthy that an elevated level of blood ANP 
is related to mortality rates in patients with heart problems, and 
a correlation between heart disease and untreated OSA has 
been strongly established (Umlauf, et.al. 2004).
Nocturia is often associated with aging. This association is 
due to the general aging process, and in men due to prostate 
hypertrophy, and in women due to decreased bladder volume. 
Aging is also a risk factor for OSA, and as such, its another 
possible cause of the increase in nocturia with age in both men 
and women. The connection between untreated OSA and noc-
turia is one way to explain why, in many individuals, nocturia is 
not resolved with the treatment for benign prostate hypertro-
phy. It has also been documented that the incidence of sleep 
apnea doubles in women post menopause- probably as a result 
of low estrogen levels. This correlates well with the increase 
in nocturia in women post menopause. Attributing nocturia in 
post-menopausal women to untreated OSA may be more accu-
rate than attributing it to a simple decrease in bladder volume. 
The effects of over elimination of fluids and how this may affect 
proper hydration and general fluid management in the body also 
needs to be considered when evaluating the impact of nocturia 
(Umlauf, et.al. 2004).
Many individuals with OSA are obese. Obesity is a risk factor 
in OSA, but OSA can, in of itself, also cause weight gain. Weight 
gain can be attributed to lack of physical activity. People with 
OSA often experience chronic fatigue, and this can possibly 
cause OSA patients to limit their physical activity. However, in 
addition to this secondary cause for weight gain, OSA can be 
directly responsible for altered metabolic factors which lead 
to obesity. Leptin levels are often found to be at abnormally 
high levels in obese individuals. Patients with untreated OSA 
often have even higher levels of leptin than obese individuals. 
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The current understanding is that leptin is found at high lev-
els because of resistance to their appetite suppressing activity. 
Patients with untreated OSA have sometimes been found to 
have high levels of leptin and gain weight in the year prior to 
diagnosis, and these patients tend to return to normal leptin 
levels and lose the weight once proper treatment is undertaken. 
It is also noteworthy that a high leptin level is considered a risk 
factor for cardiovascular disease (Adegunsoye, Ramachandran, 
2012, Shamsuzzaman, et.al. 2003, Milleron, et.al. 2004).
Another metabolic factor linked to OSA is impaired glu-
cose tolerance. Insulin resistance has been directly correlated 
to OSA, and several studies demonstrate that individuals with 
OSA are several times more likely to develop diabetes mellitus 
than those without OSA (Adegunsoye, Ramachandran, 2012, 
Gottlieb, et.al. 2010, Bayram, et.al. 2009).
One of the most extensive areas of study concerning untreat-
ed OSA is the effect it has on the heart. In fact, about 50% of pa-
tients with heart failure have OSA, and medication for heart fail-
ure seems to have little, if no effect on alleviating OSA (Bradley, 
Floras, 2003). In addition to the effect of pulmonary hyperten-
sion on the heart (discussed above), there are additional ways in 
which untreated OSA can cause cardiac health problems. When 
the body tries to breath while the airway is obstructed, an enor-
mous amount of negative pressure is generated in the thoracic 
cavity. This negative pressure pulls large amounts of blood from 
the superior and inferior vena cava into the right atrium of 
the heart, thus effectively increasimg afterload (Shekerdemian, 
Bohn, 1999). The negative intrathoracic pressure increases ve-
nous return and distends the right ventricle which effectively 
impairs left ventricular filling (Bradley, Floras, 2003). Additionally, 
the negative pressure may prevent the left ventricle from re-
laxing and filling properly (Shamsuzzaman, et.al. 2003). These 
mechanisms effectively decrease cardiac output (Adegunsoye, 
Ramachandran, 2012, Mooe, et.al. 2001, Gottlieb, et.al. 2010). 
Individuals with OSA can thus have high blood pressure due to 
vasoconstriction from sympathetic nervous system stimulation 
but decreased cardiac output due to impaired left ventricular 
filling. Unnatural configuration of the heart and aortic stretching 
are also caused by this large negative pressure. This stress on 
the heart can cause either rapid or reduced heart rate, and 
even complete sudden heart failure. The longer the apneic ep-
isode the greater the risk of cardiac malfunction (Adegunsoye, 
Ramachandran, 2012).
Aside from rhythmic and filling problems for the heart, there 
is also a risk for myocardial hypertrophy which can cause irre-
versible hypertension. The hypertrophy is caused by the con-
stant strain on the heart muscle- just as constant strain on any 
muscle leads to muscle growth. If the strain is primarily right 
sided, then the hypertrophy will affect the right side of the heart. 
If the strain is primarily left sided then it will affect the left side 
of the heart. If the strain is on both sides then the entire heart 
can be effected.  Hypertension caused by OSA can last beyond 
the actual apnea episodes, and even in the absence of myocardi-
al hypertrophy, this hypertension can last for many hours after 
awakening (Peppard, et.al. 2000, Peker, et.al. 2002). However, 
treatment for OSA can often reverse systemic and pulmonary 
hypertension if myocardial hypertrophy has not yet set in. This 
is one on the many reasons why it’s important to properly treat 
OSA at the earliest opportunity (Adegunsoye, Ramachandran, 
2012, Jean-louis et.al. 2010).
In addition to myocardial hypertrophy, there is concern 
that untreated OSA may cause ion channel remodeling in the 
heart. This condition can lead to sudden cardiac death (Chahal, 
Somers, 2016). Gene expression effecting potassium ion chan-
nels was studied by examining mRNA associated with potas-
sium ion channels. It was discovered that there was significant 
altering of several potassium pump genes which may result in an 
extended repolarization period. Potassium pumps are needed 
to pump positively charged potassium ions across the myocar-
dial cell membranes so that a new muscle contraction can begin. 
If they don’t pump ions efficiently, then this period of repolar-
ization will take longer. One potential problem with this is that 
there is a danger of ventricular extrasystole (premature ven-
tricular contraction). This kind of arrhythmia can cause sudden 
cardiac death. The mechanism for how exactly the OSA causes 
the altered gene expression has not been fully elucidated, but it 
seems to be multifactorial, including stressors such has hypoxia, 
sympathetic stimulation, and increased intrathoracic pressure. 
Individuals who undergo treatment for OSA can reverse the 
pathologic alterations to the potassium ion channels and regain 
proper gene expression for potassium pumps that work cor-
rectly (Chahal, Somers, 2016, Bradley, Floras, 2003).
The risk of sudden cardiac death in patients with untreated 
OSA is not limited to extrasystole due to ion channel mal-
function. In fact, there are quite a few additional mechanisms 
by which sudden cardiac death may occur. For example, during 
REM sleep, there is a general increase in sympathetic stimula-
tion. (This is in contrast to other stages of sleep where the 
sympathetic nervous system is depressed.) The transition from 
non-REM to REM thus creates a situation which increases ox-
ygen demand. Experiencing an apnea, with the simultaneously 
occurring hypoxia, is thus of greater consequence at this point 
in the sleep cycle. This ensuing trauma to the heart can cause 
arrhythmias (Chahal, Somers, 2016).
Sudden cardiac death is of even greater concern in the 
morning hours because that is typically when the longest REM 
period takes place and because the apneas at this point tend 
to last for longer periods of time. In addition to the risk of 
arrhythmias being increased during this longer REM period, 
there is great risk of myocardial infarction or stroke at this 
point as well (Mooe, et.al. 2001). In general, blood pressure 
rises at different points in the sleep cycle. Individuals with 
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untreated OSA often experience an even greater increase in 
blood pressure- probably due mainly to the overstimulation 
of the sympathetic nervous system. The risk for MI or stroke 
is always increased with an increase in blood pressure, and as 
such, these individuals will be in the most danger during REM 
sleep. The longer REM and the prolonged apneas associated 
with it have claimed many lives (Michael Katzoff MD, personal 
communication May 2017).
Stimulation of the sympathetic nervous system can also result 
in tachycardia which further puts a large demand for oxygen 
on the heart at a time when the heart cannot get oxygen due 
the apnea. This situation can be even more life-threatening in 
patients with coronary artery disease (CAD) (Milleron, et.al. 
2004). Additionally, a myocardial infarction or stroke is often 
caused by a plaque rupture which is made more likely by the 
increase in blood pressure and also because of the intrathorac-
ic pressure caused by the obstructed airway (Chahal, Somers, 
2016). In fact, 43-91% of patients who experience a stroke also 
have sleep apnea (Leung, Bradley, 2001, Shamsuzzaman, et.al. 
2003). It is noteworthy that the rise in intrathoracic pressure 
has also been known to cause the rupture of an aortic aneurism 
which is typically fatal (Chahal, Somers, 2016).
In patients with pre-existing coronary artery disease (CAD) 
there is at least a 60-70% increase in sudden cardiac death or 
myocardial infarction when the individual also has untreated 
OSA. In addition to heart related problems there is an increase 
in cerebral vascular complications such as stroke. The cerebral 
vascular complications may result from the increase in the pro-
thrombotic effect connected with untreated OSA as well as 
from other factors effecting hemodynamics (Mooe, et.al. 2001, 
Peker, et.al. 2002). Fortunately, proper treatment for OSA has 
been shown to decrease the number of new cardiac issues or 
at least to dramatically slow the rate of coronary artery disease 
progression (Milleron, et.al. 2004, Peker, et.al. 2002, Jean-louis 
et.al. 2010). It is likely that treatment would be similarly benefi-
cial to cerebral vascular health (Gottlieb, et.al. 2010).
In general, the sympathetic system stimulation, which often 
lingers throughout the day in untreated OSA individuals, is 
known to increase platelet aggregation. This aggregation is detri-
mental to patients with CAD (Milleron, et.al. 2004). Additionally, 
prolonged platelet aggregation as well as increased levels of fi-
brinogen, and general inflammation in individuals with untreated 
OSA, may be a risk factor in developing a deep vein thrombosis 
on top of the risk these factors pose to CAD (Milleron, et.al. 
2004, Bayram, et.al. 2009).
It is noteworthy that many patients with nocturnal angina 
experience relief when undergoing proper treatment for OSA. 
This suggests that the cause of pain, which is normally due to a 
lack of oxygen, is caused by the OSA and is effectively treated 
with standard CPAP therapy (Peker, et.al. 2002).
Another area of recent study is the possible connection 
between untreated OSA and dementia. One study found that 
the correlation between sleep apnea and dementia may be af-
fected by factors such as age, gender, and duration of the con-
dition. The mechanism for the connection between untreated 
OSA and dementia are not yet conclusive, but the connection 
between hypoxia, which is a side effect of untreated OSA, and 
neurological malfunction has been documented a number of 
times. For instance, rats which were exposed to hypoxic con-
ditions experienced a greater incidence of apoptosis in their 
hippocampus, and advanced brain imaging showed reduced grey 
matter in parts of the brain responsible for executive functions 
and memory. Damage to these areas in humans may be a factor 
in the cause of dementia (Svatikova, et.al. 2003, Ju, et.al. 2013).
Another disturbing finding is that rodents placed in hypoxic 
conditions developed large amounts of cerebral amyloid plaque. 
Similar results have been found in humans with levels of serum 
amyloid A being two and a half times higher in patients with 
untreated OSA (Svatikova, et.al. 2003, Ju, et.al. 2013). Cerebral 
amyloid plaque is one of the hallmark findings in individuals with 
Alzheimer’s disease.  It was also found that there was significant 
phosphorylation of the tau proteins. Tau proteins are abundant 
in neural tissue and function in support of microtubules. When 
they are over-phosphorylated, they can malfunction and cause 
the structure of the cells in which they are found to become 
pathologically altered. Additionally, microtubules function as a 
sort of road or transport pathway for various particles within 
the cell.  The intracellular functions which rely on these trans-
port pathways may stop working properly if the tau proteins 
become over phosphorylated. Quite tellingly, another common 
finding in Alzheimer’s disease is tau protein phosphorylation. In 
lab mice, cerebral amyloid plaque buildup and tau phosphor-
ylation has been connected to decreased memory function 
(Daulatzai, 2015). It is also possible that the general damage to 
the vasculature throughout the body due to hypoxia can be a 
factor in dementia because the vasculature in the brain is nega-
tively affected (Chang, et.al. 2013).
It has been shown that treatment of OSA in the early stages 
of Alzheimer’s disease can aid in dramatically slowing its pro-
gression. One study demonstrated that with treatment of OSA 
with CPAP machine, memory and mental processing speed im-
proved in any stage of dementia. Treatment also helped reduce 
or eliminate neuroinflammation. Additionally, the cardiovascular 
improvements experienced with CPAP treatment have had pos-
itive impact on patients with neurological illnesses. Conversely, 
some research indicates that the onset of mental decline may 
begin as much as one decade earlier in individuals with untreat-
ed OSA (Emamian, et.al. 2016).
Another connection between sleep apnea and brain function 
loss in humans is the presence of a common gene known as 
APOE4 (apolipoprotein epsilon 4) which has been shown to 
play a role in obstructive sleep apnea as well as being connected 
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to the development of dementia. The association could be a 
shared genetic fate, but it could also suggest that the gene is tied 
mainly to the development of OSA which, if left untreated, could 
lead to the damage which can cause dementia. Further studies 
would be necessary to determine the exact nature of the cor-
relation. The long-term effects of sleep deprivation caused by 
sleep apnea should be considered when determining the long-
term effects of untreated OSA on brain function (Chang, et.al. 
2013).
A recent study has implicated untreated OSA as one possible 
cause of Parkinson’s disease. The mechanisms seem most likely 
to include the general oxidative stress caused by hypoxia and 
reperfusion and the general inflammation characteristic of the 
body’s response to untreated sleep apnea. There is even evi-
dence to support the possibility that the blood brain barrier 
may be interrupted as a result of cerebral vascular damage 
which may allow molecules harmful to brain tissue to cross the 
barrier and reach cells involved in Parkinson’s disease and other 
neurological pathologies (Sheu, et.al. 2015).
Conclusion
Extensive research reveals that untreated obstructive sleep apnea 
is extremely traumatic and damaging to the body. It has been 
clearly linked to physical diseases in the heart, brain, endocrine 
system, and vasculature, and it has been implicated as a cause for 
psychological and emotion distress, as well as secondary hazards. 
Mortality rates are consistently higher and earlier in individuals 
with untreated OSA and as such, individuals presenting to their 
health care providers with significant health issues associated 
with OSA should be tested for it. It is extremely important for 
health care providers to realize the severity of OSA and to un-
derstand that it can be present even in patients who experience 
few of the symptoms commonly indicative of OSA. Even patients 
with a relatively low AHI of about 4 or 5 are at risk because 
the trauma to the body is consistent and repeated every time 
the person sleeps, and this trauma has a tendency to have a cu-
mulative effect on the body. Early diagnosis is key because the 
negative effects of OSA can be eliminated with early treatment. 
Treatment should be adamantly encouraged even in individuals in 
whom permanent damage has already occurred because treat-
ment can reverse some of the damage and certainly help stabilize 
the patient and prevent the progression of further health issues. 
Unfortunately, the symptoms of sleep apnea are not always con-
nected immediately to the condition and are often written off as 
symptoms of other medical or phycological issues. It is therefore 
prudent of heath care practitioners to be mindful of sleep apnea 
and diagnose it as early as possible.
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As early as the early 1900’s, oral sepsis and tooth extractions 
were suggested as causes of cardiac infection. However, due 
to the lack of compelling scientific evidence, the idea of oral 
disease as a cause of systemic illness was basically disregarded. 
That focus was revived in the early 1990’s after reports of the 
connection between periodontal disease (PD) and cardiovas-
cular disease (CVD). Although many subsequent studies have 
postulated positive associations between PD and CVD, others 
have maintained that no such correlation exists. Additionally, 
several potential mechanisms have been proposed describing 
how PD could cause systemic inflammation, initiate or exacer-
bate atherogenesis, and possibly lead to cardiovascular catastro-
phes such as myocardial infarction (MI) or stroke. The purpose 
of this article is to review the relevant articles, predominant 
theories, and proposed mechanisms relating periodontitis and 
atherosclerotic vascular disease. Specifically, does the inflamma-
tory PD contribute causally to heart disease and stroke, or are 
these two conditions coincidentally associated?
Methods
The information gathered in this paper has been collected from 
numerous sources including databases such as GoogleScholar, 
Touro Library, and PUBMED. The information was read, analyzed 
and compared to determine each study’s validity and authority.
Results and Discussion: 
Defining PD and CVD
CVD, or more specifically atherosclerotic vascular disease, 
affects the heart and the blood vessels.  Coronary heart dis-
ease (CHD)- also referred to as coronary atherosclerosis, or 
simply heart disease- is a subset of CVD and is characterized 
by dysfunction of the arteries supplying blood to the muscle 
tissue of the heart, depriving it of sufficient amounts of blood. 
Atherosclerosis, or the hardening and narrowing of the arteries, 
silently and slowly blocks arteries, putting blood flow at risk. 
CHD includes blockage of blood vessels (thrombosis) and can 
eventually cause acute myocardial infarction (heart attack). 
CVD is the number one cause of death in the United States and 
other industrialized countries, and is among the major causes of 
mortality worldwide. Traditionally, CVD has been attributed to 
risk factors such as treated and untreated systolic blood pres-
sure, total cholesterol, high-density lipoprotein (HDL) choles-
terol, and body-mass index. However, these factors only occur 
in about half of all patients that experience heart attacks. For 
example, 40% of CHD deaths occur in patients who have cho-
lesterol levels that are lower than the population average. This 
has led researchers to investigate additional causes of CHD, in-
cluding bacterial induced inflammation (Taylor, et. al. 2009). 
Periodontitis is a bacteria-induced, chronic inflammation of the 
gingival tissue in response to dental plaque accumulation. PD 
is always preceded by gingivitis, an earlier and less severe form 
of gum disease, though not all cases of gingivitis will progress 
to PD. Untreated PD leads to deepening of the gingival sulcus, 
which evolves into a periodontal pocket, destruction of the con-
nective tissue and bone supporting the teeth, including gingival 
tissue, periodontal ligament, and alveolar bone. Clinical criteria 
for PD include bleeding on probing, pocket depth and degree of 
tooth attachment loss. 
Evidence of Correlation Between CVD and PD
Many studies have been conducted assessing the possible con-
nection between CVD and PD. The results have varied, and at 
times proposed conflicting views. The fact that oral pathogens 
can come to lesions far from the oral cavity has been proven 
by Lockhart, et. al.. The authors showed how poor oral hygiene 
or dental disease are risk factors for developing bacteremia 
after a simple tooth brushing or after a single tooth extraction. 
One hundred and ninety-four patients participated in the study. 
The authors assayed blood samples before, during and after the 
toothbrushing or single tooth extraction to identify Infective 
Endocarditis (IE)- associated bacteria. The authors found that 
oral hygiene and gingival disease indices were strongly correlat-
ed with IE-related bacteremia after toothbrushing. Patients with 
a mean plaque and calculus score of 2 or more had an increased 
risk of 3.78 and 4.43-times for developing bacteremia. Thus, we 
see that it is easy for bacteria in the oral cavity to enter that 
blood stream. This, as well as other similar studies, present a 
strong basis for the idea that oral pathogens can make their 
way to regions far from the oral cavity (Lockhart, et. al. 2009). 
Additionally, many studies show that bacteremia is present after 
oral examination and probing  Loos, 2006).
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Siddeshappa, et. al. (2016) conducted a study to determine 
whether nonsurgical periodontal therapy can impact vari-
ous hematological parameters in patients with periodontitis. 
Traditionally, the total number of white blood cells (leukocytes) 
and erythrocyte sedimentation rates in peripheral blood has 
been used as  diagnostic measures to determine whether or 
not a patient suffers from an infection or an inflammatory 
disease. Leukocytes become more numerous through the in-
nate immune system response to periodontal bacteremia. The 
suggestion has been made that higher numbers of leukocytes 
makes the blood more viscous. Additionally, cells may adhere to 
the endothelial lining of the blood vessels causing decrease of 
blood flow. Furthermore, periodontitis has been associated with 
an increase in plasma fibrinogen and platelet activation which 
increase the risk of atherosclerosis and CVD. The aim of the 
study was to investigate the effect of nonsurgical periodontal 
therapy on total leukocyte count (TLC), differential leukocyte 
count (neutrophils, lymphocytes, eosinophils, basophils, and 
monocytes), erythrocyte sedimentation rate (ESR), and the total 
platelet count  on patients with periodontitis. Thirty patients 
were selected for the study. The results of this experiment were 
that a decrease in clinical parameters of PD (ex. plaque index, 
gingival index, etc.) was accompanied by a statistically significant 
change in TLC, platelet count and ESR. The authors concluded 
that there is a decrease in hematological parameters after non-
surgical periodontal therapy, which may also reduce the risk of 
atherosclerosis (Siddeshappa, et. al. 2016). 
In a similar vein, animals with experimentally induced periodon-
titis had more extensive accumulation of lipids in the aorta than 
did those without t.  There was a positive correlation between 
the severity of PD and the extent of lipid deposition (Jain, et. al. 
2003).,  A study of 711 subjects, suggestaaed that tooth loss is a 
marker of past periodontal disease, and is related to subclinical 
atherosclerosis. Among those with 0 to 9 missing teeth, 46% had 
carotid artery plaque, and among those with ≥10 missing teeth, 
carotid artery plaque prevalence was about 60% (Desvarieux, 
et al. 2003).
However, such correlations are vague and broad. The above 
studies merely show increased atherosclerotic suseptability. 
This can be due to an overall systemic increase of inflammatory 
organisms. A more direct demonstration of correlation can be 
had by discovery of specific periodontal oral cavity bacteria in 
the atherosclerotic lesion. Such findings would show that in-
flammatory PD contributes causally to heart disease and stroke, 
and that these two conditions are not merely coincidentally as-
sociated. Research in this area is more questionable, and not as 
consistent in its results.
In a study conducted in 2004, 52 patients were studied who were 
scheduled for carotid endarderectomy to ascertain the presence 
of periodontal bacteria DNA, including that of Actinobacillus acti-
nomycetemcomitans, Fusobacterium nucleatum, Porphyromonas 
gingivalis, Prevotella intermedia, and Tannerella forsythensis, in 
carotid atheromatous plaque. In subgingival plaque samples of 19 
test patients, T. forsythensis, F. Nucleatum, P. intermedia, P. gingivalis 
and A. actinomycetemcomitans were found. However, no peri-
odontal DNA was detected by PCR in any of the carotid samples. 
The authors concluded that the presence of periodontal DNA 
in atheromatous plaques could not be confirmed by this study, 
and thus no correlation could be established between species 
associated with periodontal disease and putative bacteria con-
tributing to atheromatous plaques (Cairo, et. al. 2004). This study 
brings into question the causality relationship of periodontitis and 
gingival disease to CVD.
Other studies have produced results indicating a small num-
ber of matching pathogens. A study was conducted  to isolate 
and identify bacteria from the periodontal pockets of different 
patients and to compare them with the microorganisms detect-
ed in atheromatous plaques obtained from the same patients. 
Clinical isolates were obtained from 12 patients with periodon-
tal wounds and atheromatous plaques. These samples were 
then used to identify periodontal bacteria using polymerase 
chain reaction (PCR) assays. The results were as follows. From 
the 12 patients studied, 9 presented different periodontopathic 
species. In two patients Actinobacillus actinomycetemcomitans, 
a gram-negative coccobacillus, was present in the periodontal 
pockets and the respective atheromatous plaques. The authors 
were unable to explain the mysterious absence of P. intermedia 
and P. gingivalis growth in atheroma samples, even though these 
bacteria are usually present in periodontal samples. The authors 
concluded that the presence of A. actinomycetemcomitans in 
both the atheromatous plaque and the periodontal pockets of 
the same patients could indicate a role for periodontal patho-
genic bacteria in the atherosclerosis disease process (Padilla, et. 
al. 2006). Similarly another investigation was aimed at testing the 
validity of the translocation hypothesi and its role in promot-
ing plaque development. The authors used 16s cloning and se-
quencing, to determine the microbial diversity of the subgingival 
environment and atheroma plaques of patients concomitantly 
suffering from periodontitis and obstructive coronary artery 
atherosclerosis (OCAA). Subgingival biofilm and coronary bal-
loons used in percutaneous transluminal coronary angioplasty 
were collected from 18 subjects presenting with generalized 
moderate to severe periodontitis and OCAA. DNA was ex-
tracted and the gene 16S was amplified, cloned and sequenced. 
The authors results were similar to those obtained by Padilla, 
et al.. They observed significant differences in microbial diver-
sity between the two environments. While subgingival samples 
mostly contained the phylum Firmicutes, in coronary balloons, 
Proteobacteria was predominant. Additionally, the most com-
monly detected genera in coronary balloons were Acinetobacter, 
Alloprevotella, Pseudomonas, Enterobacter, Sphingomonas and 
Moraxella, while in subgingival samples Porphyromonas, Filifactor, 
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Veillonella, Aggregatibacter and Treponema were found. Despite 
such diversity, 17 identical phylotypes were found in atheroma 
and subgingival samples, indicating possible bacterial transloca-
tion between periodontal pockets and coronary arteries (Serra 
e Silva Filho, et. al. 2014). Again, these findings are seemingly 
small pieces of data regarding the overwhelming question of 
a periodontal-atheroscleric connection. Nevertheless, sev-
eral studies do indicate a strong correlation with respect to 
Porphyromonas gingivalis (P gingivalis). Porphyromonas gingiva-
lis has been strongly associated with adult periodontitis. This 
bacterium is a Gram-negative, nonmotile, obligate anaerobe 
that can invade and infect 
epithelium, endothelium, 
and vascular smooth muscle 
cells. Another group used 
ApolipoprotienE knockout 
(apoE−/−) mice which were 
orally administered the peri-
odontal disease pathogen 
Porphyromonas gingivalis. 
The P. gingivalis was detect-
ed in the blood and aortic 
tissue of the mice. The mice 
challenged with P. gingivalis 
presented with an increase 
in atherosclerotic plaque, 
as well as expression of the 
innate immune response 
markers Toll-like receptors 
(TLR)-2 and TLR-4 in the 
aortic tissue (Gibson, 2004).
In order to determine 
whether recurrent intrave-
nous injections of P. gingivalis, 
mimicking periodontitis-as-
sociated bacteremia, pro-
motes coronary artery and 
aortic atherosclerosis the 
researchers chose pigs for this experiment since they develop 
coronary lesions that closely simulate human disease. Showed 
Thirty-six pigs were sensitized with 109 killed P gingivalis sub-
cutaneously. Four weeks later all sensitized pigs in the group 
to be challenged started intravenous injections three times a 
week for 5 months with 106 to 107  units of P gingivalis while 
controls received saline. Pigs were euthanized 2 weeks after the 
last injection, and coronary arteries and aortas were analyzed. 
The results were significant. The authors found that the pigs 
that received intravenous P gingivalis challenges demonstrated 
a >100-fold increase in anti–P gingivalis antibody levels. This was 
in conjunction with the result that pigs challenged with recur-
rent P gingivalis bacteremia develop significantly larger coronary 
and aortic atherosclerotic lesions than those that were not 
challenged. The average coronary and aortic intimal areas were 
between≈3 times and ≈5.9 times larger than controls, a signifi-
cant difference. These lesions were predominantly composed of 
smooth muscle cells. In addition, hypercholesterolemic pigs like-
wise challenged with recurrent P gingivalis bacteremia develop 
larger coronary and aortic atherosclerotic lesions, both having 
an intimal area that was ≈2.2 times larger than controls. Brodala, 
N et al. summarized their results in Table 1 and Table 2.
Additional significant information was reported by the au-
thors. We mentioned previously the lack of evidence showing 
periodontal bacteria within the atheromatous legions. Previous 
studies only showed a correlation between the two diseases. 
Brodala, et al. discovered the following. P gingivalis ribosomal 
DNA was detected in the carotids (5 of 5) and the aortas (4 of 
5) from the 5 P gingivalis-treated pigs on the low-fat diet and
the aortas of all 7 P gingivalis–challenged pigs on the high-fat 
diet. However, none of the aortas or carotids from saline-chal-
lenged control pigs, whether sensitized or not, had amplifiable 
P gingivalis ribosomal DNA. The authors themselves note two 
limitations in their study. Firstly, the pig model used does not 
entirely and accurately replicate the bacteremia of oral or-
igin from inflamed human periodontal tissues. Nonetheless, 
as seen previously in rodents, the P gingivalis–challenged pigs 
Low-Fat Diet Aorta Coronary Arteries
Intimal Area, μm2 Intimal Area as % 
Medial Area
Intimal Area, μm2 % Luminal 
Narrowing by 
Intima





982.7±217.5 8.06±2.5 192.09±93.92 5.25±0.89 5.45±2.19
Group 2. P 
gingivalis FDC381–
challenged
768.5±318.3 5.08±1.10 158.19±33.45 4.56±0.85 3.83±0.83
Group 3. P gingi-
valis A7436–sensi-
tized controls




203.6±247.1 1.15±1.46 48.9±29.1 1.3±1.0 1.7±1.3
TABLE 1. Aortic and Coronary Artery Atherosclerosis Morphometry in Pigs Fed a Low-Fat Diet
High-Fat Diet Aorta Coronary Arteries
Intimal Area, μm2 Intimal Area as  
% Medial Area
Intimal Area, μm2 % Luminal 
Narrowing by 
Intima









1976.6±1014.7 7.9±4.0 695.1±804.5 16.3±15.7 11.8±10.4
TABLE 2. Aortic and Coronary Artery Atherosclerosis Morphometry in Pigs Fed a High-Fat Diet
47
The Relationship between Periodontitis and Cardiovascular Disease
developed an anti–P gingivalisantibody response as a conse-
quence of P gingivalis challenges in association with increased 
atherosclerosis. Second, the number of pigs was not sufficient 
to exclude an effect of gender in this study. Data that was not 
available at the time of this study suggests that human males 
have a greater prevalence of asymptomatic carotid disease 
than females with comparable severity of periodontitis. This 
study does not account for such differences (Brodala, et al. 
2005). 
Other systemic markers also present evidence that peri-
odontitis can lead to a systemic inflammatory response. Loos, 
(2006) outlines several systemic effects of periodontitis. He 
writes that in severe periodontitis, characterized by exten-
sive plaque buildup, bacteremia occurs frequently, leading to 
leakage of lipopolysaccharides, a major component of peri-
odontopathogens. Additionally, Loos was involved in several 
studies which investigated the presence of systemic markers 
of cardiovascular disease in patients with periodontitis. The 
author took peripheral blood from  patients and analyzed the 
presence and levels of white blood cells, red blood cells and 
thrombocytes. He also analyzed the presence of important 
marker molecules such as acute phase proteins, proinflamma-
tory cytokines, and markers of procoagulant state. The sug-
gestion is that increased numbers of white blood cells may 
make the blood more viscous and increase blood rheology. 
Additionally, white blood cells tend to stick to the inside of 
blood vessels, particularly where there is inflammation. This 
may contribute to reduced blood flow which in turn increases 
the risk of microthrombus formation. The author writes that 
he found that the highest number of white blood cells were 
present in patients with severe periodontitis, the lowest num-
bers were found in control groups, and subjects with moderate 
periodontitis presented levels in between. Thus, the presence 
of elevated WBC’s in the blood stream due to periodontitis is 
evident. We can then postulate that such inflammatory mark-
ers can exacerbate an atherosclerotic lesion.  
The presence of other systemic markers of inflammation in 
periodontitis is also evident. One of the important markers of 
CVD is proinflammatory cytokines. In particular, interleukin-6 
(IL-6) is produced by monocytes, neutrophils, endothelial cells, 
and B cells, and stimulates the hepatocytes to produce acute 
phase reactants. The author found that in general, patients 
with severe periodontitis had much higher levels of IL-6 than 
the controls. In many controls the levels of IL-6 could not 
be detected at all. Additionally, when patients with aggressive 
periodontitis were treated, IL-6 levels decreased, highlighting 
the correlation between periodontitis and IL-6 levels. 
C-reactive protein (CRP) is another systemic marker of peri-
odontitis. CRP is one of several acute phase proteins produced 
in the liver. The liver produces these acute phase proteins in 
response to infection or an inflammatory process, mainly due 
to elevated IL-6. CRP acts as a substance that binds to foreign 
microorganisms or cells, making them more susceptible to 
phagocytosis, also known as an opsonization. What is especially 
important is that CRP is associated with CVD. The relative risk 
of CVD is increased 90% when CRP levels are equal to or more 
than 2 mg. Thus, a possible mechanism would also be associated 
with these findings (Loos, 2006).
Evidence of the Role of Inflammation in CVD 
Until recently, most believed that atherosclerosis was an arterial 
collection of cholesterol, complicated by smooth muscle cell 
accumulation. According to that theory, endothelial denuding 
injury led to platelet aggregation and release of platelet factors 
which would trigger the proliferation of smooth muscle cells 
within the arterial wall. It is now widely accepted that a major 
component of CVD in general, and atherosclerosis in particu-
lar, involves numerous components of the adaptive and innate 
immune systems leading to an inflammatory response within 
atheromatous lesion. A brief synopsis of these findings follows.
The innate immune system plays a major role in the inflam-
matory response in atherosclerosis. Considerable evidence 
supports the notion of early involvement of the monocyte/ 
macrophage, the most prominent cellular component of the in-
nate immune system, in atherosclerosis. Observations in human 
arterial samplings have identified monocyte recruitment as an 
early event in atherogenesis. Additionally, recent examinations 
of monocyte recruitment in mouse atherosclerotic lesions have 
shown that monocyte entry into the atherosclerotic lesion 
continues throughout lesion maturation. High levels of proin-
flammatory monocytes in mice are recognized by the high levels 
of a marker known as Ly6C, or Gr-1, and may correspond to a 
human monocyte subset marked by the presence of P-selectin 
glycoprotein ligand (PSGL) These proinflammatory monocytes 
express high levels of proinflammatory cytokines and other 
macrophage mediators. Recent studies have also highlighted 
the possible participation of mast cells, which exhibit numer-
ous functions implicated in atherogenesis. For example, mast 
cells are known to release certain serine proteinases, histamine 
and leukotrienes, and heparin, a cofactor in atherogenesis. An 
additional area of evidence links thrombosis with inflammation. 
Thrombin may induce the expression of proinflammatory cyto-
kines (Libby Peter,  2009). 
The adaptive immune system also contributes to the inflam-
matory response in atherosclerosis. T lymphocytes populate ath-
erosclerotic plaques and can be stimulated by certain heat shock 
proteins, components of plasma lipoproteins and other molecules. 
These T cells, upon further stimulation, produce cytokines and trig-
ger inflammation. Additionally, biomarkers, such as highly sensitive 
C-reactive protein (CRP), apolipoprotein B (ApoB), and lipoprotein 
(a) amongst others, have been identified in conjunction with ath-
erosclerosis predictability (Libby Peter, 2009) (Wong , 2012).
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Proposed Mechanisms Linking Periodontitis to 
Cardiovascular Disease
Based on this review regarding systemic effects of periodontitis 
and inflammatory roles in CVD, we can begin to hypothesize 
the different mechanisms that link the two diseases. The au-
thors suggest that the host response to bacteremia may vary 
between patients with periodontitis due to individual variation 
in inflammatory pathway. It is also possible that inherited genetic 
variations could enhance these mechanisms. 
The authors maintain that a number of inflammatory mediators 
and markers are present in higher concentrations in the systemic 
circulation of periodontal patients than in those with healthy oral 
cavities. There are theoretically two pathways by which this could 
occur. There are ample data indicating that inflammatory cyto-
kines and other mediators are produced in the periodontal lesion 
(Siddeshappa, et al. 2016)( Loos, 2006). It has been hypothesized 
that these mediators could enter into the circulation from the 
oral cavity. If this occurs, and the mediators achieve adequate con-
centrations, they would then impact tissues and organs distant 
from the oral cavity. In particular, these mediators from the peri-
odontium could affect other organs, such as the liver, to initiate an 
acute-phase response that would impact other organs. The result 
is that the mediators themselves cause inflammation, as well as 
stimulate other organs to produce a pro-inflammatory response. 
This would lead to inflammatory changes in the endothelium 
such as up-regulation of adhesion molecules and promotion of 
cytokine production, which directly causes initiation and/or accel-
eration of atheroma development. It should be noted that there is 
not strong evidence supporting this mechanism for inflammatory 
cytokines and other mediators accessing the circulation (Teles, 
Wang, 2010).
In addition, it has been shown patients with periodontitis have 
frequent bacteremic incidents and that detectable concentrations 
of lipopolysaccharides are frequently found in the circulation. 
Thus, bacteria, or their pro-inflammatory components, may stim-
ulate systemic inflammatory responses as well as local inflamma-
tory responses in atheromatous lesions. This would follow their 
association with, or modification of serum lipids, engagement of 
receptors on inflammatory cells and endothelium, invasion of en-
dothelial cells, or seeding of atheromatous lesions with bacteria 
or bacterial components. Bacteria or their products could then 
promote inflammatory changes that would contribute to the de-
velopment or propagation of atheromatous lesions.
There are a number of antibodies that can also effect an 
inflammatory response. Some of these anti-bodies have been 
found to react as models of “molecular mimicry,” which is de-
fined as the theoretical possibility that sequence similarities 
between foreign and self-peptides are sufficient to result in the 
cross-activation of autoreactive cells. This is the case in which 
antibodies that have arisen due to infection by oral bacteria in 
the oral cavity make thier way into the systemic blood, engage 
with the host antigens and regulate their operation. These are 
cross-reactive antibodies. It is possible that sometimes these 
antibodies promote cardiovascular disease by exacerbating the 
endothelial reaction to their presence which causes further 
endothelial inflammation, or increasing the absorption of lipids 
into phagocytes. 
Several studies indicate that serum concentrations of poten-
tially inflammatory lipids, including LDLs, triglycerides,  and very 
low-density lipoproteins (vLDLs) are elevated in periodontitis 
patients. These lipid subforms are thought to enter the blood 
vessel wall more easily, may be more susceptible to modification 
and therefore more likely to be incorporated in to the athero-
sclerotic lesion. This would accelerate and  promote the devel-
opment and maturation of the lesions (Schenkein, Loos, 2013).
It is thought that patients who present with periodontal dis-
ease are at risk for some or all of the activities outlined above. 
These mechansims may separately, or in partnership with each 
other, be implicated in arterial disease in periodontal patients. If 
these mechanisms work together, their cumulative effects could 
impact greatly on the severity of the cardiac and arterial disease 
in the periodontal patient.
Conclusion
In conclusion, to date the research does not absolutely prove 
that periodontitis causes cardiovascular disease. However, as 
seen above there is strong evidence supporting this idea, and 
many possible and logical mechanisms have been delineated 
through which periodontitis with all of its ramifications could 
effect cardiovascular disease. More recently, patients being ad-
mitted for surgeries with no seeming connection to periodon-
titis, for example hip replacement surgery, have been required 
to receive authorization from their oral care providers that 
they do not have any periodontal diseases. This is due to the 
mounting evidence, over the last few years, that there is indeed 
a correlation between PD and the rest of the body. Oral care 
providers should be wary of these problems and should advise 
their patients accordingly of the importance of oral care, not 
only with regard to the oral cavity.
References
Brodala, N. M. (2005). Porphyromonas gingivalis bacteremia 
induces coronary and aortic atherosclerosis in normocho-
lesterolemic and hypercholesterolemic pigs. Arteriosclerosis, 
Thrombosis, and Vascular Biology 25. 1446–1451.
Cairo, F., Gaeta, C., Dorigo, W., Oggioni, M. R., Pratesi, C., 
Pini Prato, G., & Pozzi, G. (2004). Periodontal pathogens in 
atheromatous plaques. A controlled clinical and laboratory trial. 
journal of periodontal research, 442-446.
Desvarieux, M., Demmer, R. T., Rundek, T., Boden-Albala, 
B., Jacobs Jr, D. R., Papapanou, P. N., & Sacco, R. L. (2003). 
49
The Relationship between Periodontitis and Cardiovascular Disease
Relationship Between Periodontal Disease, Tooth Loss, and 
Carotid Artery Plaque: The Oral Infections and Vascular 
Disease Epidemiology Test (INVEST). Stroke, 2120-2125.
George W. Taylor, W. S. (2009). Associations between 
Periodontal Disease and Atheroscleric Cardiovascular Diseases 
(CVD). Delta Dental Plans Association (DDPA).
Gibson, F. C. (2004). Innate immune recognition of invasive bac-
teria accelerates atherosclerosis in apolipoprotein E-deficient 
mice. American Heart Association.
Jain, A., Batista Jr., E. L., serhan, C., Stahl, G. L., & Van Dyke, T. 
E. (2003). Role of Periodontitis in the Progression of Lipid 
Deposition in an Animal Model. 
Libby Peter, R. P. (2009). Inflammation in Atherosclerosis. 
Journal of the American College of Cardiology, 54(23).
Lockhart PB, B. A. (2012). Periodontal Disease and 
Atheroscleric Vascular Disease: Does the Evidence Support an 
Independant Association? . The American Heart Association .
Lockhart, P. B.-M. (2009). Poor oral hygiene as a risk factor 
for infective endocarditis-related bacteremia. Journal of the 
American Dental Association, 140, 1238–1244.
Loos, B. G. (2006). Systemic effects of periodontitis. Int Journal 
of Dental Hygiene, 34-38.
Padilla, C., Lobos, O., Hubert, E., Gonzalez, C., Matus, S., Pereira, 
M., . Descouvieres, C. (2006). periodontal pathogens in athero-
matous plaques isolated from patients with chronic periodon-
titis. journal of periodontal research(41), 350-353.
Schenkein, H. A. (2013). Inflammatory mechanisms linking peri-
odontal diseases to cardiovascular diseases. Journal of Clinical 
Periodontology, 51-69.
Schenkein, H., & Loos, B. (2013). Inflammatory Mechanisms 
linking Periodontal Diseases to Cardiovascular Diseases. 
Journal of Clinical Periodontology, S51-S69.
Serra e Silva Filho W, Casarin RCV, Nicolela Junior EL, Passos 
HM, Sallum AW, Gonçalves RB (2014) Microbial Diversity 
Similarities in Periodontal Pockets and Atheromatous Plaques 
of Cardiovascular Disease Patients. PLoS ONE 9(10): e109761. 
https://doi.org/10.1371/journal.pone.0109761
Siddeshappa, S. T., Nagdeve, S., yeltiwar, R. K., Parvez, H., 
Deonani, S., & Diwan, V. (2016). Evaluation of various hema-
tological parameters in patients with periodontitis after non-
surgical therapy at different intervals. Journal of Indian Society 
Periontology, 20(2), 180-183.
Teles, R., & Wang, C.-Y. (2010). Mechanisms Involved in the 
Association between Periodontal Diseases and Cardiovascular 
Disease. John Wiley & sons.
Wong Brian W, M. A. (2012). The Biological Role of 




In the year 1856, the German scientist Freidrich Ludwig 
Meissner described what may have been the first recorded 
case of the Long QT syndrome (LQTS).  He recorded a case in 
which a deaf female student died suddenly during a moment of 
emotional stress. There had been two other children in her fam-
ily who had died previously under similar circumstances.  Since 
a diagnosis of LQTS requires an electrocardiogram, and at that 
time the ECG had not yet been invented, (Rivera-Ruiz, 1927) 
it is not known for certain that these cases were an example 
of LQTS (Vincent, 2002).  Over a hundred years later, a study 
was performed on a family of 10 children. Four of the children 
had profound deafness and would often faint during moments 
of emotional or physical stress (Jervell, Lange-Neilson, 1957). 
Later, a similar familial tendency to faint during stress was ob-
served in case studies (Ward, 1964). A prolonged QT interval 
was observed in the ECGs of subjects. At that time, two familial 
heart diseases known collectively as Long QT Syndrome were 
fully discovered and defined.
The advent of molecular and genetic science has revolu-
tionized the medical world’s approach to this disease, as it has 
done for that of many others. Molecular studies have divided 
the cases of LQTS, which seemed in the past like one basic 
condition, into larger categories differentiated based upon mo-
lecular mechanism. Genetic differences were discovered be-
tween these types in the lab, and since genetic testing became 
available to the public in 2004, 15 categories including over 
1500 different mutations have been found to be the underlying 
cause of a prolongation of the QT interval. This study focus-
es on the three categories which make up the overwhelming 
majority of cases. In some cases, certain genetic origins and 
molecular mechanisms have been linked to certain phenotypic 
characteristics, and some believe that genetic diagnosis may 
aid in recommendations and treatment for LQTS patients. 
This study aims to give a full description of the physiological 
and molecular mechanisms of LQTS based upon the latest re-
search, and analyze the contribution of genetic research to the 
understanding and treatment of the disease. Most importantly, 
the primary objective of this study is to answer the question: 
Should genetic testing be universally recommended to LQTS 
patients and their relatives?
Methods
The Touro library system was an invaluable source of recent, 
high-quality academic papers. In addition, the National Institutes 
of Health and NCBI provided excellent references to PubMed 
articles which provided useful information. The author sought 
out independent studies and other primary sources to pro-
vide up-to-date reports of developments in the molecular and 
genetic understanding of the disease. Studies regarding recent 
attempts at gene-specific treatments and current academic 




The QT interval indicates the length of time from the begin-
ning of the depolarization of the ventricles to the end of their 
repolarization. A prolonged QT interval will mean that the 
ventricles are taking too long to repolarize. This usually does 
not interfere with cardiac function, but occasionally can cause 
life-threatening ventricular fibrillation. The major mechanism 
of ventricular fibrillation which is brought about by a pro-
longed QT interval is the result of Early Afterdepolarizations 
(EADs). The plateau curve caused by the delay in repolariza-
tion can cause some of the heart’s cells to begin depolarizing 
while others are in the process of repolarizing. This can cause 
heterogeneous activity in the heart tissue, especially the ven-
tricles, with some regions contracting and others relaxing. The 
result is a quivering or fibrillating heart, which cannot produce 
sufficient blood output and quickly leads to syncope and death 
(January, et. al. 2000).
Clinical Manifestation
Normally, depolarization and excitation of the cells of the heart 
are caused by a quick flow inwards of positively charged ions. 
These are usually Sodium and Calcium ions. However, the repo-
larization of the cells is not the result of those same ions flowing 
back out; it is an outward current of positively charged Potassium 
ions which causes repolarization. As the Potassium outflow in-
creases, it overtakes the Sodium inflow, and the cell begins to 
repolarize. In all forms of LQTS, the symptoms are caused by 
a surplus of positive charges remaining within the cell. When 
some channels malfunction, the extra positive charge is caused 
Abstract
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by reduced outward Potassium current. When other channels 
malfunction, the extra positive charge is caused by increased or 
unchecked inward Sodium current. In either case early afterde-
polarizations can result, meaning that depolarization may still be 
going on after the effects of repolarization have subsided. This can 
cause what is called a U wave (Roden, et. al. 1996). This U wave, 
however, is not a homogenous contraction of the heart. Some of 
the cells will show this depolarization, and others will not. If this 
EAD is still going on when the next beat occurs, it can cause the 
heart to contract in an uneven way (Antzelevitch, Sicouri, 1994). 
This leads to a characteristic ECG graph known as Torsades de 
Pointes.  This is French for “Twisting of the Points,” and is named 
for the peculiar way the wave form seems to twist around the 
isoelectric line (El-Sherif, et. al. 1996).
Torsades de Pointes is not able to sustain a sufficient stroke 
volume of blood to support brain function. After some time 
with this abnormal ECG morphology, the patient will faint. Most 
of the time, the heart will overcome the Torsades and regain a 
normal heartbeat. At other times, the heart will not be able to 
“snap out of it” and the rhythm will deteriorate to ventricular 
fibrillation, without providing any meaningful output of blood. 
Unfortunately, this situation leads to death within minutes.
A patient who presents with Torsades is considered a medical 
emergency due to the risk of ventricular fibrillation which may 
result. However, the situation rights itself in the vast majority of 
cases. Therefore, DC shock defibrillation is not used as a pri-
mary course of action since it can cause recurrent arrhythmias. 
One of the major aspects of treatment is preventing the patient 
from returning to a state of Torsades; whatever caused it the 
first time might cause it again. Therefore, it is urgent to remove 
or mitigate the effects of any drugs which may have caused the 
Torsades. It is also advisable to take measures to suppress EADs, 
among other things. Magnesium is effective at suppressing EADs 
(Viskin, 1999).
Since the danger resulting from a prolonged QT interval de-
pends not only on the actual length of the interval but also the 
way it interacts with the surrounding segments of the ECG wave, 
it is important to have a method with which to accurately mea-
sure the clinical significance of any particular QT prolongation. 
To this end, the concept of QTc was developed, in which the 
actual length of the QT interval is mathematically corrected to 
take heart rate into account (Bazett, 1920). Since that time, many 
other methods have been proposed, and the medical community 
is currently in debate over which is most useful and accurate.
Molecular Mechanisms
To understand the cellular and molecular mechanics of Long 
QT Syndrome, we must understand the process of the ac-
tion potential itself. At rest, nerve cells have a higher level of 
positive charge outside the cell than they do inside.  When a 
nerve cell is stimulated, the chemical or electrical impulse it 
receives activates voltage- or ligand-gated Sodium channels. 
This creates an influx of positive current (depolarization). After 
a certain amount of positive flow is admitted to the cell, volt-
age-gated Potassium channels are activated, creating an outflow 
of Potassium ions and returning the cell to its resting state with 
more positive charge on the outside. Many different types of 
channels are involved in these processes. Cardiac muscle cells 
are unusual in the sense that they act to carry an action poten-
tial as efficiently as nervous tissue can, and therefore depend 
upon a similar set of ion channels (Sanguinetti, Jurkiewicz, 1990). 
We will delve deeper into this process shortly.
Some years ago, a groundbreaking study uncovered infor-
mation about the process of repolarization in cardiac tissue. 
The goal was to understand electrophysiological differences 
between different areas of the heart.  Microelectrodes were 
used to measure delays in repolarization found in certain canine 
heart cells, known as M cells. These cells, which had been previ-
ously found to show markedly longer repolarization times, are 
found in the deep sub-pericardial and mid-myocardial regions. 
The researchers measured the durations of their action poten-
tials to have a mean of 358 ms, as opposed to 282 ms or 287 ms 
found in other regions of cardiac muscle. Upon further exam-
ination of the M cells, it was shown that they show differences 
in IK when compared to other cells. IK means Potassium ion 
current, which is the current responsible for the repolarization 
that ends every action potential. There are two distinct currents 
found in cardiac cells, the IKr, or rapid-activating current, and 
the IKs, or slow-activating current. These currents are mediated 
by two separate transmembrane voltage-gated protein channels. 
The M cells have smaller IKs (Slow-acting Potassium current) 
than the other cells, while IKr (Rapid-acting Potassium current) 
is generally the same. (Of course, the mechanism for the rate 
of an action potential has many factors, and depends upon the 
inward rectifier (IK1), Calcium ion inward current, Sodium-
Potassium pump inward current, Sodium-Calcium inward cur-
rent, and others.) (Sanguinetti, Jurkiewicz, 1990). The IKs in the 
M cells was measured using a selective IKr blocker, E-4031. The 
Potassium current was measured in the cells with E-4031 and 
in the cells without E-4031. The difference between the two 
measurements was the IK due to IKr, and the common portion 
was the IK due to IKs. It was found that the IKr in different cell 
types was essentially the same, and reduced IKs current was 
responsible for the delayed repolarization in the M cells. It was 
discovered in this study that IKr differs from IKs in its kinetics of 
activation, more negative threshold for activation, and different 
protein structure suggested by its selective blockage by meth-
ane sulfonamide class III agents like E-4031. However, studies of 
M cells demonstrated that delayed IKs can play a principle role 
in delayed repolarization. The researchers predicted that the M 
cells may be found to be the culprits of diseases such as LQTS 
(Liu, Antzelevitch, 1995). 
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Later the same year, it was shown that the plateau portion of 
repolarization is accomplished principally by the IKs protein. It 
was also discovered that in the heart in general, blocking either 
IKr or IKs can prolong duration of the action potential by the 
same degree.  This means that either protein can be a target for 
antiarrhythmic drugs for tachycardia. By the same token, either 
protein could also be the culprit of an arrhythmia with extend-
ed action potentials, such as LQTS (Zeng, et. al. 1995.) As we 
will see soon, genetic studies have confirmed that LQTS can 
result from mutations in the genes which code for either of the 
proteins, and others as well.
Genetic Variation
It has been known for many years that not all cases of LQTS 
have the same symptoms. For example, some cases of LQTS 
are dangerous specifically under situations of emotional stress. 
Other cases are set off especially by exercise, whereas some 
cases seem to cause syncope specifically during swimming. It 
was established that in these cases it was not the stress or 
exercise of swimming which caused the ill effects, but rather the 
actual immersion of the face in cold water (Mayumi, et.al. 1995).
Genetic research has since shown that mutations in several 
genes, coding for several proteins, can cause LQTS. Different 
types of the disease have been linked to different genes, and 
over 1500 different novel mutations have thus far been discov-
ered on 15 different genes which code for 15 different proteins. 
One such gene is the KCNQ1 gene. This gene on chromosome 
11 codes for the alpha subunit of the voltage-gated Potassium 
channel. It has six transmembrane domains. Even though there 
is ion pore function for this protein alone, some of the func-
tioning of the channel requires it to be co-assembled with the 
beta subunit. This subunit is called KCNE1.  The two subunits 
together account for the cardiac IKs. Mutations in different seg-
ments of this protein channel cause varying degrees and kinds 
of diseases. The S4 domain contains a voltage sensor, and loss-
of function mutations in this area can cause LQTS. In addition, 
there is a pore helix selectivity filter segment which can, when 
its shape is altered, severely affect the functioning of the IKs 
current. In this segment, certain mutations cause more loss of 
function than others. For example, an I313K mutation in the se-
lectivity filter segment can cause all of the symptoms of LQTS, 
including syncope and risk of death, whereas an I313M mutation 
will prolong the QT interval, but the patient will be otherwise 
asymptomatic. All KCNQ1 and KCNE1 mutations are included 
in the category LQT1 (Ikrar, et. al. 2008).
LQT2 is a result of a loss of function in the HERG channel. 
HERG stands for Human Ether a go go related gene, so named 
for the fact that a mutation in its homolog in fruit flies causes 
them to “dance” when exposed to ether. More than 80 mutations 
were known in this gene in 2000, and many more are known 
today. HERG is a gene located on chromosome 7 that codes for 
the pore-forming subunit for the IKr channel. There are several 
mechanisms by which HERG mutations cause reduced IKr. One 
of them is that a certain degree of codominance exists in het-
erozygous individuals with certain mutations. The protein which 
comprises the HERG channel is actually a tetrameric structure 
formed by the co-assembly of four copies of the HERG gene 
product. Depending on how the subunits combine, the mutant 
gene products might be excluded from the ion pores, causing 
a 50% reduction in pore function. On the other hand, the mu-
tants might be included in some of the complete proteins, causing 
more than 50% to be defective. Other mutations in the HERG 
gene are truly dominant, and produce channels which activate 
at voltages which are more negative than usual.  One mutation, 
N629D, was found to make the pore channel nonselective and 
allow ions other than K+ to pass through. Interestingly, many 
mutations in the HERG protein affect not the actual functioning 
of the ion pore, but its “trafficking,” i.e. its ability to be properly 
packaged and transported to the plasma membrane.  In these 
cases, the mutant proteins are marked as abnormal by the cell’s 
quality control systems and are kept in the endoplasmic reticu-
lum and degraded. In these scenarios, applying E-4031 to affected 
cells was shown to allow trafficking of the proteins to the plasma 
membrane, and the drug could later be washed off. Applying this 
method in vivo is still an area of study for these particular mutant 
forms.  This is a form of gene-specific therapy for LQT2. Another 
form may be increasing serum K+ concentration, since HERG 
current is highly sensitive to extracellular K+ concentration. 
(January, et. al. 2000) 
More work was done recently on attacking the gene-specific 
therapy problem from the trafficking angle. It has been shown 
that certain mutations cause misfolding of the protein, and this 
is what prevents it from leaving the endoplasmic reticulum. This 
was discovered by causing chemical unfolding of several differ-
ent mutant forms and measuring the difference between the 
stabilities of each mutant’s folding. It was found that there was 
a direct correlation between the conformational stability of the 
protein and its degree of trafficking deficiency (Harley, et. al. 
2012).
LQT3 is has a very different molecular basis from that of both 
LQT1 and LQT2. The first two forms of Long QT syndrome 
are caused by malfunction of Potassium channels. These chan-
nels function to create an outflow of positive current during 
repolarization of the heart’s muscle cells. These mutations are 
examples of what is known as “loss of function” mutations. In 
other words, the protein coded for by the gene does not work 
as well with the mutation as it does in the wild type. LQT3, 
however, is a “gain of function” mutation. It causes the Sodium 
channel pores to become more effective than in the wild type. 
This means that the depolarization process lasts longer, thereby 
slowing repolarization and extending the QT interval (Mazzanti, 
et. al. 2016).
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Gene-Specific Recommendations and Therapies
Phenotypic differences have been found between LQT1 and 
LQT2. Heterogeneity has been noticed among LQTS patients 
regarding the effect that exercise has in precipitating Torsades 
de Pointes and ventricular fibrillation. It was discovered that 
patients matched for age and gender showed differing QT ad-
aptation patterns during exercise. Patients with LQT1 showed 
a steady QTc prolongation, even at higher heart rates. Since 
each heart beat occurs at a faster rate, and the QT prolonga-
tion remains the same, it is more likely that the repolarization 
process will interfere with the following QRS complex, bringing 
about Torsades de Pointes and ventricular fibrillation, causing 
syncope or death. In LQT2, however, the QT interval prolon-
gation is actually reduced as the heart rate increases, meaning 
that the QT interval occupies the same proportion of the total 
ECG sequence that it does at lower heart rates, such as during 
rest. Therefore there is no greater risk of syncope in LQT2 
during exercise than at any other time. This is consistent with 
the molecular and genotypic understanding of the differences 
between these two disease types. Exercise creates an increase 
in sympathetic activity, i.e. the heart is being driven not only 
by its internal pacemaker, but also by hormonal and systemic 
nervous impulses and stimulants, such as epinephrine and other 
adrenergic agents. In this situation, the predominant current for 
the increase in the rate of repolarization has been proven to be 
the IKs current, precisely that one which is affected by LQT1. 
Therefore, it is understandable that LQT1 patients will be more 
susceptible to syncope brought on by exercise-related stress. 
These differences are generalizations; actual recommendations 
to patients still must be based upon observation and testing 
under different types of stress (Sy, et. al. 2010).
In addition, many symptoms have been found to be associat-
ed with different forms of LQTS. As stated, LQT1 is associated 
with syncope brought on by exercise, with swimming being a 
particular stimulus in certain cases. LQT2 is associated with 
cardiac events connected with mental stress such as fear or 
anger. LQT2 patients also faint when they hear sudden noises 
such as alarm clocks and phones.  LQT3 seems to be associated 
with attacks which come while a person is resting or sleeping. 
Knowledge of the genetic basis of the disease can thus be helpful 
in advising the patient which activities to avoid. However, even 
though statistically there is a significant association of these 
properties with these forms of the disease, a genetic diagnosis 
is by no means conclusive of a specific expression. Among the 
1500 variations discovered thus far, most do not exactly fit the 
general trend. Therefore, although genetic testing can be helpful 
in planning an avoidance or treatment plan, clinical manifestation 
is the ultimate deciding factor (Mangset, Hoffman, 2014). 
Several gene-specific therapies have been proposed for 
LQTS. Beta Blockers are effective for LQT1 and LQT2, whereas 
they can have negative effects in the case of LQT3. Potassium 
supplements also are suggested for LQT2, since an elevated 
blood potassium level has been shown to enhance the activity of 
the HERG channels. Mexiletine, a methane sulfonamide Sodium 
channel blocker, may be effective for LQT3, as described before. 
Although some of these have shown promise, comprehensive 
and clear proof of their efficacy and safety has not yet been es-
tablished (Viskin, 1999.) Recent studies have shown Mexiletine 
to be effective at reducing the QTc of more than two thirds of 
patients with LQT3. These studies had certain limitations, how-
ever, and were not sufficient basis for widespread use of this 
gene-specific therapy (Mazzanti, et. al. 2016).
Implications of Genetic Testing
Since 2004, genetic testing has been made available on symp-
tomatic people to discover what the genetic source of their 
syncopal episodes may be. However, in many cases there is a 
dilemma for the patient. Most cases of LQTS do not require 
genetic testing for diagnoses, and if pathology is suspected in a 
newborn based on heredity, risk of serious effects can usually be 
effectively determined by ECG. In addition, even if the genetic 
testing comes up clear, preventive measures will still be taken 
for anyone whose QTc is over the limit of .45 ms. Therefore, 
the primary justification for genetic testing is not identifica-
tion, but rather the possibility that gene-specific therapy will 
be available. As explained, most gene-specific therapies which 
require a genotypic diagnosis are still not available to the public. 
Those therapies and recommendations which are available can 
be safely used without genetic testing. This creates a dilemma 
for many patients and their relatives. On the one hand, there 
is the patient’s right to know. A clear, empirical knowledge of 
the source of their disease helps some patients adjust and cope 
psychologically. On the other hand, who would want to know 
for certain that they carry a gene which may or may not have 
deleterious effects on their children? Since there are effective 
screening methods, and this knowledge can be a significant 
source of fear and anxiety as well as causing moral dilemmas, 
many people are uncomfortable going for testing. Sensitivity to 
this discomfort has been termed by some as “the patient’s right 
not to know.” This consideration is rarely addressed by health 
care providers, and the National Society of Genetic Counselors 
is making an effort to educate providers about the psychological 
impact of genetic testing (Mangsett, Hoffman, 2014).
 A longitudinal study was done to observe the long-term ef-
fects of congenital LQTS. Individuals from 328 families with mul-
tiple cases of LQTS were observed over the course of several 
years.  The probands had usually fainted at some time during 
their childhood years, with an episode of fainting or death oc-
curring in 50% of them by age 12.  The majority were women, 
showing that the effects of the gene are more serious in females. 
The yearly rate of fainting spells till age 50 was 5.0% per year for 
those enrolled in the study, and the rate of death was .9%. This 
54
Menachem Braun
was higher not only than the rates in unaffected family members, 
but also higher than the rates in affected family members. This 
shows that LQTS genes can have a variable level of expression 
even among affected people (Moss, et. al. 1996). Since the dis-
ease can have varying levels of effect even among those who are 
stricken by it, it may be true that testing of all family members 
can help in discovering mildly affected people.
More recently, however, a survey was taken to determine the 
effects of genetic abnormalities on people who were otherwise 
clinically normal in terms of ECG and symptoms. Interestingly, 
no ill effects were found to be associated with genetic defects 
alone, even in situations where those same genetic defects pro-
duced significant disease in other patients. Some suggest that 
this might be affected by the fact that genetically positive pa-
tients tend to take care to avoid activities which bring on syn-
copal episodes. This information was not part of the study how-
ever, and it is therefore unclear whether clinically normal but 
genetically abnormal individuals need to take any action at all 
to protect themselves from syncope or death (Lampert, 2015).
One other argument has been made in favor of genetic testing 
of family members of affected individuals. Some drugs which are 
administered by psychiatrists to relieve psychological symptoms 
either function directly through changing the electrophysiolog-
ical workings of the heart, or have side effects which can affect 
or alter the action potential of the heart cells. It is suspected 
that an increased rate of sudden death among psychiatric pa-
tients may be caused by underlying QT interval abnormalities 
which may, when augmented by the effects of the drugs, come to 
have deadly effects upon the heart’s rhythm (Sayako, et.al. 2014.) 
However, the effects were only observed in a small percentage 
of the psychiatric population.
Certain specific mutations have been identified as conclusive-
ly pathogenic. Individuals who carry these variants are advised 
to take beta blockers as a prophylactic measure. Although these 
are official recommendations due to an abundance of caution, 
there is still no evidence that these mutations pose a significant 
risk in unaffected people, and the testing of relatives is not uni-
versally required (Vincent, 2001).
Conclusions
The Long QT Syndrome is a great example of how a little infor-
mation can be a dangerous thing. This is an area in which there 
has been a recent surge in pure information: exact mutation types, 
statistics, symptoms, etc. However, the tying together and under-
standing of this information is lagging far behind its production, 
and that which exists is ambivalent and confusing. Since people 
rely on their healthcare providers not only for information, but 
also for confidence and reassurance, it can be difficult for the pro-
vider to respond appropriately to questions about this disease. 
One patient commented that he gets different recommendations 
from the same doctor on different occasions. In these situations 
the doctor must try to convey confidence to the patient while 
honestly admitting that he or she does not know the full signifi-
cance of genetic results, and possibly nobody in the world knows 
(Mangsett, Hoffman, 2014).
Genetic testing is definitely a powerful tool in the understand-
ing of LQTS. However, both methods of interpreting the genetic 
data and the treatments that might be tailored to the specific 
types have not yet been developed in a way which provides in-
stitutionally recognized necessary medical benefit. In addition, in 
most cases, only minor benefits have been shown to come from 
testing unaffected relatives for identification purposes. This makes 
it difficult to argue that all patients and relatives should universally 
submit to genetic testing, since research has observed emotion-
al and ethical difficulties which can arise from the testing itself. 
However, a specific genetic diagnosis can influence the recom-
mendations and, to some degree, the treatment that a patient will 
be provided with. In addition, since treatment is recommended 
for some variants even in the absence of ECG symptoms, relatives 
of individuals with those variants have more reason to submit 
for genetic testing. A physician and genetic counselor should 
therefore discuss the benefits as well as the pitfalls of testing with 
the patient or relative, and the patient or relative should decide 
whether or not to submit to testing. In the coming years, the ap-
proval of developing gene-specific treatments may make genetic 
testing more important for affected individuals.
References
Antzelevitch C, Sicouri S. Clinical relevance of cardiac arrhyth-
mias generated by afterdepolarizations: role of M cells in the 
generation of U waves, triggered activity and torsade de pointes. 
J Am Coll Cardiol.1994; 23: 259–77.
Bazett HC. An analysis of the time-relations of electrocardio-
grams. Heart.  1920;7:353–370.
El-Sherif N, Caref EB, Yin H. The electrophysiological mecha-
nism of ventricular tachyarrhythmias in the long QT syndrome: 
tridimensional mapping of activation and recovery patterns. 
Circ Res. 1996; 79:474–92.
Harley, CA, Jesus, CSH, Carvalho, R, et. al. Changes in Channel 
Trafficking and Protein Stability Caused by LQT2 Mutations in 
the PAS Domain of the HERG Channel. PLoS ONE. 2012;7(3): 
e32654
Ikrar, T, Hanawa, H, Watanabe, H. A Double-Point Mutation in 
the Selectivity Filter Site of the KCNQ1 Potassium Channel 
Results in a Severe Phenotype, LQT1, of Long QT Syndrome. J 
Cardiovasc Electrophysiol. 2008;19:541-549. 
January, CT, Gong, Q, Zhou, Z.  Long QT Syndrome: Cellular 
Basis and Arrhythmia Mechanism in LQT2.  J Cardiovasc 
Electrophysio. 2000;11(X):1413-1418 
Jervell A, Lange-Nielsen F. Congenital deaf-mutism, functional 
heart disease with prolongation of the QT interval, and sudden 
death. Am Heart J. 1957;54:59–68.
55
Should Genetic Testing be Recommended for Long QT Syndrome Patients
Lampert, R. Reassuring News for Genetically Tested, 
Appropriately Treated, Low-Risk LQTS Patients. J Cardiovasc 
Electrophysiol. 2015;26:859-861.
Liu, D, Antzelevitch, C. Characteristics of the Delayed Rectifier 
Current (IKr and IKs) in Canine Ventricular Epicardial, 
Midmyocardial, and Endocardial Myocytes: A Weaker IKs 
Contributes to the Longer Action Potential of the M Cell. 
Circ Res. 1995;76:351-365 http://circres.ahajournals.org/con-
tent/76/3/351.long. Accessed 2017.
Mangset, M, Hofmann, B. LQTS Parents’ Reflections About 
Genetic Risk Knowledge and their Need to Know or Not 
to Know their Children’s Carrier Status. J Genet Counsel. 
2014;23:1022–1033
Mayumi, K, Tohru O, Yoshio A. Abnormal Response to Exercise, 
Face Immersion, and Isoproterenol in Children with the Long 
QT Syndrome. PACE. 1995;18:2128-2134
Mazzanti, A, Riccardo, M, Faragli, A, et. al.  Gene-Specific 
Therapy With Mexiletine Reduces Arrhythmic Events in 
Patients With Long QT Syndrome Type 3. J Am Coll Cardiol. 
2016;67(9):1053–1058.
Moss AJ, Schwartz PJ, Crampton RS, et al. The long QT 
syndrome: Prospective longitudinal study of 328 families. 
Circulation. 1991;84(3):1136-44. https://www.ncbi.nlm.nih.gov/
pubmed/1884444. Accessed 2017.
Rivera-Ruiz M, Cajavilca C, Varon J. “Einthoven’s String 
Galvanometer: The First Electrocardiograph”. Texas Heart 
Institute journal. 1927 35 (2): 174–8.
Roden DM, Lazzara R, Rosen M, Schwartz PJ, Towbin J, Vincent 
GM. Multiple mechanisms in the long QT syndrome: current 
knowledge, gaps, and future directions. Circulation. 1996; 94: 
1996–2012.
Sanguinetti, MC, Jurkiewicz, NK. Two components of cardiac 
delayed rectifier K+ current. Differential sensitivity to block by 
class III antiarrhythmic agents. J Gen Physiol. 1990;96(1):195. 
http://jgp.rupress.org/content/96/1/195/tab-pdf. Accessed 2017. 
Sayako K, Noriko S, Yuta H, et. al. Molecular analysis of potas-
sium ion channel genes in sudden death cases among patients 
administered psychotropic drug therapy: Are polymorphisms in 
LQT genes a potential risk factor? Journal of Human Genetics. 
2014; 59: 95–99    
Sy, RW, Chattha, IS, Klein, GJ, et. al. Repolarization Dynamics 
During Exercise Discriminate Between LQT1 and LQT2 
Genotypes.  J Cardiovasc Electrophysiol. 2010;21:1242-1246
Viskin, S. Long QT syndromes and torsade de pointes.  Lancet. 
1999;354:1625–33
Vincent, GM. The Long QT Syndrome. Indian Pacing 
Electrophysiol J. 2002;2(4):127–142. https://www.ncbi.nlm.nih.
gov/ pmc/articles/pmc1557415/. Accessed 2017.
Vincent GM. Role of DNA testing for diagnosis, management, 
and genetic screening in long QT syndrome, hypertrophic 
cardiomyopathy, and Marfan syndrome. Heart. 2001;86:12-4. 
Ward OC. A new familial cardiac syndrome in children. J Ir 
Med Assoc. 1964;54:103,106.
Zeng, J, Laurita, KR, Rosenbaum, DS, et al. Two Components of 
the Delayed Rectifier K+ Current in Ventricular Myocytes of 
the Guinea Pig Type: Theoretical Formulation and Their Role 




In 1957 the world was exposed to what was then known as 
Multiple Personality Disorder (MPD) through the storyline 
of the movie, Three Faces of Eve. A classic example of MPD, a 
woman named Eve White was having symptoms of headaches 
and blackouts while being unaware of her disorder. One of the 
three identities, known as Black, is the reason her husband aban-
dons her and is also why she tries to kill her own daughter. Black 
knows about White, but White does not know about Black. 
Through therapy the third identity emerges, known as Jane. Jane 
knows about all three identities and eventually all three identi-
ties merge (Lehman, 2014). This story of the Three Faces of Eve 
is a glimpse into the world of MPD.  As time progressed new 
research has been developed and continues to develop regard-
ing MPD, currently referred to as Dissociative Identity Disorder 
(DID), broadening the subject in all areas.
DID is a psychophysiological disorder that affects about 
1-3% of the world’s population (Vermetten et.al.,2006). DID 
diagnosis requires a minimum of two identities residing in one 
body. Each of these identities have their own biology, memo-
ries, perceptions and preferences. Common symptoms of DID 
include hallucinations and amnesic periods. An average of 8-13 
identities develop and Daniel Goleman (1923) states that it is 
possible for one to be living with up to 60 different identities 
within oneself. The different identity types include the childlike 
personality type, the protector, and the persecutor. A miscon-
ception that the host personality is in fact the patient’s original 
identity since it is the identity or alter ego will commonly seek 
treatment. The split in identities originates from the childhood 
of the patient. People with DID have a history of either sexu-
al or physical abuse typically between the ages 3-8. Coherent 
with the common identity types, the childlike personality is 
the age in which the abuse took place. The persecutor is the 
identity that mirrors the abuser. The protector is the identity 
that feels responsible to protect the rest of the personalities 
from any abuse or trauma (Goleman, 1985). Each identity can 
be categorized as either an emotional personality or a normal 
personality. The emotional personalities are the ones that react 
and respond to the trauma they experienced. The normal per-
sonalities are the ones that deal with normal and daily functions 
(Nijenhuis, Steele, 2010) . DID is often misdiagnosed as other 
personality disorders due to the complexity of the various 
identities. An identity in itself may have a personality disorder 
such as Obsessive Compulsive Disorder and be treated for that. 
From an outsider’s perspective what might seem like a suicide 
attempt may actually be one identity trying to kill another and 
thus must be dealt with appropriately.  Additionally, DID is very 
similar to Post Traumatic Stress Disorder (PTSD) except that in 
a patient with DID the trauma happens in early childhood and in 
PTSD it occurs in adulthood (Gillig, 2009).In addition, 80-100% 
of patients diagnosed with DID are diagnosed with PTSD as 
well (Vermetten et.al., 2006). 
There are cases in which one alter ego can be deathly allergic 
to bee stings, or may need glasses to see, while another alter 
ego in the same body may not have any reaction to bee stings 
or may not need glasses to see. There is a case study involving 
a 33-year-old female diagnosed with DID who suffered from 
blindness after a car accident. She was confirmed to be visually 
impaired after going through tests such as ocular fundus inspec-
tion, Humphrey refractometry, and intraocular tension mea-
surement, which are all ways to test for vision or lack thereof. 
She even failed to show signs of involuntary refluxes such as eye 
watering and winking. After years of treating the patient with 
therapy for DID, one of the identities became visually active 
and soon many of the identities followed and retrieved vision. 
Because only some identities were blind, just like any identi-
ties can fluctuate, the patient was fluctuating between sight 
and blindness within seconds. Proof of complete blindness in 
one identity and complete sight in another was seen by visual 
evoked potential (VEP) recording system. In a blind identity the 
pattern evoked potentials showed a disorganized blind pattern. 
When the VEP was run on a sighted identity, there were or-
ganized patterns cohesive to a visually active person. The VEP 
results for the blind identity shows lack of vision, yet insufficient 
for complete blindness. The blindness that was relayed by the 
tests can be explained as psychogenic blindness that was acti-
vated by a temporary loss of vision caused by the accident. The 
psychogenic blindness is proof that in DID psychology takes a 
toll on the biology of a person (Strasburger, Waldvogel, (2015). 
Dissociative identity disorder creates questions within the 
realms of sense of self; how can it be that two completely dif-
ferent identities are being controlled by one brain? Experiments 
using Positron Emission Tomography (PET) were performed to 
see how the brain creates these two different senses of self. 
To help explain this phenomena Damasio and coworkers cre-
ated a theory that there is a core self, constantly synchronized 
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with the body and controlled by the body’s biology, and the 
autobiographical self that are memories and is influenced by 
environmental factors. According to this theory only the auto-
biographical self is capable of change, yet the core self remains 
intact because it comes from the same biological makeup. Since 
the autobiographical manner of processing memory can be 
disrupted, the neutral personality state processes trauma in a 
non-autobiographical way, causing different senses of self in the 
brain. A study consisting of 11 females with DID in four different 
conditions was done. These four conditions included a neutral 
memory exposed to both the neutral and traumatic personality 
state, as well as a traumatic memory exposed to both a neutral 
and traumatic personality state. There were decreased amounts 
of regional cerebral blood flow (rCBF) perfusions when a trau-
matic memory was exposed to the traumatic personality state. 
The rCBF perfusions were unchanged when a traumatic mem-
ory was exposed to the neutral personality state, and when a 
neutral memory was exposed to both traumatic and neutral 
personality state. The areas that showed a decrease in rCBF 
perfusion correlated with the areas associated with the autobi-
ographical senses-of-self. Decreased perfusion in the visual as-
sociation area and the middle occipital gyrus causes the lack of 
integration of information and blocks emotional processing; this 
is the defense system manifested by patients with DID. Another 
symptom of DID is depersonalization, which is caused by de-
creased perfusion in parietal and occipital areas of the brain. 
Additionally, there is decreased perfusion in the medial prefron-
tal cortex that plays a big part in a person’s sense of self. The 
only part of the brain that shows increased perfusion of rCBF 
is the parietal operculum regulating emotions in response to 
pain. This comes forth as emotional dissociation in the traumatic 
personality state of a DID patient (Reinders et.al., 2003). 
Testing the autonomic nervous system through heart rate 
and skin conductance is an additional test that proves the au-
thenticity of the various alter egos. Nine patients diagnosed 
with DID were brought in each day for testing. Each patient 
had three identities involved in the study: the host personality 
and two other identities. As the researchers hypothesized, each 
identity showed differing results of heart rate and skin conduc-
tance when exposed to specific stimuli. Since the autonomic 
nervous system is completely voluntary it is safe to assume that 
the identities are genuinely distinct (Putman et.al., 1990). 
Amnesia and Memory Transfer
According to the DMV, DID should be a possible diagnosis when 
there is an “inability to recall important personal information that is 
too extensive to be explained by ordinary forgetfulness.” Amnesia 
is the most dominant symptom in a patient with DID and accord-
ing to the Journal of Abnormal Psychology is said to be a psycho-
logical disorder as a response to stress or trauma. Furthermore, 
it’s questionable whether inter-identity memory transfers exist. A 
study was conducted proving that DID patients only show mem-
ory transfer of implicit memories/words, but when there was an 
emotional or explicit word the patient regressed into an amnesic 
state. When these memories are restored it’s possible to develop 
dissociative memories in which at times the trauma is remembered 
and at times the patient has amnesia. 
The amnesic periods are only found between different iden-
tities and not within one identity. Therefore, in order to get 
to that amnesic state the identity fluctuates. Accordingly, the 
psychological perspective to DID is believed to be that DID 
patients are capable of switching identities in order to forget, 
and to avoid re-experiencing the trauma (Elzinga et.al., 2003). 
Trauma During Childhood
Vermetten et. al. (2006) describe DID as a childhood-onset 
posttraumatic developmental disorder. The post traumatic 
model of DID states that when a child goes through the trau-
matic experience of physical or sexual abuse it is natural that 
the child will dissociate, mentally compartmentalize, and have 
amnesic periods as a response. This coping mechanism removes 
unbearable memories that the child cannot deal with. As the 
child grows up, each painful experience gets compartmentalized 
and is expressed as a different identity (Piper, Mersky, 2004). 
Studies show that childhood trauma is imperative to the devel-
opment of DID. Traumatic is a relative word and is not referring 
to a one-time beating. The trauma endured is unusually sadistic 
abuse and it happens about twice a week for 50 weeks out of 
the year for 10 years. Statistically the type of abuse that will 
cause DID is 60-75% physical abuse, and 68-83% sexual abuse 
(Piper et.al., 2004).
DID specifically only develops when the trauma occurs in 
childhood because children are not yet equipped with the re-
sources to react. Furthermore, children are more prone to per-
itraumatic dissociation, and do not personalize the trauma that 
they are experiencing. DID can be classified as a developmental 
disorder due to the child not being able to handle dealing with 
the trauma and it takes a toll in later years. When a normal per-
son deals with stress their mental health is improving. However, 
when the stress is overbearing it reduces the mental health of a 
person (Goleman, 1985). Stress in early development biological-
ly embeds itself in a person and has long lasting effects. When a 
child experiences abuse versus being cared for it will affect his 
social experiences in later life (Mcewen et.al., 2015). 
Hippocampus and Amygdala
Stress related trauma plays a role psychologically and biological-
ly in patients with DID. 
Changes in the limbic system have been linked to stress fac-
tors (Gulyaeva, 2014). Parts of the limbic system such as the 
hippocampus and amygdala are two major parts of the brain 
that are involved in the formation of DID. Patients with DID 
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have a significantly reduced sized hippocampus and amygdala. 
The hippocampus and amygdala are located in the medial tem-
poral lobe (Figure 1) and although they have different functions 
they ultimately influence each other (Phelps, 2004). 
The hippocampus is the part of the brain that is involved in 
episodic memory and the primary memory system of the brain. 
Learning and stress regulation are also part of hippocampal 
function. The amygdala controls fear conditioning and processes 
emotion. Although the hippocampus and amygdala reside adja-
cent to each other, studies introducing a blue box that gives a 
shock proved that the hippocampus and amygdala have inde-
pendent functions. The study was performed by introducing a 
blue box that gives a shock.. People with focal lesions on the 
amygdala understood that the blue box causes a shock but 
failed to show any sign of fear. Focal lesions to the hippocampus 
caused one to fear the shock but fail to register that the shock 
comes from the blue box (Phelps, 2004). 
The hippocampus and amygdala are dependent on each other 
when it comes to emotional memories. The amygdaloid com-
plex consists of the subunits of the amygdala that are difficult to 
distinguish in MRIs. The amygdaloid complex is divided by func-
tion, receives, and relays information involved in fear condition-
ing and response. The forebrain receives input from the amygda-
la to stimulate attention, and the brainstem stimulates fear. The 
hypothalamus receives input from the amygdala for hormone 
release during stress that eventually affects the hippocampus. 
Through animal studies researchers were able to see that 
stress hormones were attacking androgenic receptors on the 
basolateral amygdala that were affecting hormones in the hip-
pocampus. Further research revealed through fMRI scans that 
activity of the hippocampus causes less activity of the amygdala 
and vice versa(Phelps, 2004). When studies were done remov-
ing the temporal lobe (which includes both hippocampus and 
amygdala), symptoms normally seen in patients with DID, such 
as amnesia and hypermetamorphosis were present. (Cristinzio 
et.al., 2007). 
Amygdala and Hippocampal Size Difference
The difference in hippocampal volume between a patient with 
DID and a healthy person is significant. The hippocampus in a 
patient with DID is 19.2% smaller and the amygdala is 31.6% 
smaller than that of an average person. In addition to stress 
causing smaller hippocampal volumes in patients with DID, 
other disorders such as PTSD that are associated with abuse 
in childhood show smaller hippocampal volumes, which can 
be seen on MRI readings. On the contrary, people who expe-
rienced childhood abuse and did not develop PTSD or DID, 
showed a normal sized hippocampus. There is no proven de-
crease in the size and volume of the amygdala in PTSD patients 
with no childhood trauma. In contrast, a PTSD patient with re-
cord of childhood abuse revealed a 15% decrease in amygdala 
size (Vermetten et.al., 2006). 
Methods
To research the different mechanisms and causes that stress has 
on DID, search engines such as Touro College Library, Proquest, 
and Google Scholar were used. Keywords such as “dissocia-
tive identity disorder”, “glucocorticoids”, and “hippocampus 
and amygdala” were used to retrieve appropriate information. 
Multiple articles and medical journals were found presenting 
the different perspectives to answer the question above.
Discussion
Not much is known regarding the neurobiology of DID, but the 
way that stress affects parts of the brain associated with DID is 
discussed. The parts of the brain affected may be the underlying 
cause of the symptoms of DID.  
The homeostasis of the body is disrupted as a result of stress 
(Krugers et.al., 2010). Allostasis is the body adapting to stress-
ors through mediators. Mediators can be steroid hormones 
such as glucocorticoids. Through glucocorticoids the body is 
able to adjust and adapt to the stress that it is handling. These 
effects of glucocorticoids can either be helpful for the person’s 
survival or detrimental to the brain. The brain can be altered 
through the expansion or retraction of the dendrites or change 
in synaptic density. Receptors in the brain are important factors 
in brain alterations (Mcewen et.al., 2015),
Glucocorticoids
Glucocorticoids are adrenal steroid hormones that are pro-
duced in the zona fasciculata of the adrenal cortex in response 
to stress. One major class of glucocorticoids is cortisol. 
Glucocorticoid or cortisol secretion from acute stress is cru-
cial for the survival of a person. Stored energy is retrieved to 
Figure 1: illustration of the hippocampus and amygdala. Notice how 
the hippocampus and amygdala are neighboring each other. Source: 
Mechanism of stress in the brain. Mcewen, et. al.. (2015) 
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enable the body to react appropriately to stressors. The harmful 
effect of glucocorticoids appear in the hippocampus and can 
take a toll on a person’s memory, specifically explicit memory 
(Sapolsky, 2003). 
HPA Axis 
A major gland involved in stress regulation is the adrenal gland. 
Located superior to the kidney, the adrenal gland either reacts 
to stress in a fight or flight response or supplies energy for the 
body’s response via the HPA axis. The adrenal gland is made up 
of the adrenal cortex and the adrenal medulla. The stimulation 
of stress causes the adrenal medulla to secrete epinephrine 
(adrenaline) and norepinephrine (noradrenaline) so the body 
can respond in a fight or flight manner. When the stress is con-
tinuous the adrenal cortex secretes glucocorticoids or cortisol 
which mostly bind to proteins. The cortisol that does not bind 
to proteins exists as free cortisol and supplies the body with 
the energy it needs to react to the stress. Cortisol acts in dif-
ferent reactions to produce glucose through gluconeogenesis, 
fatty acids from triglycerides, and amino acids from proteins to 
create new energy or to repair cells that were damaged by the 
stress (Hannibal, Bishop 2014). 
Hypothalamic pituitary adrenal axis (HPA axis) is a negative 
feedback mechanism that helps regulate glucocorticoid pro-
duction in times of stress (figure 2). The reaction begins in the 
hypothalamus, the link between the nervous and endocrine sys-
tem. The paraventricular nucleus in the hypothalamus responds 
to a relative amount of stress and causes the release of corti-
cotropin releasing hormone (CRH). The CRH thus stimulates 
the anterior pituitary to release adrenocorticotropic hormone 
(ACTH) that travels through the blood to the adrenal cortex. 
Glucocorticoids are released and supply energy to the body. 
When there is an excess of glucocorticoids the hypothalamus 
and anterior pituitary receive signals to stop the production of 
CRH and ACTH in order to inhibit the overproduction of glu-
cocorticoids (Zhu et.al., 2014). However, this negative feedback 
mechanism may be disrupted. Only a small amount of stress is 
required to activate the HPA axis, but when there is too much 
stress it is possible for the HPA axis to become hyperactive. 
HPA Axis Hyperactivity
Hyperactivity of the HPA axis can be caused by many factors, 
including excess glucocorticoids. Excess glucocorticoids in the 
brain can be attributed to receptor changes. Two different glu-
cocorticoid receptors in the brain are: glucocorticoid receptors 
(GR) and mineralocorticoid receptors(MR). GR and MR are 
found on both the hippocampus and the hypothalamus. MR are 
more likely to attract glucocorticoids even when glucocorticoid 
levels are low. GR only receive glucocorticoids when there is an 
excess amount of glucocorticoids from stress (Krugers et.al., 
2010). If there is a decrease in GR in the hippocampus it can 
help cause the hyperactivity of the HPA axis (Zhu et.al., 2014). 
A study using metyrapone was conducted on rats to deter-
mine the correlation between glucocorticoids and HPA axis 
hyperactivity that causes depressive behaviors. Enzyme 11-b-hy-
droxylase, found in the adrenal cortex, is responsible to convert 
deoxycorticosterone to glucocorticoids. Metyrapone, is used to 
block the function of 11-b-hydroxylase therefore terminating 
the process which would result in hyperactivity and depressive 
behaviors (Zhu et.al., 2014). 
MR-NNOS Pathway-Hyperactivity of HPA Axis
An additional pathway that decreases the activity of GR in the 
hippocampus is the MR-nNOS pathway. Glucocorticoids react 
with neuronal nitric oxide synthesis  enzyme (nNos), causing the 
overproduction of nitric oxide (NO) in the hippocampus. The GR 
in the hippocampus, which is crucial for the HPA axis to maintain 
homeostasis, interacts with the NO causing the negative feedback 
mechanism to be disrupted. The relatively decreased amount of 
GR in the hippocampus explains why excess glucocorticoid ex-
posure would generate hyperactivity of the HPA axis. 
Figure 2: A clear chart of the HPA axis. The arrows with a positive 
depicts stimulation of hormone release . The arrows with a negative 




The reason that the hypothalamus is not involved with the 
hyperactivity of the HPA axis is because of the low amount of 
MR in the hypothalamus. Thus, the MR-nNOS-NO pathway is 
non-existent in the hypothalamus and the hypothalamus is only 
capable of activating the negative feedback of the HPA axis (Zhu 
et.al., 2014). 
Different Pathways of Glucocorticoids
There are two effects that glucocorticoids can have: genomic or 
nongenomic. A non-genomic effect is a transcription independent 
mechanism that can interact with a cell membrane specifically 
or nonspecifically. The genomic effect works through interaction 
with Glucocorticoid Response Element directly or indirectly. 
Direct interaction is through receptors themselves and indirect 
interaction is through other transcription factors. Direct inter-
action of glucocorticoids is responsible for glutamate secretion. 
Indirect interaction of glucocorticoids uses endocannabinoids to 
control glutamate and GABA (Mcewen et.al., 2015). 
NMDA and AMPA Receptors
One type of glutamate receptor is N-methyl-d-aspartic acid 
(NMDA) receptor found on the hippocampus. NMDAR is ac-
tivated by glutamate with glycine and when activated permits 
charged ions to travel through the cell membrane (Mcewen 
et.al., 2015). Studies show that ketamine, an NMDA antagonist, 
causes the same symptoms seen in DID: amnesia, out of body 
experiences, and time standing still (Vermetten et.al., 2006). 
Alpha-amino-3-hydroxyl-5-methyl-4-isoxazole-propionate recep-
tor(AMPAR) or quisqualate receptor is a transmembrane recep-
tor. AMPAR only requires glutamate to activate the ion channel. 
Recent research show that activated glucocorticoids regulate 
AMPAR and effect learning and memory in the hippocampus. 
Learning and memory are disrupted by the synaptic connectivity 
in the hippocampus. Plasticity of the brain is in the control of 
the pre- and postsynaptic sites, and can be controlled by either 
limiting the neurotransmitters or the neurotransmitter receptors 
at the pre and postsynaptic sites, respectively. Further research 
proves that AMPAR also causes changes in synaptic function and 
plasticity of the brain. Miniature excitatory postsynaptic currents 
(mEPSC) are used to measure the strength of a synapse. When 
the nongenomic effect (fast) on AMPARs was measured the in-
crease in the mEPSC of the hippocampus and amygdala were 
similar to those experienced upon glucocorticoid exposure. The 
genomic effect (slower) of AMPARs is detrimental to the function 
of neurons (Krugers et.al., 2010). 
Brain Plasticity
Brain plasticity is caused by the conjunction of glucocorticoids 
and amino acids. 
Dendrites are altered in the way of expansion or retraction, 
and increase or decrease of dendritic synapses. For example, 
CRH, released in the hippocampus, down regulates thin spines. 
Parts of brain affected by hormones and intra and extracellular 
mediators are the hippocampus, amygdala and prefrontal cortex 
(Mcewen et.al., 2015). 
Studies show that chronic stress leads to permanent alter-
ations to the brain. Regardless if the chronic stress subsides, 
the brain creates a new way to handle stress and hippocampal 
changes remain. Additionally, experiments with rats prove gene 
alterations due to stress, including delayed alterations. The delay 
in gene response comes from epigenetic regulators. Even though 
the dendrites can regrow they are different in that the dendrites 
grow more proximal to the cell body (Mcewen et.al., 2016). 
The neuroendocrine model was postulated regarding the ef-
fects that stress has on the hippocampus and the role of the 
amygdala in hippocampal plasticity. It was proven that hippo-
campal plasticity can be achieved through limiting input from 
the amygdala.  
A part of the hippocampus, the dentate gyrus, is known for 
its constant rearrangement and its reproduction of its cells to 
replace lost cells. Reproduction of the new cells is inhibited by 
the amount of adrenal hormones in the brain through a mecha-
nism involving NMDA receptors. Stress exposure results in glu-
cocorticoid production and the release of glutamate from the 
hippocampus which blocks the reproduction of neurons in the 
dentate gyrus. Only chronic stress has effect on proliferation in 
the dentate gyrus, because small amounts of stress were seen to 
have no effect on neurogenesis in the dentate gyrus. 
In acute stress the new cells that are produced take part in 
stress response. When there is an excess amount of glucocorti-
coids caused by chronic stress the dendrites in the hippocampus 
retract and do not partake in stress response (Gulyaeva, 2014). 
Hippocampal and Amygdalar Role in Memory
Both the hippocampus and the amygdala contain GR and MR. As 
a result of stress, the role of the amygdala in fear conditioning 
is altered. According to Sapolsky (2016) when the hippocam-
pus is affected by stress the amygdala will start to process the 
memories. For example, amygdala long term potentiation will 
substitute the hippocampal long-term processing. Studies show 
that when hippocampal dendritic processes go through atrophy 
it causes the extension of the amygdalar processes’. The mech-
anism as to why this happens is currently unknown. Despite the 
fact that the hippocampus is irrelevant in memory processing, 
the hippocampus is said to process explicit memories. The rea-
son is that the hippocampus and the amygdala work together to 
process the memories.  Since the hippocampus cannot process 
the memories normally and neutral it acts like the amygdala 
and processes the memories inaccurately, causing flashbulb-like 
memories. The mechanism is controlled by the sympathetic 
nervous system and is activated by stress. Stress causes cate-
cholamines to be released by the adrenal medulla and stimulates 
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the vagus nerve. Thus, the vagus nerve stimulates the nucleus of 
the tractus solitarius (NTS) to have an effect on the amygdala. 
The amygdala begins to play a part in memory processing from 
the glucocorticoids in the hippocampus, amygdala and the NTS 
(Phelps, 2004). 
Animal studies show that by exposing glucocorticoids to 
the hippocampus it causes a decrease of pyramidal neurons 
and dendritic branching that are used to integrate memories 
(Nijenhuis, Steele, 2010). 
Genetic Factors 
Genetics are very influential in the development of any disorder. 
People that are born with a smaller hippocampal or amygdalar 
volumes have been seen to be more prone to developing DID 
(Vermetten et.al., 2006). When one is born with an overabun-
dance of  glucocorticoid receptors, there is an increased prob-
ability to develop mood disorders and are more responsive to 
antidepressant drugs. The opposite effect is on those who are 
born with less GR than an average person (Mcewen et.al., 2016). 
It is more common for a male to develop DID than a female. 
The hippocampus in a male naturally becomes reduced 1-1.5% 
per year while the amygdala is unchanged. Female resistance to 
this reduction is attributed to the production of estrogen which 
somehow acts as a prevention (Vermetten et.al., 2006).  
Conclusion
It is clear how much damage stress can do in terms of brain 
plasticity. Through mechanisms of how stress affects the brain 
it can be understood how DID can possibly develop. Treatment 
regarding DID is not proven to be 100% efficient or effective, 
but it may improve and make the disorder livable. Therapists 
dealing with DID patients will try to bring forth all their identi-
ties and help the patient deal with the trauma they experienced 
that sparked this disorder. As seen in the Three Faces of Eve, 
therapists may attempt for years to merge all the personali-
ties together in order to diminish symptoms of dissociation. 
Cognitive behavior therapists introduce the patient to various 
coping mechanisms as an alternative to switching identities. One 
form of treatment that is not effective is to diminish person-
ality states that are not positive or that may be detrimental 
to the environment. Since those identities exist to protect the 
patient from abuse it should be incorporated appropriately into 
their comprehensive personality (Gillig, 2009). Antidepressants 
may be another form of treatment for DID because in rodents 
neurogenesis of hippocampus was induced by them (Vermetten 
et.al., 2006). Recent studies show that the drug paroxetine may 
be useful in treating DID. Paroxetine has proven to regener-
ate hippocampal growth by 4.6% and to limit the symptoms of 
DID and PTSD . The correlation between DID and PTSD has 
shown to be very similar in neurobiology and causation of the 
disorders (Nijenhuis et.al., 2010). So many factors are involved 
in the development of DID, thus making the disorder very rare. 
The treatments noted are just a step in the direction to help 
understand the disorder and to further the subjects of research 
on DID. Even though it is understood how stress causes plas-
ticity to the hippocampus and amygdala creating symptoms in-
volved in DID, there is still so much about DID that is unknown 
to the world and is a mystery till today. 
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Cancer is the second leading cause of death worldwide, taking 
the lives of over 8.2 million people every year. The standard can-
cer treatments, such as chemotherapy and radiation therapy, are 
often inadequate and debilitating, destroying healthy fast-grow-
ing cells in the process of treatment.  Over the past decade, 
gene therapy has become a more prevalent option for treating 
cancers.  Gene therapy avoids targeting healthy cells, selecting 
only cancerous cells for treatment.  There are three approaches 
to gene therapy immunotherapy: stimulating a patient’s immune 
system to recognize and attack cancer cells, oncolytic virother-
apy, which generally uses viruses to infect and kill cancer cells, 
and gene transfer, which is the insertion of genetic material into 
the cancerous cells.  This paper aims to consider the viability of 
gene transfer therapy. Gene transfer therapy is an exciting new 
technology that is shifting the paradigm of cancer treatment. 
It involves inserting a foreign gene directly into the cancerous 
cells or surrounding tissue’s genome (Cross, Brumester 2006). 
With all the strides and progress made in gene transfer there 
are still problems that need to be rectified.  In early safety test 
cases, gene transfer scared many by causing the death of a pa-
tient (Raper, et. al. 2003).  Also, in some cases, gene transfer 
methods have promoted leukemia in their attempt to cure the 
patient of his disease (Thomas, et. al. 2003). Additionally, there 
is still plenty of research yet to be done in this area due to its 
relative newness.   This paper will assess how much of an option 
gene therapy is for cancer patients, taking into account its nu-
merous benefits and sometimes severe drawbacks. 
Methods
Research literature for this paper was obtained through the 
Touro College Online library. Searches done on the Touro 
College Online library led the student to Proquest and Pubmed, 
where majority of the articles were obtained. Articles found on 
other scholarly sites were also used.  The articles discussed ex-
perimental studies done and the thorough analysis of these ar-
ticles allowed for the assessment of gene therapy’s practicability. 
Review articles also assisted in composing the formal analysis.  
Discussion
The standard treatment method for cancer today is chemother-
apy. Chemotherapy can cause an array of both short term and 
long term side effects. Short term side effects are side effects 
that are present during the time of treatment and are often 
reversible, while long term side effects cause more severe and 
permanent damage.  Short term side effects include hair loss, 
nausea, and vomiting, which can sometimes hinder patient com-
pliance. Long term side effects such as arthritis, appendicitis, 
and thyroid damage have less of a probability of occurring, but 
do occur in some patients (Ramirez, et. al. 2009). The above 
mentioned are general side effects, but each patients’ individual 
circumstance can pose other possible risks.  If patients could be 
assured that chemotherapy would remove the cancer in totality, 
undergoing chemotherapy would be more tolerable, yet in many 
cases the chemotherapy fails to rid the body from the cancer 
and therefore, is often not a preferable option.
In this paper, gene therapy will be analyzed to assess whether 
it is a better option of treatment for cancer patients or whether 
it is yet another treatment method that provides partial results 
and causes severe side effects. How efficient gene therapy is in 
treating cancer, what side effects it includes and what the severi-
ty of the side effects are all questions that need to be addressed.
Insertion Approaches
There are two approaches to gene insertion; it can be done 
by means of either a viral or a non-viral vector (Amer, 2014). 
A viral insertion uses a virus as a vector to harbor the drug. A 
non-viral vector, which generally uses naked DNA or toxic ma-
terial for the cell as a vector, can be inserted either chemically 
or physically. Physical insertion can be done by a gene gun or 
ultra sound.  Another physical approach is that of electropora-
tion, which uses high voltages of electricity to disrupt the cell’s 
membrane, allowing the drug to enter the cell (Baranyi, et. al. 
2013).
Viral Insertion
Viruses have long been a choice for a vector because of some 
important properties they contain.  Viruses are small pathogenic 
particles that contain either DNA or RNA encoded in a protein 
coat.  Some viruses also contain a lipid bilayer surrounding the 
protein coat.  The mechanism in which a virus infects a cell is 
by implanting itself on the host cell’s membrane and inserting 
its viral DNA into the host cell. The host cell then transcribes 
and translates the viral DNA, which codes for the creation and 
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assembly of more viral particles.  These new viruses cause the 
cell to burst and proceed to infect more cells. The mechanism 
by which the virus operates is useful, for genetic material that 
will lead to cancer cell death or degeneration can be placed 
in a virus vector, which is essentially the outer protein coat of 
the virus deprived of its viral genome, and then infect the tar-
get tissue area.  Before using it as a vector, the virus has to be 
rendered non replicative so it no longer behaves as a pathogen. 
Viral vectors are advantageous since they can be produced in 
high concentrations and have minimal side effects (Amer, 2003).
The most popularly used viral vector is the adenovirus. The 
adenovirus is favored since it can be made in high titers and can 
infect both dividing and non-dividing cells. When using a viral 
vector such as the adenovirus, steps must be taken to ensure 
that the virus will not reproduce in the host’s body like it nat-
urally would. Prevention of the adenovirus replication can be 
achieved by removing early regions of the adenovirus vector’s 
genome (Pulkkanen, et. al. 2005).
Comparing Adenovirus to Retrovirus
A comparison of the efficiency of the adenovirus and the retro-
virus as vectors for gene transfer was done.  Ten patients with 
malignant glioma, a spreading brain tumor, were treated with a 
beta galactosidase gene via retrovirus and adenovirus vectors. 
This was done by inserting a catheter into the tumor and in-
jecting the patient with retroviruses and adenoviruses for three 
consecutive days.  This was followed by resection of the tumor 
one to two days later.  X-gal staining was then used to highlight 
the beta galactosidase gene and to evaluate its efficacy in gene 
transfer. Findings showed that beta galactosidase was well tol-
erated with both vectors.  In all but two patients, no systemic 
or tissue complications were apparent.  The gene transfer was 
successful, with an efficacy between <.01- 4% for the retrovirus 
and an efficacy <.01-11% for the adenovirus.  The adenovirus 
was thus more efficient then the retrovirus as a gene transfer 
vector (Puumalainen, et. al. 1998).
Malignant Glioma Adenoviral Gene Therapy
Although adenoviral vectors have some of the highest efficacies 
of gene transfer amongst other viral vectors, they still fall short of 
producing significant effects on the treatment of tumors.  A study of 
the treatments of malignant glioma was conducted with the aim of 
evaluating the safety of the adenoviral vector as well as determining 
the maximum possible dose that would be tolerated. Fourteen pa-
tients with relapsed malignant glioma were treated with adenoviral 
vector containing the Herpes simplex virus thymidine kinase (HSV-
tk) and its promoter (IG.Ad.MLPI.TK), and were then treated with 
ganciclovir, an antiviral drug.  Prior to this the retrovirus had been 
used as a vector for HSV-tk gene therapy treatment.  However, the 
adenovirus was used in this study because of its advantages of high 
titer production and efficacy of gene transfer. 
The patients underwent as much debulking of the tumor as 
was considered safe. The wound bed was then infiltrated with 
around 50 evenly spaced injections of the HSV-tk gene.  The 
patients were treated with different dose levels and then mon-
itored for any adverse events.  The patients reported either 
adverse events or serious adverse events.  From surgery until 
completion of the ganciclovir treatment, 27 adverse events and 
5 serious adverse events were reported. However none of the 
adverse events or serious adverse events were from the ade-
noviral vector.
After surgery, the patients were kept in strict isolation in the 
ICU, and viral cultures were taken until there were two consec-
utive days of negative culture results. None the cultures taken 
were found to be positive, indicating that the viral vector did 
not shed during its administration and did not pose a hazard to 
the environment. 
The adenovirus was thus considered to be a safe vector in-
ternally and externally.  However, in regard to the results of the 
patients’ tumor responses, the adenovirus does not appear as 
promising.  Unfortunately, none of the tumors responded to the 
successful gene transfer.  Overall the patients did not fare well. 
The median survival time was four months, with four patients 
surviving for over a year.  The median survival time attained in this 
study with the injection of the adenoviral vector was no better 
than the survival time in respective studies of malignant glioma 
with no gene therapy treatment.  According to the study, even the 
survival of patients with the favorable prognosis was most likely 
due to the nature of the tumor and not the gene transfer.
It is clear that the adenoviral vector used in this study is a 
safe method of choice but not significantly effective in dimin-
ishing the tumor growth. It is not definitive from this study if 
the adenoviral gene transfer had even any effect on the tumor. 
(Smitt, et. al. 2003).
In contrast to viral vectors, non-viral vectors are generally 
more economical and easier to produce in large quantities. They 
also have limited immunogenicity which allows for re-dosing. 
There is no concern of a gene recombination causing the virus 
to become competent and pose a danger to the body (Amer, 
et. al. 2014).
Physical Insertion
Physical insertion involves injecting naked DNA or liposomes 
directly into the target cell through a breach in the membrane 
made by rapid needle or jet injections, particle impact, electric 
pulse, laser radiation, or ultrasound. A novel method of physical 
insertion is the Jet injection, which was first introduced in 1947 
as an alternate to needle injections. Jet injection uses a pres-
surized gas, like carbon dioxide, to drive an ultrafine high speed 
stream of DNA into the target tissue in the form of plasmids. 
Comparisons done between jet and needle injections demon-
strated that gene expression was fifty times greater when 
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done by jet injection than it was done by the standard needle 
injection. 
A phase 1 study was conducted to determine the safety and 
feasibility of jet injection on patients with skin metastases from 
melanoma and breast cancer. Seventeen patients received five jet 
injections of B-galactosidase, a LacZ- expressing DNA plasmid, 
into a single cutaneous lesion.  To monitor the clearance of the 
plasmid in the blood stream, real time quantitative PCR of blood 
samples was done throughout the study.  After two to six days, 
the lesions were resected and a series of tests were performed 
to determine the efficiency of the plasmid uptake, as well as the 
transcription of DNA to mRNA and translation to a protein.  
All the patients responded well to the jet injections.  Four 
weeks after jet injection, all the patients were alive and none 
showed any adverse effects from the jet injection.  Within 
forty-eight hours any small bleeding and jet penetration at 
the injection site disappeared.  Additionally, the LacZ plasmids 
were successfully taken up by all the tumors, with variation in 
amounts detected in each tumor (Wolfgang, et. al. 2008).
Because this was a phase 1 study, research was taken to de-
termine the safety of the jet injection and did not cover the 
efficacy of jet injection in reducing cancerous growth.  The LacZ 
gene did not have any association to reduction of cancerous 
growth, but rather served as a marker to determine if jet injec-
tion was a viable method of gene transfer.  Research on humans 
using jet-injection-based gene transfer as antitumor therapy is 
limited and quite recent. There have been studies done on mice, 
though, with encouraging results. 
A study was conducted on mice containing human colon carcino-
ma to test the effectiveness of gene transfer jet injection in its ability 
to inhibit tumor growth.  The mice were injected four times with 
a suicide gene, Escherichia coli cytosine deaminase, and then after 
forty-eight hours treated with 5-flurocytocine, an antifungal drug. 
Tumor volumes were monitored, and starting on day five, there was 
a significant decrease in the size of the tumors treated with the jet 
injected suicide gene in comparison to the control groups’ tumors. 
Additionally, protein and mRNA levels revealed that the suicide 
gene was sufficiently expressed (Walther, et. al. 2005).
Although this study was not conducted on humans, it still has 
significant findings, chiefly that non-viral jet injection of suicide 
genes is an alternate method to injection via viral vectors, with 
comparable therapeutic response.  Though there are studies, as 
mentioned above, of successful adenoviral vector gene transfers, 
the adenoviral vector does have limitations that the jet injection 
does not.  When using the adenovirus as a vector, there is always 
the concern that it may have a pathogenic effect on the patient, 
or that the patient’s immune system will respond to the viral 
proteins and inhibit the vector in completing its task.  Jet injec-
tion looks promising for cancer treatment, but it is only useful 
for subcutaneous cancerous growths, like that of melanoma and 
breast cancer, since it cannot penetrate very deep. 
Suicide Genes
Once the genetic material is successfully transferred into the 
host cancer cells and incorporated into the nuclear genetic 
DNA, there are a few methods by which it represses tumor 
growth.  A key method being the injection of suicide genes, 
which are genes that cause apoptosis, or cellular death, when 
expressed.  These genes are usually transcribed by various pro-
moters found within the host cell. The H19 RNA gene is an 
example of one such promoter.  The H19 gene locus was the 
first imprinted non-coding RNA identified.  Recently, extensive 
study has been done on the role of the H19 gene and tum-
origenesis.  It is found that there is an abnormal expression 
of the H19 RNA gene in many cancerous cells, causing cancer 
cell proliferation, genetic instability, vascular angiogenesis, and 
tumor metastases.  In a number of studies, blocking the H19 
gene led to tumor regression and necrosis (Amer, et. al. 2014).
H19 Locus and tumorigenesis
The H19 RNA gene is greatly expressed in fetal organs but 
is rapidly turned off at birth.  In tumor cells, the H19 gene 
becomes highly expressed or shows an abnormal expression 
pattern when compared to normal non-cancer cells.  In cancer 
cells, the H19 gene expression can be activated by a combina-
tion of various transcriptional modulators and regulators that 
have malfunctioned.  The interplay of the H19 gene locus and 
the modulators in tumorigenesis is highly complex, involving 
many regulatory factors that rely on many other regulatory 
factors (Matouk, et. al. 2013).
Hypoxia and H19
One such approach to the H19 gene’s upregulation in can-
cerous cells is through hypoxia.  Hypoxia is the loss of oxy-
gen to areas of cancerous growth, and is considered a major 
trigger for metastasis, tumor angiogenesis, and chemotherapy 
resistance.  Hypoxia is also considered to increase H19 ex-
pression in tumor cells.  A study was done to investigate the 
relation between hypoxia and H19 upregulation in tumor cells. 
Carcinoma and Hepatocellular carcinoma cell lines were placed 
in an Aneropack rectangular jar and supplemented with Gaspak 
to create a hypoxic environment.  Some cells where left with 
normal oxygen conditions as a control.  The cells were then 
monitored by a hypoxic indicator.  After twenty-four hours, the 
cells were examined and RNA from each cell was extracted and 
amplified through PCR.  Viewed on the gel, the cells under an-
aerobic conditions expressed the H19 RNA significantly more 
than the cells under normal oxygen conditions. 
In a similar study, mice were injected with Hep3B, cells contain-
ing hepatitis B, which caused the proliferation of Hepatocellular 
carcinoma on their dorsal side.  A group of those mice were 
then injected with siRNA, a H19 gene knockout.  The results 
showed that the mice that were treated with the siRNA showed 
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a significant retardation of tumor growth of 82%. Thus, from this 
study it is clear that H19 plays a large role in tumor growth, and 
is activated by hypoxia, which is common in cancerous growths 
(Matouk, et. al. 2007, Matouk, et. al. 2005).
c-Myc and H19
Another factor that induces H19 transcription is the c-Myc 
transcription factor.  C-Myc is a transcription factor that, to-
gether with its obligate partner, protein Max, another transcrip-
tion factor, binds to E-boxes, which are enhancer sequences on 
the DNA that initiate transcription. C-Myc then promotes gene 
transcription by initiating chromatin remodeling on the DNA 
or RNA polymerase clearance.  To assess the role of c-Myc in 
tumor cells with increased H19 expression, a study was de-
signed in which c-Myc was inserted into breast and glioblastoma 
cell lines.  Cells inserted with c-Myc showed a seven-fold to 
ten-fold increase of H-19 expression based on Real-time PCR 
readings. Breast and lung cancer cell lines were also used to 
determine the correlation between elevated levels of c-Myc 
and H19 and tumor growth.  The cell lines containing elevated 
levels of H19 and c-Myc were treated with siRNA to knock 
down H19 expression.  The cells with knockdown H19 exhib-
ited significant retardation of tumorigenesis. Thus, c-Myc was 
established as another factor that induces H19 upregulation and 
thereby increases tumor growth (Barsyte, et. al. 2006).
E2F1 and H19
Another basis for increased H19 expression in cancer cells is 
the E2F1 regulatory factor. E2F1 belongs to the E2F protein 
family that regulates DNA by binding to promoters.  E2F1 binds 
to the H19 promoter and initiates its transcription. E2F regula-
tion is based on the stages of the cell cycle. E2F1 is considered 
a key factor in the transition from G1 to S in the cell cycle, as 
it promotes the transcription of genes whose protein products 
are necessary for the progression of the cell cycle and for imi-
tating DNA duplication.  Thus, increased E2F1 expression when 
it is not the appropriate cell stage or time for cell replication 
can lead to cancerous growths.  
A study conducted assayed the correlation between increased 
E2F1 and H19 gene expression in the S phase, as well as E2F1’s 
impact on tumor growth.  First, epithelial breast cells were 
transfected with a luciferase reporter gene, a selectable marker 
gene that, when expressed, causes the cells to emit a biolumi-
nescence. Half of the cells were transfected with a luciferase re-
porter gene carrying the wild type H19 gene and the other half 
with a mutated promoter site of an H19 gene, so E2F1 binding 
is inhibited.  The breast cells were then serum starved, and after 
twenty-four hours, some cells were placed in a fresh medium to 
stimulate their entry into cell cycle.   After a set time, the cells 
were then compared using FACS analysis, a fluorescent strength 
intensity test, because the luciferase reporter that was used 
contains bioluminescence.  Results showed that serum-starved 
cells had very little H19 expression, while cells in S phase had 
remarkably increased levels of H19.  The cells transfected with 
the mutated promoter site had low H19 expression compared 
to the wild type cells that had overall increased H19 expression, 
especially at S phase (Fig. 1).  
The correlation between H19 and E2F1 binding to its pro-
moter is demonstrated when the comparison between the wild 
type and mutated transfected cells are noted. The cells with wild 
type H19 promoter sites showed a higher concentration of lu-
ciferase activities, since E2F1 was able to bind to the promoter 
site and activate transcription, while the cells with the mutated 
promoter sites exhibited a lower concentration of luciferase 
activities since E2F1 was not able to bind to the mutated pro-
moter site.    Additionally, H19’s and E2F1’s definite role in G1/S 
phase is observed by the fact that the greatest percentage of 
cells were recorded during the S phase of the cell cycle. 
Figure 1:  A. Cells were treated with luciferase reporter gene with 
either wild type (WT) H19 promoter sites or H19 promoter 
mutated in two E2F sites (DMut). The cells with the wild type 
promoter exhibited the higher concentration of luciferase activities 
than the mutated cells .  
B . Shows the percentage of cells distributed throughout the cell 
cycle.  Note the elevated S phase line. (Berteaux, et. al. 2005)
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The second step of the study was to examine the roles of 
H19 and E2F1 in cancer proliferation.  Breast cancer cell lines 
were obtained and the levels of E2F1 mRNa and H19 RNA were 
calculated.  Normal breast cells were used as a control. The data 
showed that the expression of E2F1 and H19 were generally 
corresponding.  In the healthy breast cells there were low levels 
of both E2F1 and H19 expression, while most of the cancer 
cells showed notable activation of E2F1 and H19 gene. In one 
line of cancer cells however, the E2F1 expression was high but 
the H19 expression was comparatively low. This discrepancy 
was attributed to heterogeneity of breast tumors.  In general, 
there is a correlation between E2F1 and H19 upregulated gene 
expression in cancerous tissue (Berteaux, et. al. 2005).
Based on the studies discussed above, increased H19 ex-
pression is regulated by a number of regulatory factors, such as 
c-Myc and E2F1.  Their upregulation is also triggered by environ-
mental stress conditions such as hypoxia and S phase induced 
cells after serum starvation.  However, cells under normal con-
ditions do not demonstrate significant H19 expression (Ayesh, 
et. al. 2002). These findings reinforce the evidence that H19 is 
upregulated in many cancer cells, for hypoxia and serum starva-
tion are considered normal stages in tumor growth.  Thus, the 
tumor’s growth causes its further proliferation. As it outgrows 
its blood supply, some portions of the tumor lack sufficient ox-
ygen and reside in hypoxic microenvironments, which in turn 
triggers the increased expression of H19, further promoting 
cancerous growth.
Some of the explanations of H19 gene upregulation in tumor 
cells have been presented, and the therapeutic methods involv-
ing the H19 locus will now be discussed.
BC-819 Gene Therapy
In the past couple of years, BC-819, a plasmid involving a suicide 
gene and the H19 promoter, has been developed and has suc-
cessfully improved treatment of a number of cancers.  BC-19 is 
a double-stranded DNA vector that contains Diphtheria toxin 
A sequence, which isused to destroy the cancer cell, and an H19 
promoter sequence. It is mixed with Polyethylenimine transfec-
tant (PEI), which allows for easier entry of the plasmid into the 
rapidly dividing tumor cells.  In some cases, PEI is not used and 
BC-819 is injected intratumorally or by hepatic artery infusion 
(Matouk, et. al. 2013).
Once BC-819 is in the cancer cell, the H19 promoter is ac-
tivated and transcribed continuing with the Diphtheria toxin A 
sequence, which causes cell death by disrupting protein syn-
thesis.  BC-819 can actively select tumor cells to destroy, since 
only tumor cells have increased levels of H19 transcriptional 
factors.  BC-819 will enter healthy cells as well, but since they 
lack the H19 regulatory factors, they will not transcribe the 
plasmid and the cells will not be destroyed.  BC-819 is an in-
genious development that acts as a ‘search and destroy’ unit by 
only killing cells that contain H19 transcriptional factors thereby 
triggering their own demise (BioCanCell, 2017).  BC-819 has 
been semi-successful at treating bladder, pancreatic and ovarian 
cancer patient (Fig. 2)s. 
Bladder Cancer
In the United States, bladder cancer is the fourth most com-
mon cancer in men, with an estimated 74,000 annual incidents. 
Around 70% of bladder cancer patients suffer recurrence within 
five years. A chief goal of battling bladder cancer is in preventing 
its recurrence.  For decades, the standard care option was the 
BCG vaccine but the vaccine included drawbacks such as re-
currence, resistance to the treatment, and negative side effects 
(Matouk, et. al. 2013).
A phase 2b study was conducted testing the efficacy of BC-
819 treatment of bladder cancer.  Patients who had confirmed 
recurrent bladder cancer and for whom BCG and chemother-
apy had failed were recruited and BC-819 with PEI was admin-
istered to them.  First, they were given six weekly treatments 
of BC-819, and at week nine, safety and efficiency of transfer 
were assessed. In cases of no toxicity or recurrence therapy 
was discontinued in patients and follow up maintenance therapy 
was given for the duration of the year.  From the first cohort, 
nine out of eighteen patients had complete resolution of the 
target lesion within eight to ten weeks.  Overall, 63% of pa-
tients had recurrence-free tumors for the first three months 
after treatment and 48% had tumors for a year after treatment. 
Additionally, the patients tolerated the treatment well with only 
mild to moderate adverse effects. 
Reports of Phase III trials have not yet been published but 
trials are in progress as of the year 2016.
Pancreatic Cancer 
The eighth leading cancer cause of death in the United States 
is pancreatic cancer, with a poor prognosis of five year survival. 
The standard treatment for pancreatic cancer is gemcitabine, 
a chemotherapy drug. However, gemcitabine has limited effect 
because of its poor intracellular metabolism. Other methods 
have been tried in combination with gemcitabine in the hope 
of a more effective treatment, but none proved worthwhile. 
Recently, BC-819 and gemcitabine were tested together on pan-
creatic patients in a phase 2b study that showed more promising 
results. Patients received four week treatments of gemcitabine 
Figure 2 (BioCanCell, 20170
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and were then administered with BC-819 through endoscopic 
ultrasound.  Continued treatment with gemcitabine and BC-819 
was done for as long as the cancerous growth did not progress. 
After three months, nine out of eleven patients showed en-
couraging results.  Two had partial recovery and seven reached 
a point of stable disease. There were several adverse events 
mostly relating to liver function, but it was concluded that the 
adverse events were not related to the BC-819 , but were rath-
er due to the advanced stage of the cancer that all the patients 
had (Matouk, et.a. 2013).
Ovarian Cancer 
For women, ovarian cancer has a high mortality rate and is the 
fifth leading cause of cancer related death in the United States. 
Ovarian cancer patients generally have a poor prognosis, because 
the initial detection of the cancer is usually after it has reached an 
advanced stage.  The typical course of treatment includes surgical 
removal of the tumor followed by chemotherapy.  Unfortunately, 
most patients with the advanced stage tumor experience re-
lapse after treatment.  In the hopes of finding a better alternative 
treatment course, a phase ½ study testing the efficacy of BC-819 
plasmid was conducted on fourteen ovarian cancer patients.  All 
fourteen women had been pretreated with extensive chemother-
apy.  Different doses of BC-819 were administered to different 
groups of the patients.  The first cohort of patients were treated 
for three weeks with BC-819, rested for a week, and were then 
treated for six more consecutive weeks. This was followed by a 
four week rest period. The second and third cohort were treat-
ed with increased dosages for three weeks, with four weeks of 
rest and then an attempt at repeat treatment when possible. Of 
the fourteen subjects, only 3 completed the study, while the rest 
withdrew prematurely due to overall clinical deterioration.  There 
were fifteen reported severe adverse events, yet none were from 
the drug.  There were, however, five adverse events that were 
possibly related to BC-819 administration.  The best outcome of 
the treatment was a stable disease, with insufficient shrinkage or 
growth to qualify as either a partial response or progressive dis-
ease.   The patients in the study all had advanced tumor growth, 
but the findings suggest that with less advanced stage ovarian 
cancer, BC-819 treatment would yield a partial response (Lavie, 
et. al. 2017).
BC-819 shows great promise for cancer patients. Although 
not every patient treated in the studies mentioned above had 
a positive outcome from the treatment, no one’s medical state 
was worsened.  The study of the BC-819 treatment is still in 
progress. The studies mentioned above are phase one or two 
studies, which means they are being done to determine the 
maximum tolerable dose of the drug, its safety, and efficiency.  A 
phase three trial is generally the final test performed before the 
drug can be open to the public. A phase three trial is presently 
ongoing for bladder cancer, and a phase one/two has been com-
pleted for ovarian and pancreatic cancer.
Based on the various studies presented, gene therapy appears 
to be a viable option for cancer treatment.  Although in each 
study there were some patients who did not fare well with this 
form of treatment, as an overall option, gene therapy looks like 
a promising alternative for cancer patients for whom standard 
treatment is insufficient.  
Gene Therapy and Leukemia
However, there have been studies that have shown that in its 
attempt to rid the patient of his illness, gene therapy can actually 
promote one of the deadliest cancers, leukemia. 
In 2002, a group of infants with severe combined immunode-
ficiency (SCID) were treated with gene therapy, but four out of 
the nine patients developed leukemia within the next five years. 
This alarmed many patients and researchers, and was a major 
setback in the advancement of gene therapy.  
SCID is caused by a genetic mutation, making a patient with 
it lack the IL-2 receptor γ (IL2RG) gene. To restore the absent
gene, the infants in the study were treated with a therapeu-
tic gene via a retroviral vector.  However, the retroviral vector 
works by inserting its genome near a transcription start site 
in the host genome, allowing the virus’ long terminal repeats, 
which are repeated identical sequences of DNA that enable 
insertion into the host genome, to unintentionally  turn on 
transcription of other nearby sites. In these infants with SCID, 
the LMO2 oncogene site was found near the insertion site and 
was turned on, promoting leukemic growth (Hacein-Bay-Abina, 
et.al. 2008).
The events of this gene therapy treatment were unfortunate, 
and did remove some of the enthusiasm for gene therapy at the 
time.  However, the fact that this occurred on SCID patients and 
not on cancer patients must be taken note of, thus gene therapy 
might not be the right choice for SCID patient, but that does 
not rule out cancer patients.  Cancer patients may not have an 
oncogene site near the insertion site for their therapeutic gene, 
which completely removes the possibility of inducing leukemia. 
In the research done, no reports have been made demonstrat-
ing that gene therapy for cancer patients further induced new 
cancerous growths. 
Conclusion
Although gene therapy as a treatment option for cancer has 
had some setbacks and inconclusive results, it still provides 
a large source of hope for cancer patients.  The paradigm of 
treating cancer is slowly shifting due to the ongoing progress 
of gene therapy.  Based on the studies presented above, overall 
gene therapy, whether administered through a viral vector or 
a non-viral vector, was successful in treating a portion of the 
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patients.  Additionally, even in the studies done in which small or 
no substantial recovery was obtained, there were no consider-
able adverse effects on the patients treated with gene therapy. 
This greatly contrasts standard treatments like chemotherapy 
that cause an array of adverse effects on the patient without 
necessarily providing complete removal of the cancer.  Thus, 
even though gene therapy may not provide a complete cure 
against cancer, it is a promising alternative to standard cancer 
treatment.  With the constant hard work and progress of medi-
cal researchers and physicians that is presently taking place, it is 
anticipative to say that gene therapy will provide great relief to 
many cancer patients in the coming years.
References
Amer MH. Gene therapy for cancer: present status and future 
perspective. Molecular and cellular therapies. 2014;2:27. 
doi:10.1186/2052-8426-2-27.
Ayesh S., Matouk I., Schneider T., Ohana P., Laster M., Hochberg 
A. Possible physiological role of H19 RNA. Mol. Carcinog. 
2002;35:63–74
BC-819 Plasmid/Polyethylenimine Complex. In: NCI Thesaurus 
(17.06d). National Cancer Institute. (2017-06-26). https://ncit.
nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=N-
CI%20Thesaurus&code=C107685.Accessed May 11, 2017.
BC-819: Unique Technology, Potent Mechanism. BioCanCell. 
http://www.biocancell.com/. Accessed July 21, 2017.
Baranyi L, Slepushkin V, Dropulic B: Ex vivo gene therapy: 
utilization of genetic vectors for the generation of genetically 
modified cell products for therapy. Gene Therapy of Cancer. 
Edited by: Lattime EC, Gerson SL. 2013, San Diego (CA): 
Elsevier, 3-18. 3
Barsyte-Lovejoy D, Lau SK, Boutros CK, Khosravi F, Jurisica 
I, Andrulis IL, Tsao M, and Penn LZ. The c-Myc Oncogene 
Directly Induces the H19 Noncoding RNA by Allele-Specific 
Binding to Potentiate Tumorigenesis. Cancer Research. 
May 15 2006 (66) (10) 5330-5337; doi: 10.1158/0008-5472.
CAN-06-0037.
Berteaux N, Lottin S, Monte D, Pinte S, Quatannens B, Coll J, 
Hondermarck H, Curgy JJ, Dugimont T, Adriaenssens E. H19 
mRNA-like noncoding RNA promotes breast cancer cell 
proliferation through positive control by E2F1. J Biological 
Chemistry. 2005;280:29625–29636.
Cross D, Burmester JK. Gene Therapy for Cancer Treatment: 
Past, Present and Future. Clinical Medicine and Research. 
2006;4(3):218-227.
Lavie O, Edelman D, Levy T, et al. A phase 1/2a, dose-escala-
tion, safety, pharmacokinetic, and preliminary efficacy study 
of intraperitoneal administration of BC-819 (H19-DTA) in 
subjects with recurrent ovarian/peritoneal cancer. Archives of 
Gynecology and Obstetrics. 2017;295(3):751-761. doi:10.1007/
s00404-017-4293-0.
Matouk I, Raveh E, Ohana P, et al. The Increasing Complexity 
of the Oncofetal H19 Gene Locus: Functional Dissection and 
Therapeutic Intervention. International Journal of Molecular 
Sciences. 2013;14(2):4298-4316. doi:10.3390/ijms14024298.
Matouk IJ, DeGroot N, Mezan S, et al. The H19 Non-Coding 
RNA Is Essential for Human Tumor Growth. Wölfl S, ed. PLoS 
ONE. 2007;2(9):e845. doi:10.1371/journal.pone.0000845.
Matouk I., Ohana P., Ayesh S., Hochberg A. The oncofetal H19 
RNA in human cancer, from the bench to the patient. Cancer 
Ther. 2005;3:249–266.
Pulkkanen, Kalevi J. et al. Gene Therapy for Malignant Glioma: 
Current Clinical Status. Molecular Therapy , Volume 12 , Issue 4 
, 585 – 598. doi.org/10.1016/j.ymthe.2005.07.357
Puumalainen AM, Vapalahti M, Agrawal RS, Kossila M, Laukkanen 
J, Lehtolainen P, Viita H, Paljärvi L, Vanninen R, Ylä-Herttuala S. 
Beta-galactosidase gene transfer to human malignant glioma 
in vivo using replication-deficient retroviruses and adeno-
viruses. Hum Gene Therapy. 1998;9:1769–74. doi: 10.1089/
hum.1998.9.12-1769.
Ramirez LY, Huestis SE, Yi Yap T, Zyzanski S, Drotar D, Kodish 
E. Potential Chemotherapy Side Effects: What Do Oncologists 
Tell Parents? Pediatric blood & cancer. 2009;52(4):497-502. 
doi:10.1002/pbc.21835.
Raper Steven E, Chirmule Narendra, Lee Frank S, Wivel Nelson 
A, Bagg Adam, Gao Guang-ping, Wilson James M, Batshaw Mark 
L. Fatal systemic inflammatory response syndrome in a orni-
thine transcarbamylase deficient patient following adenoviral 
gene transfer. Molecular Genetics and Metabolism. doi: http://
dx.doi.org/10.1016/j.ymgme.2003.08.016
Salima Hacein-Bey-Abina, Alexandrine Garrigue, Gary P. Wang, 
Jean Soulier, Annick Lim, Estelle Morillon, Emmanuelle Clappier, 
Laure Caccavelli, Eric Delabesse, Kheira Beldjord, Vahid Asnafi, 
Elizabeth MacIntyre, Liliane Dal Cortivo, Isabelle Radford, 
Nicole Brousse, François Sigaux, Despina Moshous, Julia Hauer, 
Arndt Borkhardt, Bernd H. Belohradsky, Uwe Wintergerst, 
Maria C. Velez, Lily Leiva, Ricardo Sorensen, Nicolas Wulffraat, 
Stéphane Blanche, Frederic D. Bushman, Alain Fischer, Marina 
Cavazzana-Calvo. Insertional oncogenesis in 4 patients after 
retrovirus-mediated gene therapy of SCID-X1. Citation 
Information: J Clin Invest. 2008;118(9):3132-3142. doi:10.1172/
JCI35700.
Smitt PS, Driesse M, Wolbers J, Kros M, Avezaat C. Treatment 
of relapsed malignant glioma with an adenoviral vector con-
taining the herpes simplex thymidine kinase gene followed by 
ganciclovir. Mol Ther. 2003;7:851–58.
Thomas Clare E, Ehrhardt Anja, and Kay Mark A. Progress and 
problems with the use of viral vectors for gene therapy. Nature 
Reviews Genetics 4, 346-358 (May 2003). doi:10.1038/nrg1066
Walther, W., Robert Siegel, Dennis Kobelt, Thomas Knösel, 
Manfred Dietel, Andreas Bembenek, Jutta Aumann, Martin 
Schleef, Ruth Baier, Ulrike Stein and, Peter M. Schlag. Novel 
Jet-Injection Technology for Nonviral Intratumoral Gene 
Transfer in Patients with Melanoma and Breast Cancer. Clinical 
70
Aliza Applebaum
Cancer Res. November 15 2008 (14) (22) 7545-7553. doi: 
10.1158/1078-0432.CCR-08-0412
Walther W, Stein U, Fichtner I, et al. Nonviral jet-injection 
gene transfer for efficient in vivo cytosine deaminase sui-






Alzheimer’s disease is named after Dr. Alois Alzheimer who first 
discovered the disease in 1906. Dr. Alzheimer had a patient with 
severe memory loss, aphasia, and unnatural behavior who died 
of complications related to her disease. Upon her death, he 
performed an autopsy and noticed two unusual features in the 
brain, tangles of fibers and protuberances. We now know these 
as neurofibrillary tangles and beta amyloid plaques. It is difficult 
to accurately measure tangles and plaques during the lifetime 
of a patient with the disease; therefore, Alzheimer’s disease is 
diagnosed based on symptoms. The symptoms that are used to 
diagnose Alzheimer’s disease today are much like those of Dr. 
Alzheimer’s original patient. The common symptoms are mem-
ory related issues, trouble with organizational skills, getting lost, 
confusion, and personality changes. Eventually the deterioration 
escalates and the patient may hallucinate, become unable to 
recognize others, and then become unable to talk or eat. Lastly, 
the parts of the brain that directly control living processes are 
affected and death occurs. (National Institute on Aging, 2012)
The progression of Alzheimer’s disease does not happen 
quickly, in fact Alzheimer’s is a very slowly progressing disease, 
and there is usually 5-10 years between the first appearance of 
symptoms and death. This being the case, it is theorized that 
even before symptoms occur, perhaps years prior, there is a 
form of “pre-Alzheimer’s”. This can be defined as asymptomatic 
changes in the brain which are the true first steps of Alzheimer’s 
disease. The ability to detect these changes would greatly assist 
in the struggle to find a cure and is currently being researched. 
(National Institute on Aging, 2012)
Unfortunately, it is not possible with our current level of 
technology to reliably detect the changes in the brain that are 
present in Alzheimer’s, even advanced Alzheimer’s. Although we 
have come a long way with neuroimaging methods, they are un-
able to determine Alzheimer’s disease directly. Instead, after the 
onset of symptoms, brain imaging techniques such as MRIs and 
PET scans are used to rule out other probable causes of brain 
dysfunction; such as stroke or other forms of dementia. If these 
are not indicated, a diagnosis of probable Alzheimer’s is given 
until death and autopsy. Upon autopsy, if there are neurofibril-
lary tangles and amyloid plaques, the diagnosis is then confirmed 
(National Institute on Aging, 2015).
Neurofibrillary tangles and beta amyloid plaque are the two 
main physical phenomena that define Alzheimer’s disease, but 
the mechanism that they use to influence Alzhiemer’s disease 
and cause the deterioration of the brain is not yet understood. 
Neurofibrillary tangles are also called tau tangles as they are 
composed and caused by defective tau proteins. Tau proteins 
are microtubule-associated proteins that are common in the 
central nervous system. In a healthy person, these tau proteins 
hold microtubules in place and keep them steady. However in 
Alzheimer’s disease the tau proteins become hyperphosphory-
lated and they cease to support the microtubules. The micro-
tubules unwind and collapse and the hyperphosphorylated tau 
builds up. Together they form filamentous clumps which are the 
neurofibrillary tangles of Alzheimer’s disease. It is not certain if 
the tangles participate in the cause of Alzheimer’s disease or are 
just an effect of it (C. Bancher, 1989). However, the density of 
the tau tangles correlates with the extent of dementia and  they 
are located in the affected brain areas.  A possible mechanism 
by which the brain degenerated by neurofibrillary tangles is as 
follows. When disrupted microtubules are abundant, the neu-
ron is weakened and it becomes unable to transmit impulses 
at a normal rate. The body’s immune system detects compro-
mised neurons and triggers apoptosis of the cells (Wang, Xia, 
Grundke-Iqbal, & Iqbal, 2013).
The more significant Alzheimer’s disease marker is beta amy-
loid plaque. In the healthy brain, tangles and plaques are present 
in small quantities and pose no problem. It is when the beta 
amyloid amounts build up that issues arise. It is understood that 
this build up is the result of a difference between the amount 
of beta amyloid plaque that is formed and the amount that is 
removed. Beta amyloid plaque is formed by the breakdown of 
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amyloid precursor protein (APP), which is present in the syn-
apses of neurons. APP is present all over the brain and is thought 
to perform a function relating to neuron growth (Thinamaran 
& Koo, 2008).  APP is broken down by several enzymes known 
as alpha, beta, and gamma secretase. When amyloid precursor 
protein is broken down by a combination of alpha and gamma 
secretase it forms a protein called αAPP which may have effects
that protect the brain (Krishnaswamy, Verdile, Groth, Kanyenda, 
& Martins, 2009). However, when beta secretase takes the place 
of alpha secretase, it forms beta amyloid, which is sticky and in-
soluble allowing it to form plaques. The process of how beta am-
yloid plaque is removed from the brain is not fully understood 
but it could be performed in a variety of ways including protein 
transport through the blood or destruction by enzymes, such 
as insulin. Beta amyloid plaque is neurotoxic and it can inhibit 
synapse formation, disrupt mitochondrial action, contribute to 
inflammation in the brain, and promote the hyperpolarization of 
tau proteins which in turn causes neurofibrillary tangles. Beta 
amyloid plaques may be more important than neurofibrillary 
tangles and tau proteins in the onset of age related Alzheimer’s. 
Other diseases have tangles but Alzheimer’s disease is associat-
ed with plaque formation. (Lee, Goedert, & Trojanowski, 2001) 
Additionally, it is supposed that beta amyloid plaque forms earli-
er in the progression of Alzheimer’s disease and contributes to 
the neurofibrillary tangles (Villemagne, et al., 2013). This theory, 
that beta amyloid plaque is the most significant factor in the 
Figure 1: Nuerofibrillary tangles in the Hippocampus of an elderly man with Alzheimer’s related pathology.  
(Above: The tangle is enlarged and is visible above the the dark stain) (Patho, 2015).
Figure 2: Cerebral autopsy specimen 
of a patient diagnosed with Alzheimer 
Disease. In the HE stain numerous 
plaque formations within the neuropil 
background are visible. (Neurofibrillary 
tangles in the Hippocampus of 
a person with Alzheimer-related 
pathology, HE 1.JPG) (Patho, 2015)
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pathogenesis of Alzheimer’s is called the “amyloid hypothesis” 
(Burnham & Thornton, 2015).
There are two forms of Alzheimer’s and they have inherently 
different causes. Early onset Alzheimer’s is when Alzheimer’s 
disease occurs to people under 65. Most people with this form 
of the disease have a mutation in one of three genes, APP, PSEN 
1, and PSEN 2. These mutations run in families and create a 
disposition to suffer from early onset Alzheimer’s. (Bird, 2015) 
This is a genetic disease but it is far less common than late 
onset Alzheimer’s disease and it accounts for about 5 percent of 
total Alzheimer’s cases. In late onset Alzheimer’s disease, there 
is also a genetic component connected with the APOE gene 
but the main risk factor is age. The older someone is, the more 
they are at risk of late onset Alzheimer’s disease. The reasons 
why age should increase risk for Alzheimer’s disease are not yet 
understood. Research is being done into the natural changes 
that occur in the body with age as possible contributors to 
Alzheimer’s disease. The age-related changes to the hypotha-
lamic/pituitary/gonadal feedback loop that regulates sex hor-
mone levels in the blood is a strong candidate for this research.
The sex hormones are produced in the context of a feed-
back loop with Gonadotropin-releasing hormone in the hy-
pothalamus and the gonadotropins, luteinizing hormone and 
follicle stimulating hormone which are released by the pituitary 
gland. In a healthy individual, Gonadotropin-releasing hormone 
is released from the hypothalamus in surges in response to in-
ternal and environmental factors. It travels to the anterior pi-
tuitary gland where it stimulates gonadotropic cells to produce 
luteinizing hormone and follicle stimulating hormone These 
hormones travel to the gonads, the testicles and the ovaries, 
and they stimulate them to release testosterone and estrogen 
respectively. To prevent too much of these hormones from being 
made, testosterone and estrogen in sufficient quantities provide 
negative feedback that discourages the further production of 
GnRH by the hypothalamus. However, with advancing age the 
process changes. Testosterone levels fall gradually in men, and in 
women estrogen drops rapidly after menopause. Without the 
negative feedback of the endpoint, gonadotropin levels tend to 
rise, although this is not true in all cases. (Jones, 2012)
For many years it was thought that the lowered levels of 
testosterone and estrogen that come with age were involved in 
the cause of Alzheimer’s. It was assumed that these hormones 
had neuroprotective properties and their absence allowed 
Alzheimer’s disease to creep in. However, it was found that 
giving testosterone or estrogen directly did not lower risk for 
Alzheimer’s disease and in fact raised it. (Manly, et al., 2000) 
Since supplementing with testosterone/estrogen was not useful 
in preventing or understanding Alzheimer’s disease, the next 
logical step was to look at the heightened levels of gonado-
tropins that relate to the lower sex hormone levels. However, 
even in this case distinctions must be made.
Luteinizing hormone and follicle stimulating hormone are 
both released by the anterior pituitary gland in response to 
Gonadotropin-releasing hormone. Structurally, LH and FSH 
are similar. They both are heterodimeric glycoproteins and are 
composed of an alpha and beta subunit. The alpha subunit of lu-
teinizing hormone and follicle stimulating hormone are identical, 
however, the beta subunit is different and this is how they con-
nect to different receptors and have a different scope of action. 
In men, luteinizing hormone is released throughout the day and 
stimulates Leydig cells to produce testosterone. Follicle stimu-
lating hormone stimulates Sertoli cells which help sustain the 
Figure 3: A feedback loop regulates the Hypothalamic – Pituitary – Gonadal axis (Boundless.com, 2017).
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maturing sperm cells. In women, follicle stimulating hormone 
stimulates growth of the follicle in the ovary which increases 
production of estradiol and estrogen. When the follicle is ma-
ture, there is a critical level of estrogen that is reached and that 
stimulates a surge in luteinizing hormones, which in turn causes 
the release of the egg from the follicle. LH and FSH are different 
in both structure and function and how they interact with am-
yloid plaque as well. Many studies have shown links specifically 
between luteinizing hormone and the levels of beta amyloid 
plaque in the brain and this will be presented and evaluated.
If increased levels of luteinizing hormone contribute to 
Alzheimer’s disease, it would be useful to have an explanation 
for how it does so. The presence of luteinizing hormone in the 
brain is not expected as it is not lipid soluble and in theory can-
not cross the blood brain barrier. However luteinizing hormone 
is found in the brain and it has been found that LH can pass 
through this barrier in small amounts (Lukacs, Hiatt, Lei, & Rao, 
1995). It is also a possible that luteinizing hormone is synthe-
sized in the brain itself. LH receptors are found not only in the 
gonads but also in the brain which would imply that it may be 
active there as well. It may be that signals which are mediated by 
luteinizing hormone receptors affect the processing of APP and 
influence it so it is more likely to be cleaved by beta secretase 
than alpha secretase. This would result in a higher level of beta 
amyloid plaque formed relative to αAPP and could trigger a cas-
cade of beta amyloid plaque buildup and ultimately Alzheimer’s 
disease. 
Possibility of Treatment
Since elevated levels of luteinizing hormone could be a fac-
tor in the pathogenesis of Alzheimer’s disease, they are also a 
target for prevention or reversal of the disease. By lowering 
levels of luteinizing hormone in the blood, the contribution lu-
teinizing hormone is making to the disease could be negated. 
A potential medicine that could be effective in this therapy is 
leuprolide acetate. Leuprolide, also called leuprorelin, is a syn-
thetic hormone that is currently prescribed under the name 
Lupron to treat prostate cancer, sex hormone imbalance, 
and even less serious issues such as early onset of puberty 
(World Health Organization, 2015). Leuprolide acts as an ag-
onist to the Gonadotropin-releasing hormones. It binds to the 
Gonadotropin-releasing hormone receptors in the pituitary 
gland and interrupts their stimulation. This results in a downreg-
ulation of luteinizing hormone and follicle stimulating hormone. 
Leuprolide is delivered by injection and it can be self-adminis-
tered after training. It has mild short-term side effects including 
dizziness, itching, and headaches. As a long-term treatment, it 
can weaken bone density (Norsigian, 2005). However, with the 
research we currently have, the long-term side effects do not 
seem to be very significant, specifically when weighed against 
the pathology of Alzheimer’s. The effectiveness of Leuprolide as 
a treatment to lower luteinizing hormone levels, improve cogni-
tion, and prevent or even reverse the accumulation of amyloid 
plaque will be discussed in this paper.
Methods
All the information that was used in this article was gathered 
from online using the Touro Library search and Google Scholar. 
The search terms that were used were leuprolide acetate, le-
uprorelin, Alzheimer’s disease, beta amyloid plaque, luteinizing 
hormone, gonadotropins, hormone, gonadotropin releasing 
hormone. The articles were drawn from accepted and peer re-
viewed scientific journals and are all available online. Websites 
that were used were selected from dependable sources, govern-
ment websites or scientific institutions.
Discussion:  
Alzheimer’s Disease and Heightened Luteinizing 
Hormone Levels in Humans
In one study, plasma samples were taken from 284 patients seen 
at a tertiary care center and measured for concentrations of lu-
teinizing hormone and follicle stimulating hormone. The patients 
were divided into three groups, 134 with probable Alzheimer’s 
disease, 45 with frontal temporal dementia (FTD), and 105 cog-
nitively normal controls. The researchers logged each patient’s 
score on the Mini-Mental State Examination (MMSE) to mea-
sure severity of dementia. They recorded length of sickness, the 
sex and age of the subjects, and, in the case of women, if they 
were taking an estrogen supplement. It was found that there 
was no relationship between follicle stimulating hormone lev-
els in men between the controls and the Alzheimer’s disease 
group and although there was one with luteinizing hormone, 
it was not significant when controlled for age. The important 
finding was that in the women who were not taking estrogen, a 
significant difference in luteinizing hormone level was observed 
compared to the controls after a univariate analysis (Figure 4)
In women who were not taking any form of estrogen, this 
study found elevated levels of luteinizing hormone and follicle 
stimulating hormone compared to controls. The luteinizing hor-
mone levels were higher in the Alzheimer’s group compared 
to the frontotemporal dementia group which indicates that 
they were not just an effect of dementia or brain deteriora-
tion. There was no significant difference found for women who 
were taking estrogen but that is not unexpected, considering 
that estrogen is part of a negative feedback loop that limits lu-
teinizing hormone production. Within the men, there was no 
difference found between the FTD group and the Alzheimer’s 
disease group. It is possible that this is due to the small sample 
size. An important part of this study found that in estrogen free 
women, there was a connection between elevated levels of go-
nadotropins and Alzheimer’s disease.
In a previous study by the same authors, a difference was 
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found for men as well. The study tested 40 males who were 
diagnosed with Alzheimer’s disease in a long-term care center 
and compared them to 29 controls.  The study found that the 
Alzheimer’s disease patients were significantly higher in both 
luteinizing hormone and follicle stimulating hormone levels rela-
tive to the control group. (Bowen, Isley, & Atkinson, 2000).
In another study, 585 normal and healthy men between the 
ages of 70 and 87 years were tested for luteinizing levels to try 
to find a relationship between luteinizing hormone levels and is-
sues with memory recall. Men were chosen specifically because 
in previous studies, this correlation had not been demonstrated 
for men as strongly as in women. The study found that higher 
levels of luteinizing hormone were related to worse perfor-
mance on CVLT-II which is a test for immediate recall (Hyde, 
et al., 2010).
In an even larger study that evaluated the effects of elevat-
ed levels of gonadotropins on cognition in elderly women, 649 
women without dementia were given cognitive testing and 
blood samples were taken. Plasma levels of luteinizing hormone, 
estradiol, follicle stimulating hormone, and beta amyloid were 
recorded. The study found that elevated levels of luteinizing hor-
mone were associated with worse cognitive performance and 
depression (Rodrigues, et al., 2008).
In the Australian Imaging Biomarkers and Lifestyle study of 
aging, more than 1000 people were assembled to conduct a lon-
gitudinal study to aid understanding Alzheimer’s beginnings and 
progression. The subjects were given full cognitive evaluation, 
their blood was analyzed and many of them had their brains 
imaged by MRI machines and various brain imaging technology. 
The participants were grouped by cognitive issues. The categories 
were healthy, subjective memory impairment, mildly impaired, and 
Alzheimer’s patients. It was not the primary focus of the study to 
test specifically for gonadotropin levels. Nevertheless, the blood 
that was taken was tested for it amongst other things. Some re-
searcher reviewed the data with an eye on luteinizing hormone 
and it was found that increased levels of luteinizing hormone in 
the blood were correlated with beta amyloid presence in the 
brain as measured by imaging techniques. This was only found in 
the subjective group, which suggests that the most important link 
between luteinizing hormone and beta amyloid plaque is in the 
preliminary stages of Alzheimer’s disease (Ellis, et al., 2009).
Animal Trials
In studying disease pathology, and possible treatment options, it 
is not always possible to use humans as some potential treat-
ments may have negative side effects, it is therefore better to 
first test their potential with animals. Mice are often used be-
cause of their biological similarities to humans. Some research-
ers have studied ties between luteinizing hormone, beta amyloid 
plaque, and cognition in transgenic mice that have genes that 
lead to Alzheimer’s disease development. To test for cognition in 
mice, researchers use a test known as ‘spontaneous alternation’. 
It is a behavioral test which tests spatial learning and memory. In 
this test, the animal is put in the center of a maze and can move 
freely. Spatial memory is tested by observing whether the mouse 
remembers which arms of the maze it has already explored. It 
should be noted that the test results can also be influenced by 
factors such as attention or sensory stimuli (Hughes, 2004).
In a study of 21, one month old transgenic Tg2576 mice, the 
effects of high luteinizing hormone levels in the mice on amyloid 
beta plaque deposition were tested. The animals were bred to 
over-express human APP to ensure that there would be beta am-
yloid plaque buildup. In this breed in general, beta amyloid plaque 
grows throughout the first 6 months of age and by the time they 
are 10 months old, the level of beta amyloid plaque is enough to 
form an accumulation. The mice were randomly split into two 
groups. One was a control group that received saline solution 
and the second group received leuprolide.  The mice were tested 
with mazes to examine spontaneous alternation and their blood 
levels of luteinizing hormone were assayed to evaluate the effects 
of leuprolide. The brains were sliced on the sagittal plane and pre-
served to find the amount of beta amyloid deposition. The mice 
that were treated with leuprolide were found to have significantly 
lower levels of luteinizing hormone compared to the saline group 
especially 3 months after the treatment. The leuprolide-treated 
mice performed better on the maze task than the control group. 
Additionally, the leuprolide-treated mice had lower levels of beta 
amyloid plaque and this correlated with the improved cognition 
(Casadesus, et al., 2006).
Mice which were bred to have an elevated level of amyloid 
beta precursor proteins had higher levels of luteinizing hor-
mone and faster cognitive decline. The group that was treated 
with leuprolide, to help lower luteinizing hormone levels, had 
Figure 4: Follicle-stimulating hormone (FSH) vs luteinizing hormone 
(LH) levels in women not taking estrogen. Note that some patients 
with Alzheimer disease (AD) (triangles) have both higher LH and 
FSH levels compared with cognitively normal (NL) controls and 
patients with frontotemporal dementia (FTD) (Short, Bowen,, 
O’Brien, & Graff-Radford, 2001).
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less beta amyloid plaque deposition and better cognitive perfor-
mance than the controls. 
In another study done with mice, Tg2576 mice that were bred 
to express the human amyloid precursor gene were crossed 
with mice that had the genes for luteinizing hormone receptors 
removed, so that they couldn’t use luteinizing hormone. There 
were two control groups. One of the control groups were APP 
expressing mice that were not crossbred. A second control 
group was mice that had luteinizing hormone receptors and did 
not express the human APP gene. Finally, a group of normal mice 
was a third control.  The animals were raised for 16 months, 
sacrificed, and then their brains were sectioned. An imaging 
software was used to compare the beta amyloid concentrations 
in the brains of each group. The most important finding in this 
study was that there was significantly less beta amyloid plaque 
in the mice which had luteinizing hormone receptor knockout 
compared to the mice with APP that did have luteinizing hor-
mone receptors. (Lukacs, Hiatt, Lei, & Rao, 1995) 
The studies mentioned above all find a correlation between 
elevated luteinizing hormone levels and Alzheimer’s disease or 
beta amyloid plaque deposition. If luteinizing hormone is a part 
of the cause of Alzheimer’s, it presents exciting treatment possi-
bilities through the lowering of luteinizing hormone levels espe-
cially to prevent deterioration in those at risk for Alzheimer’s. A 
promising candidate for a medication that can accomplish this 
safely is leuprolide. 
Leuprolide as a Treatment for Alzheimer’s Disease
Leuprolide interferes with GnRH in humans and therefore 
brings about lower levels of luteinizing hormone. It is not an 
approved treatment for Alzheimer’s disease as of now. However, 
since leuprolide is an approved treatment for prostate cancer, 
some studies have observed the effect that leuprolide has had 
on Alzheimer’s disease in the patients using it for other rea-
sons. Clinical trials are currently underway to test this possi-
bility under the code ALADDIN which is an abbreviation for 
Antigonadotropin-Leuprolide in Alzheimer’s Disease Drug 
Investigation
One study of the impact of leuprolide on Alzheimer’s disease 
in patients with prostate cancer was done in 2010. The study 
looked at the risk of death by Alzheimer’s disease in 6,647 men 
who were treated for prostate cancer. In the study, 1700 men 
who were treated with leuprolide were compared to 4,947 
controls who were treated using other drugs that do not limit 
luteinizing hormone production. After 4 years of follow up, 81 
of the group in the study had died from Alzheimer’s disease. 
Those who died of Alzheimer’s were found to be from the con-
trol group rather than from the group of patients who took 
leuprolide for at least 4 months (D’Amico, Braccioforte, Moran, 
& Chen, 2010).
The results were that Leuprolide can aid in slower regres-
sion and improved cognition in Alzheimer’s patients. Voyager 
Pharmaceuticals is not currently pursuing further research into 
Lupron and most likely will not do so in the future as it declared 
bankruptcy in 2012. In an interview for medicalresearch.com, 
Richard Bowen cited lack of marketability to account for the 
dearth in leuprolide research. “Unfortunately, there is no intel-
lectual property protection for this treatment making it unlikely 
that a pharmaceutical company will take the lead.” (R. Bowen). 
It is vitally important to find a cure for Alzheimer’s and perhaps 
the funding will come from a government the government or 
foundation, and leuprolide research will be continued. 
Conclusion
Alzheimer’s disease is a common debilitating disease that is 
one of the main leading causes of death in the United States. 
One of the main changes detected in the brain of a patient 
with Alzheimer’s disease is beta amyloid plaque. These plaques 
can only be detected after death, upon autopsy. Studies have 
shown that a rise in luteinizing hormone is linked to increased 
beta amyloid plaque and Alzheimer’s. Studies have been done 
to lower Gonadotropin-releasing hormone levels through the 
treatment of Leuprolide acetate, a Gonadotropin-releasing hor-
mone agonist. This treatment is not being financially backed and 
is therefore on hold for the time being; however, the possibility 
of this treatment for Alzheimer’s disease is somewhat promising 
and deserving of more research. 
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